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A B S T R A C T
Background
Progesterone prepares the endometrium for pregnancy by stimulating proliferation in response to human chorionic gonadotropin
(hCG), which is produced by the corpus luteum. This occurs in the luteal phase of the menstrual cycle. In assisted reproduction
techniques (ART) the progesterone or hCG levels, or both, are low and the natural process is insufficient, so the luteal phase is supported
with either progesterone, hCG or gonadotropin releasing hormone (GnRH) agonists. Luteal phase support improves implantation rate
and thus pregnancy rates but the ideal method is still unclear. This is an update of a Cochrane Review published in 2004 (Daya 2004).
Objectives
Todetermine the relative effectiveness and safety ofmethods of luteal phase support in subfertile womenundergoing assisted reproductive
technology.
Search methods
We searched the Cochrane Menstrual Disorders and Subfertility Group (MDSG) Specialised Register, Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO, CINAHL, Database of Abstracts of Reviews of Effects (DARE),
LILACS, conference abstracts on the ISI Web of Knowledge, OpenSigle for grey literature from Europe, and ongoing clinical trials
registered online. The final search was in February 2011.
Selection criteria
Randomised controlled trials of luteal phase support in ART investigating progesterone, hCG or GnRH agonist supplementation in
in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycles. Quasi-randomised trials and trials using frozen transfers
or donor oocyte cycles were excluded.
Data collection and analysis
We extracted data per women and three review authors independently assessed risk of bias. We contacted the original authors when
data were missing or the risk of bias was unclear. We entered all data in six different comparisons. We calculated the Peto odds ratio
(Peto OR) for each comparison.
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Main results
Sixty-nine studies with a total of 16,327 women were included. We assessed most of the studies as having an unclear risk of bias, which
we interpreted as a high risk of bias. Because of the great number of different comparisons, the average number of included studies in
a single comparison was only 1.5 for live birth and 6.1 for clinical pregnancy.
Five studies (746 women) compared hCG versus placebo or no treatment. There was no evidence of a difference between hCG and
placebo or no treatment except for ongoing pregnancy: Peto OR 1.75 (95% CI 1.09 to 2.81), suggesting a benefit from hCG. There
was a significantly higher risk of ovarian hyperstimulation syndrome (OHSS) when hCG was used (Peto OR 3.62, 95% CI 1.85 to
7.06).
There were eight studies (875 women) in the second comparison, progesterone versus placebo or no treatment. The results suggested a
significant effect in favour of progesterone for the live birth rate (Peto OR 2.95, 95% CI 1.02 to 8.56) based on one study. For clinical
pregnancy (CPR) the results also suggested a significant result in favour of progesterone (Peto OR 1.83, 95% CI 1.29 to 2.61) based
on seven studies. For the other outcomes the results indicated no difference in effect.
The third comparison (15 studies, 2117 women) investigated progesterone versus hCG regimens. The hCG regimens were subgrouped
into comparisons of progesterone versus hCG and progesterone versus progesterone + hCG. The results did not indicate a difference of
effect between the interventions, except for OHSS. Subgroup analysis of progesterone versus progesterone + hCG showed a significant
benefit from progesterone (Peto OR 0.45, 95% CI 0.26 to 0.79).
The fourth comparison (nine studies, 1571 women) compared progesterone versus progesterone + oestrogen. Outcomes were sub-
grouped by route of administration. The results for clinical pregnancy rate in the subgroup progesterone versus progesterone + trans-
dermal oestrogen suggested a significant benefit from progesterone + oestrogen. There was no evidence of a difference in effect for other
outcomes.
Six studies (1646 women) investigated progesterone versus progesterone + GnRH agonist. We subgrouped the studies for single-dose
GnRH agonist and multiple-dose GnRH agonist. For live birth, clinical pregnancy and ongoing pregnancy rate the results suggested
a benefit from progesterone + GnRH agonist, with significantly lower rates in the progesterone group. The Peto OR for the live birth
rate was 0.40 (95% CI 0.26 to 0.61), for the clinical pregnancy rate was 0.74 (95% CI 0.60 to 0.90) and for the ongoing pregnancy
rate was 0.76 (95% CI 0.60 to 0.97). The results for miscarriage and multiple pregnancy did not indicate a difference of effect.
The last comparison (32 studies, 9839 women) investigated different progesterone regimens:intramuscular (IM) versus oral admin-
istration, IM versus vaginal or rectal administration, vaginal or rectal versus oral administration, low-dose vaginal versus high-dose
vaginal progesterone administration, short protocol versus long protocol and micronized progesterone versus synthetic progesterone.
The main results of this comparison did not indicate a difference of effect except in some subgroup analyses. For the outcome clinical
pregnancy, subgroup analysis of micronized progesterone versus synthetic progesterone showed a benefit from synthetic progesterone,
with a significantly lower rate in the micronized progesterone group (Peto OR 0.79, 95% CI 0.65 to 0.96). For the outcome multi-
ple pregnancy, the subgroup analysis of IM progesterone versus oral progesterone suggested a benefit from oral progesterone, with a
significantly higher rate in the IM progesterone group (Peto OR 4.39, 95% CI 1.28 to 15.01).
Authors’ conclusions
This review showed a significant effect in favour of progesterone for luteal phase support, favouring synthetic progesterone over
micronized progesterone. Overall, the addition of other substances such as estrogen or hCG did not seem to improve outcomes. We
also found no evidence favouring a specific route or duration of administration of progesterone. We found that hCG, or hCG plus
progesterone, was associated with a higher risk of OHSS. The use of hCG should therefore be avoided. There were significant results
showing a benefit from addition of GnRH agonist to progesterone for the outcomes of live birth, clinical pregnancy and ongoing
pregnancy. For now, progesterone seems to be the best option as luteal phase support, with better pregnancy results when synthetic
progesterone is used.
P L A I N L A N G U A G E S U M M A R Y
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A woman’s menstrual cycle consists of different phases. After ovulation the luteal phase starts and lasts until the next menstruation. It is
named after the corpus luteum, the yellow body. This consists of the remnants of the ovulated egg in the ovary and produces different
hormones, including progesterone. Progesterone stimulates proliferation of the lining of the uterus, preparing for implantation.
When in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), are used for subfertility treatment, fertilisation takes
place outside the human body. It is standard protocol to obtain as many eggs as possible. The woman’s pituitary gland is desensitised,
making it possible to stimulate the ovaries. This process is called controlled ovarian hyperstimulation. In this way more mature eggs
are produced, increasing the chance of successful fertilisation. This hyperstimulation causes a luteal phase defect, meaning that the
multiple yellow bodies are unable to produce sufficient progesterone.
As a low progesterone level may lower the chance of implantation, the luteal phase needs to be supported. This may involve oral, vaginal
or intramuscular progesterone, human chorionic gonadotropin (hCG) (which stimulates progesterone production) or gonadotropin-
releasing hormone (GnRH) agonists. GnRH agonists stimulate the production of GnRH, a hormone responsible for follicle stimulating
hormone (FSH) and luteinizing hormone (LH) which triggers ovulation and develops the yellow body. GnRH agonists are thought to
restore LH levels and support the luteal phase naturally.
Many different interventions, dosages and administration routes of luteal phase support have been investigated. We made six different
comparisons, with an average of six studies for each comparison. We found six statistically significant results. Progesterone was more
effective than placebo for live birth and clinical pregnancy. There are two different forms of progesterone, micronized (natural) and
synthetic.Whenwe compared these the results favoured synthetic progesterone.Whenwe compared progesterone with progesterone + a
single dose ofGnRHagonist, the results favouredGnRHagonist supplementation for live birth and clinical pregnancy. In the comparison
of progesterone with progesterone + multiple-dose GnRH agonist the results again favoured GnRH agonist supplementation. We also
found that the use of hCG was linked to a significantly higher risk of ovarian hyperstimulation syndrome (OHSS), a side effect.
Because the number of studies in each comparison was small, we cannot be too certain about the results. This uncertainty is enhanced
by the unclear methodology and high risk of bias of most included studies.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
hCG versus placebo/no treatment for assisted reproduction cycles
Patient or population: patients with assisted reproduction cycles
Settings:
Intervention: hCG versus placebo/no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control hCG versus placebo/
no treatment
Live Birth Rate
Follow-up: 9 months
120 per 1000 235 per 1000
(48 to 653)
OR 2.25
(0.37 to 13.8)
38
(1 study)
⊕⊕©©
low1,2,3
Clinical Pregnancy
Rate
Follow-up: 6 weeks
169 per 1000 209 per 1000
(155 to 277)
OR 1.3
(0.9 to 1.88)
746
(5 studies)
⊕⊕©©
low1,2,3
OHSS 41 per 1000 134 per 1000
(73 to 232)
OR 3.62
(1.85 to 7.06)
387
(1 study)
⊕⊕©©
low1,2,3
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was ’unclear’ therefore there might be limitations
2 Total number of events is less than 300
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B A C K G R O U N D
Description of the condition
Assisted reproductive technology (ART), such as in vitro fertili-
sation (IVF) and intracytoplasmic sperm injection (ICSI) are in-
creasingly used to assist couples to have a family.Of the cases where
one or more embryos are transferred, less than one third result in
a live birth (CDC 2009; de Mouzon 2010; Wang 2009a). These
figures suggest that implantation failure is an important limiting
factor in the outcomes of ART.
The endometrium, which lines the uterus, prepares for implanta-
tion of the embryo. This process starts in the proliferative phase
(from menstruation to ovulation) and extends throughout the
luteal phase (from ovulation until menstruation). The luteal phase
begins on the day of the luteinizing hormone (LH) surge which
causes the ovulation. The luteal phase ends at the onset of the next
menstruation and usually lasts 12 to 16 days. During the luteal
phase, the corpus luteum undergoes morphological and biochem-
ical changes known as ’luteinization’. Under the influence of LH
specific cells called granulosa cells produce progesterone, which
in turn induces the secretory transformation of the endometrium
preparing it for implantation by thickening and increasing vas-
cularisation in order to facilitate implantation (Farquhar 2010).
Implantation occurs six days after fertilisation in natural cycles.
After implantation, trophoblastic tissue of the placenta secretes
human chorionic gonadotropin (hCG), which acts on the ovary.
It maintains and stimulates the corpus luteum, the remnant of the
follicle, to produce estradiol and progesterone (Pabuccu 2005).
This is important formaintaining the pregnancy until the placenta
takes over steroid hormone production at approximately seven
weeks.
From the early phase of assisted reproduction it has been clear
that the luteal phase in ART is deficient, although the underly-
ing mechanism is unclear (Edwards 1980). Several theories have
been proposed to explain the deficient luteal phase in ART. In
ART cycles the corpus luteum is formed from the remnants of the
aspirated follicles under the influence of LH and produces pro-
gesterone and estradiol (Messinis 2009). Initially it was thought
that oocyte retrieval caused a luteal phase defect and, in particular,
steroid secretion but this was rejected when Kerin (Kerin 1981)
demonstrated that aspiration of a single follicle did not lead to
impaired steroid function. Another theory was that gonadotropin-
releasing hormone (GnRH) agonist co-treatment caused a pro-
longed pituitary recovery which resulted in a lack of LH and thus
the corpus luteum did not develop fully (Smitz 1992a). The lack
of LH was thought to be caused by a short-loop negative feedback
mechanism after hCG administration for the oocyte maturation.
This theory was also rejected as long-loop negative feedback by
ovarian oestrogens has more effect on LH levels (Miyake 1979)
and hCG does not lower the LH secretion in non-stimulated, nor-
mal ovulating women (Tavaniotou 2003). Currently it is thought
that LH levels are lowered by high steroid levels (Fatemi 2009).
These steroid levels are high because of the multiple corpora lutea,
which produce more steroids than in a natural cycle. This causes a
negative feedback on the pituitary gland and lowers the LH levels.
In this way the length of the luteal phase is shortened (known as
premature luteolysis) and the chances of pregnancy are reduced. In
summary, premature luteolysis results from high concentrations of
steroids caused by the higher numbers of corpora lutea (secondary
to controlled ovarian stimulation) during the early luteal phase,
which in turn inhibit LH release directly by negative feedback.
In 2005, GnRH was introduced as a new way of luteal phase sup-
port. GnRH blocks the LH surge and it was assumed GnRH ag-
onists might keep their stimulatory effect throughout the luteal
phase and restore LH levels, which would support the luteal phase
(Pirard 2005). In 2004, Tesarik reported on the use of GnRH ago-
nist six days after ICSI amongst oocyte donors. This study showed
that single-dose agonist administration increased the implantation
rate without affecting the miscarriage and abortion rates, resulting
in an improved birth rate. However the multiple pregnancy rate
was also increased (Tesarik 2004).
Adequate luteal phase support is therefore essential during IVF
and ICSI to improve implantation and pregnancy rates. This can
be achieved by substituting deficient LH with GnRH agonists, or
hCGwhich has a longer half life, or directly by using progesterone
with or without oestrogen. The ideal method of luteal phase sup-
plementation remains a matter of debate and is the focus of this
review.
Description of the intervention
The following agents can be used for the luteal phase.
1. Progesterone (including micronized progesterone or
synthetic progestogens such as dydrogesterone, which have a
higher bioavailability (Schindler 2009)), administered using the
following routes:
i) intramuscular (IM);
ii) oral;
iii) vaginal, where an oral progesterone supplement
administered by the vaginal route can lead to higher serum
progesterone concentrations (Choavaratana 2004). Progesterone
can also be administered vaginally by a gel or cream, which can
generate high concentrations due to bypassing the first-pass
effect through the liver (Geber 2007a);
iv) rectal.
2. Human chorionic gonadotropin (hCG) is similar to LH in
its mode of action and physiological effects. The molecular
structure is also similar. However it differs from LH as there are
elevated sialic acid residues that are responsible for the longer
serum half-life and potency (Balasch 2004). Two types of hCG
have been used, human derived and recombinant (Mochtar
2007); hCG is administered using the following routes:
i) intramuscular (IM);
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ii) subcutaneous (sc). It has been suggested that the
bioavailability of hCG is lower after sc injections compared to
intramuscular injections but this is still unclear (Chan 2003, Saal
1991; Mannaerts 1998; Wikland 1995).
3. Oestrogen: oral administered in combination with
progesterone.
4. GnRH agonists:
i) intranasal;
ii) intramuscular (IM);
iii) subcutaneous (sc).
How the intervention might work
In ART the levels of progesterone in the luteal phase are insuffi-
cient (see above) and therefore the levels of progesterone need to
be increased. The progesterone level can be increased directly by
giving progesterone, or progesterone and oestrogen in combina-
tion, or indirectly in the form of hCG, which in turn stimulates
progesterone secretion.
Why it is important to do this review
Luteal phase support may have a positive effect on the outcome
of ART. There are many randomised trials which compare dif-
ferent methods of administration and preparations. This updated
Cochrane review examines all currently available evidence on
hCG, progesterone, oestrogen and GnRH analogues as agents for
luteal phase support in ART.
O B J E C T I V E S
To determine the relative effectiveness and safety of methods of
luteal phase support in subfertile women undergoing assisted re-
productive technology (ART).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing any of the agents
used for luteal phase support during the luteal phase of a ART
cycle were included. Crossover trials were included in the review
for completeness but only the first phase data were used in the
analysis. Quasi-RCTs were not included.
Types of participants
All subfertile women undergoing treatment with ART, includ-
ing IVF or ICSI, were included. The cause of subfertility was
not taken into account. Studies including women who had cycles
of gamete intrafallopian transfer (GIFT) or zygote intrafallopian
transfer (ZIFT) were excluded unless these treatments took place
in less than 20% of the cycles as the pregnancy outcomes with
GIFT and ZIFT are lower than with IVF. This 20% threshold was
arbitrary.
Types of interventions
Trials were included if they investigated or included:
• any type, dose or route of progesterone providing at least
five doses were given during the luteal phase, to ensure the
inclusion of true luteal phase support studies;
• any type, dose or route of hCG providing at least two doses
were given during the luteal phase, to ensure the inclusion of
true luteal phase support studies;
• progesterone combined with oestrogen;
• progesterone combined with hCG;
• GnRH agonist during the luteal phase.
All ovarian stimulation protocols were considered.
Trials were excluded if they investigated or included:
• luteal phase support after frozen embryo transfer;
• luteal phase support after embryo transfer from donated
oocytes;
• luteal phase support after embryo transfer from frozen
oocytes or frozen ovarian tissue;
• luteal phase support after in vitro maturation (IVM) cycles.
Types of outcome measures
Primary outcomes
Live birth rate (LBR) per woman (defined as the delivery of one
or more living infants)
Secondary outcomes
• Clinical pregnancy rate (CPR) per woman (defined as the
presence of a gestational sac, with or without a fetal heart beat,
on ultrasonography)
• Ongoing pregnancy rate (OPR) per woman (defined as a
pregnancy beyond 12 weeks of gestation)
• Miscarriage rate (MR) per woman
• Ovarian hyperstimulation syndrome (OHSS) per woman
• Multiple pregnancy rate per woman (counted as one)
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Search methods for identification of studies
This review used the information in the Cochrane Men-
strual Disorder and Subfertility Group (MDSG) Module regard-
ing search strategies (www.mrw.interscience.wiley.com/cochrane/
clabout/articles/MENSTR/frame.html). All published and un-
published RCTs that described progesterone or HCG, or both, for
luteal support in women undergoing ART were sought. Indexed
and free text terms were used. The search strategies were designed
in consultation with the MDSG Trials Search Co-ordinator.
Electronic searches
The following databases were searched:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library), see Appendix 1;
• MEDLINE, see Appendix 2;
• EMBASE, see Appendix 3;
• PsycINFO, see Appendix 4;
• MDSG Specialized Register, see Appendix 5;
• CINAHL, see Appendix 6;
• Database of Abstracts of Reviews of Effects (DARE) (The
Cochrane Library), see Appendix 7.
The MEDLINE search was combined with the Cochrane highly
sensitive search strategy for identifying randomised trials, which
appears in the Cochrane Handbook of Systematic Reviews of In-
terventions Version 5.0.2, chapter 6, 6.4.11 (Higgins 2011).
The EMBASE search was combined with trial filters developed
by the Scottish Intercollegiate Guidelines Network (SIGN) (
www.sign.ac.uk/mehodology/filters.html#random).
There were no language restrictions on the searches.
Searching other resources
We searched:
• ClinicalTrials.gov http://clinicaltrials.gov/ct2/home for
ongoing and registered trials in the USA using the keywords
“Luteal phase support”;
• the World Health Organisation International Trials Registry
Platform www.who.int/trialsearch/Default.aspx for ongoing and
registered trials using the keywords “Luteal phase support”;
• conference abstracts on the ISI Web of Knowledge (http://
isiwebofknowledge.com) see Appendix 8;
• OpenSigle for grey literature from Europe (http://
opensigle.inist.fr) using the search string “((chorionic
gonadotropin) OR (progesterone)) AND (luteal phase)”;
• LILACS (http://regional.bvsalud.org/php/index.php?
lang=en) with the keywords “luteal phase support”;
• Clinicalstudyresults.org (www.clinicalstudyresults.org)
using the terms “In vitro fertilisation”, “Infertility” and
“Infertility, female”.
Data collection and analysis
Selection of studies
Titles and abstracts were screened independently by two review
authors (MvdL, MM) to exclude studies that were clearly irrele-
vant. The full texts of potentially eligible studies were retrieved for
further independent scrutiny by two review authors (MvdL, MM)
and compliance with the inclusion criteria was checked using the
study eligibility form, see Appendix 9. The reasons for exclusions
are provided in the table ’Characteristics of excluded trials’. When
it was unclear whether a study was eligible the original authors
were contacted. Disagreements were resolved by a third review au-
thor (CF).
Data extraction and management
Data were extracted using a data extraction form, see Appendix
10, designed and pilot-tested by the review authors. In the case
of multiple publications, studies were referenced by their main
trial report and the references were linked. The original authors
were contacted if further information was required. Three review
authors (MvdL, MM, KB) independently extracted data and dis-
agreements were resolved by the other review authors.
Assessment of risk of bias in included studies
Risk of biaswas assessedwith regard to sequence generation, alloca-
tion, blinding of participants and personnel, blinding of outcome
assessment, completeness of outcome data, selective reporting and
other potential sources of bias. Conclusions were summarised in
a ’Risk of bias’ table, see Appendix 11. Review authors judged all
six domains as at ’Low risk’, ’High risk’ or ’Unclear risk’ of bias,
and described the methods used in the table. Where information
was missing, the authors of the studies were contacted.
• Random sequence generation (selection bias)
◦ Proper methods included using a computer random
number generator, coin tossing, throwing dice, shuffling cards or
envelopes
◦ Allocation by judgement of clinician, preference of
participant, lab tests, date of birth, record number, and
inadequate sequence generation such as day of week were not
sufficient
• Allocation concealment (selection bias)
◦ Proper methods were sequentially numbered drug
containers of identical appearance, numbered opaque sealed
envelopes or secure third party randomisation such as telephone
or computer allocation
◦ Prior knowledge of the allocation because of either an
open random allocation schedule or alternation, rotation etc
were not sufficient
• Blinding of participants and personnel (performance bias)
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◦ Low risk of bias when blinding of clinicians and
participants (where possible) was ensured, or incomplete
blinding had no effect on the outcome measurement
◦ When there was no blinding and it had an influence
on the outcome measurement, there was a risk of bias
• Blinding of outcome assessment (detection bias):
◦ Low risk of bias when blinding of researchers (where
possible) was ensured, or incomplete blinding had no effect on
the outcome measurement
◦ When there was no blinding and it had an influence
on the outcome measurement, there was a risk of bias
• Incomplete outcome data (attrition bias)
◦ Low risk of bias when missing outcome data was
unlikely to be related to true outcomes or when all outcome data
were complete
◦ High risk of bias when reasons for missing outcome
data were likely to be related to true outcome or when the
proportion of missing outcome results compared with observed
event risk was enough to induce clinically relevant bias in
observed effect size
• Selective reporting (reporting bias)
◦ Low risk of bias when all pre-specified outcomes that
were of interest or described in the protocol were reported
◦ High risk of bias when not all pre-specified outcomes
were mentioned, reported outcomes were not pre-specified, or a
key outcome which would be expected was not reported
• Free of other bias
◦ Risk of other bias e.g. embryo transfer policies
different in the different arms of the study, had extreme baseline
imbalance
When the risk of bias tables were filled in, a risk of bias summary
figure was generated (Higgins 2011).
Measures of treatment effect
We retrieved only dichotomous data for this review and thus Peto
odds ratios (OR) were calculated with 95% confidence intervals
(CI).
Unit of analysis issues
The primary analysis was per woman randomised. Multiple live
births were counted as one live birth. Crossover data from the first
phase of the study was included. Where information was missing,
the authors of the studies were contacted.
Dealing with missing data
To obtain complete data, as much as possible, the original authors
were contacted. In case data were unobtainable, imputation was
undertaken for the primary outcome. Itwas assumed that therewas
no live birth when this was not reported.When data for secondary
outcomes were missing, only the available data were analysed.
Assessment of heterogeneity
Heterogeneity was assessed by a forest plot and the I2 statistic
according to the guidelines set out in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). If substantial
heterogeneity was detected, that is I2 ≥ 50%, a sensitivity analysis
was used to explore possible explanations.
Assessment of reporting biases
Publication bias was assessed by a funnel plot if there were more
than 10 included studies. An asymmetric funnel plot indicates
possible publication bias, though there may be other causes of
the asymmetry. Within study reporting bias was assessed if study
protocols were available and there was a difference between the
outcomes in the protocol and in the subsequent publication.
Data synthesis
The data from primary studies were combined using a fixed-effect
model in the following comparisons:
1. hCG versus placebo or no treatment;
2. progesterone versus placebo or no treatment;
3. progesterone versus hCG regimens:
i) progesterone versus hCG,
ii) progesterone versus progesterone and hCG;
4. progesterone versus progesterone and estrogen;
5. progesterone versus progesterone and GnRH agonist;
6. progesterone regimens:
i) IM progesterone versus oral progesterone,
ii) IM progesterone versus vaginal or rectal progesterone,
iii) vaginal or rectal progesterone versus oral progesterone,
iv) low-dose vaginal progesterone (≤ 100 mg) versus
high-dose vaginal progesterone (> 100 mg),
v) micronized progesterone versus synthetic
progesterone.
Subgroup analysis and investigation of heterogeneity
Data were analysed in the following subgroups as well.
1. Ovarian stimulation protocols including:
i) clomiphene citrate alone without GnRH agonists,
ii) human gonadotropins with clomiphene citrate
without GnRH agonists,
iii) human gonadotropins with or without GnRH
agonists,
iv) human gonadotropins with or without GnRH
antagonists.
2. Patients with previously failed cycles:
i) ≤ 2 failed ART cycles,
ii) > 2 failed ART cycles.
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3. Duration of progesterone:
i) stop at day of positive pregnancy test,
ii) given up to 12 weeks in women who conceive.
4. Number of embryos transferred:
i) single embryo transfer,
ii) > one embryo transferred.
Sensitivity analysis
A sensitivity analysiswas done todetermine the difference in results
caused by:
• eligibility restricted to studies without high-risk of bias,
• alternative imputation strategies had been adopted,
• studies with outlying results.
Overall quality of the body of evidence: Summary of
findings table
Wehave prepared Summary of findings tables using GRADEPRO
or Guideline Development Tool software. These tables evaluated
the overall quality of the body of evidence for the primary review
outcomes, using GRADE criteria (study limitations (i.e. risk of
bias), consistency of effect, imprecision, indirectness and publi-
cation bias). Judgements about evidence quality (high, moderate
or low) have been justified, documented, and incorporated into
reporting of results for each outcome.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Our search was done on February 17, 2011 (using the strings
reported in the appendices Appendix 1; Appendix 2; Appendix 3;
Appendix 4; Appendix 5; Appendix 6; Appendix 7; Appendix 8
and OpenSigle and LILACS). It identified 715 studies, while five
studies were found using other methods, like handsearching.
On the website ClinicalTrials.gov we found 14 ongoing studies
after using the keywords “luteal phase support”. Three studies
did not have sufficient contact details, the authors of one study
(NCT00708539) replied but did not have any data available yet.
Two other studies (NCT01007851; NCT01177904) sent us their
data, but it turned out they were already published as confer-
ence abstracts (Ata 2008; Kohls 2010) and therefore we combined
the received data with the abstracts. The World Health Orga-
nization International Trials Registry Platform, searched with the
keywords “luteal phase support”, only brought up studies which
were already found at ClinicalTrials.gov. Clinicalstudyresults.org
was searched using the terms “in vitro fertilisation”, “infertility”
and “infertility, female” but did not show any relevant studies.
After removal of duplicates there were 221 studies left for screen-
ing. We excluded 59 clearly irrelevant studies. From the other 162
studies the full-text articles were obtained and fully reviewed. All
quasi-randomised trials were excluded, together with the articles
which did not meet our inclusion criteria. A total of 69 articles
were included (See Figure 1 for a study flow diagram).
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Figure 1. Study flow diagram.
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Included studies
Sixty-nine studies were included, all randomised controlled trials.
We did not find any crossover trials to include. In total 16,327
womenwere includedwith amean age of 32.5 years. The inclusion
and exclusion criteria of the studies varied. Some studies included
women with polycystic ovarian syndrome (PCOS), which was an
exclusion criterion in other studies. A few studies used women
undergoing their first cycle while most studies included women
who had already undergone ART. Overall a mean of 2.55 embryos
per woman were transferred, mostly with a maximum of three or
four embryos.
Eight studies investigated down regulation using GnRH an-
tagonists (Ceyhan 2008; Engmann 2008; Fatemi 2006; Geber
2007; Isik 2009; Rodriguez-Pezino 2004; Serna 2008; Tesarik
2006), six studies did not use down regulation with GnRH ana-
logues (Colwell 1991; Hurd 1996; Kupferminc 1990; Lewin
1994; Torode 1987; Wong 1990); clomiphene citrate, human
menopausal gonadotropin (hMG) or both were used in most of
those studies. Forty-three studies investigatedGnRHagonists. The
other studies did not define the down regulation protocol used.
For 17 studies only the abstract was published (Albert 1991;
Caligara 2007; Dunstone 1999; Geber 2007; Geusa 2001;
Kohls 2010; Loh 1996; Macrolin 1993; Miller 2010; Porcu
2003; Rodriguez-Pezino 2004; Saucedo 2000; Saucedo 2003;
Stadtmauer 2010; Strehler 1999; Sumita 2003; Ugur 2001),
the other studies were full text journal publications. Only eight
studies were multi-centre studies (Belaisch-Allart 1990; Doody
2009; Elgindy 2010; Kleinstein 2005; Miller 2010; Pouly 1996;
Stadtmauer 2010; Zegers-Hochschild 2000).
Ten of our included studies were carried out in the United
States of America (Albert 1991; Doody 2009; Engmann 2008;
Goudge 2010; Hurd 1996; Licciardi 1999; Miller 2010; Propst
2001; Stadtmauer 2010; Yanushpolsky 2010). Six studies were
from Turkey (Ata 2008; Ceyhan 2008; Gorkemli 2004; Isik
2009; Isikoglu 2007; Ugur 2001) and seven from Italy (Abate
1999; Abate 1999a; Artini 1995; Dal Prato 2008; Geusa 2001;
Perino 1997; Porcu 2003). Nineteen studies were done in other
European countries: Belgium (Fatemi 2006; Pirard 2006), Fin-
land (Vimpeli 2001), France (Belaisch-Allart 1987; Belaisch-Allart
1990; Macrolin 1993; Pouly 1996), Germany (Kleinstein 2005;
Ludwig 2001; Ludwig 2002; Strehler 1999), Greece (Drakakis
2007), the Netherlands (Beckers 2000), Spain (Caligara 2007;
Kohls 2010; Martinez 2000; Serna 2008; Tesarik 2006) and the
UK (Dunstone 1999; Tay 2005). Eleven studies were carried out
in Asia: China (Lam 2008; Ng 2003; Ng 2007; Wong 1990),
India (Chakravarty 2005; Ganesh 2011; Patki 2007; Sumita
2003), Japan (Fujimoto 2002; Iwase 2008) and Singapore (Loh
1996). We also found studies from Australia (Torode 1987),
Brasil (Geber 2007; Geber 2007a), Canada (Colwell 1991), Egypt
(Aboulghar 2008; Elgindy 2010), Israel (Friedler 1999; Golan
1993; Kupferminc 1990; Lewin 1994), Jordan (Qublan 2008),
Mexico (Rodriguez-Pezino 2004; Saucedo 2000; Saucedo 2003)
and a multi-centre, multi-national study from Chile, Colombia
and Brazil (Zegers-Hochschild 2000).
Excluded studies
Eighty-five studies did not meet our inclusion criteria and were
excluded from the review. In accordance with the guidelines of
the MDSG, we excluded all quasi-randomised trials (Anserini
2001; Anthony 1993; Buvat 1988; Buvat 1990; Herman 1990;
Herman 1996; Leeton 1985; Mahadevan 1985; McBain 1987;
Polson 1992; Smith 1989; Smitz 1993; Yovich 1984; Yovich 1985;
Yovich 1991) which were included in the previous review (Daya
2004). All studies including GIFT or ZIFT in more than 20% of
the cycles, or which did not mention their percentage of GIFT
or ZIFT cycles, were excluded (Allen 2004; Araujo 1994; Araujo
Filho 1996; Smitz 1988; Smitz 1992; van Steirteghem 1988).
Risk of bias in included studies
See the ’Summary of findings’ tables for an overall assessment of
the quality of the included studies. There is a table for each com-
parison (Summary of findings for themain comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6). See also the risk
of bias graph (see Figure 2) and risk of bias summary (see Figure
3) for an overview.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Thirty-seven studies did not report their method of randomi-
sation. The ones which did report their method mostly used
computerized randomisation (Ata 2008; Caligara 2007; Ceyhan
2008; Engmann 2008; Fatemi 2006; Gorkemli 2004; Isik 2009;
Isikoglu 2007; Iwase 2008; Kleinstein 2005; Kohls 2010; Lam
2008; Ludwig 2002; Martinez 2000; Ng 2003; Ng 2007; Pirard
2006; Pouly 1996; Serna 2008; Tesarik 2006; Yanushpolsky 2010;
Zegers-Hochschild 2000). Randomisation lists or tableswere often
used (Belaisch-Allart 1987; Belaisch-Allart 1990; Ludwig 2001;
Qublan 2008) and a third party or study investigator was also
used (Aboulghar 2008; Dal Prato 2008; Ganesh 2011). Doody
2009 used a telephone-based electronic interactive voice response
system and Elgindy 2010 and Propst 2001 used permuted block
randomisation.
Thirty-nine studies did not report their method of allocation con-
cealment. Numbered, sealed envelopes were used most of the
time (Aboulghar 2008; Ata 2008; Beckers 2000; Dal Prato 2008;
Elgindy 2010; Engmann 2008; Ganesh 2011; Geber 2007; Geber
2007a; Goudge 2010; Hurd 1996; Kleinstein 2005; Lam 2008;
Ng 2003; Ng 2007; Pirard 2006; Propst 2001; Qublan 2008;
Serna 2008; Tesarik 2006). Caligara 2007 used a phone call to an
unrelated department, Ceyhan 2008 central consultation, Doody
2009 a telephone-based electronic interactive voice response sys-
tem, Isik 2009 used a third party nurse and Isikoglu 2007, Lam
2008 and Yanushpolsky 2010 concealed allocation via an onsite
computer system utilising locked files.
Fatemi 2006 and Ludwig 2002 were the only studies reporting
that they used a non-concealed randomisation list.
Blinding
Ten studies mentioned that they used blinding (Ata 2008;
Belaisch-Allart 1990; Colwell 1991; Doody 2009; Ganesh 2011;
Geber 2007; Geber 2007a; Isik 2009; Isikoglu 2007; Tesarik
2006). The other studies did not blind their personnel, researchers
and participants (Aboulghar 2008; Caligara 2007; Ceyhan 2008;
Dal Prato 2008; Doody 2009; Engmann 2008; Fatemi 2006;
Ganesh 2011; Kleinstein 2005; Kohls 2010; Lam 2008; Miller
2010; Ng 2003; Ng 2007; Pirard 2006; Propst 2001; Serna 2008;
Yanushpolsky 2010) or did not mention blinding. The studies of
Patki 2007 and Qublan 2008 were placebo controlled but did not
specify the use of blinding. The main reasons reported (either in
the paper or after contacting the original authors) for not blinding
was that the authors felt it was difficult because of the different
routes of administration. We feel it is possible to use proper blind-
ing by using a double-dummy design.
Incomplete outcome data
Twenty-eight studies reported the number of and reasons for with-
drawal or reported that there were no drop-outs. Some studies in-
cluded a flow diagram clearly showing the exclusions, inclusions,
withdrawals and the reasons (Ata 2008; Beckers 2000; Ceyhan
2008; Colwell 1991; Dal Prato 2008; Doody 2009; Elgindy 2010;
Engmann 2008; Fatemi 2006; Ganesh 2011; Geber 2007; Geber
2007a; Golan 1993; Goudge 2010; Isik 2009; Isikoglu 2007;
Kleinstein 2005; Kohls 2010; Lam 2008; Ng 2003; Ng 2007;
Pirard 2006; Pouly 1996; Propst 2001; Serna 2008; Tesarik 2006;
Torode 1987; Yanushpolsky 2010). Qublan 2008 reported that
there were more participants recruited than analysed, but did not
report the reasons.
Live birth was only reported in 15 studies (Abate 1999; Abate
1999a; Beckers 2000; Chakravarty 2005; Dal Prato 2008; Doody
2009; Golan 1993;Goudge 2010; Isik 2009; Lewin 1994; Ludwig
2001; Pouly 1996; Propst 2001;Qublan2008; Zegers-Hochschild
2000). All studies reported (clinical) pregnancy except for five
studies which used ongoing pregnancy as their main outcome
(Colwell 1991; Fatemi 2006; Kohls 2010; Serna 2008; Tay 2005).
Selective reporting
As stated before, there was only an abstract available for 17 studies,
which meant there was a high risk of selective reporting. Most
studies reported their planned outcomes, except for 17 (Abate
1999; Artini 1995; Beckers 2000; Belaisch-Allart 1987; Belaisch-
Allart 1990; Drakakis 2007; Friedler 1999; Golan 1993; Goudge
2010;Hurd 1996;Kupferminc 1990; Lewin 1994; Licciardi 1999;
Perino 1997; Tay 2005; Torode 1987; Vimpeli 2001). Ganesh
2011 and Wong 1990 reported outcomes in the results section
that were different from those reported in the methods section.
Other potential sources of bias
Four studies were supported by the pharmaceutical companies,
which supplied the investigated interventions (Doody 2009;
Miller 2010; Propst 2001; Stadtmauer 2010). Two studies were
supported by a grant from a pharmaceutical company (Ludwig
2002; Vimpeli 2001), Kleinstein 2005 was supported by a phar-
maceutical company but this company does not supply the inves-
tigated products.
We looked at the comparisons 3.2 Progesterone versus hCG regi-
mens, outcome clinical pregnancy rate (CPR); 6.2.1 Progesterone
regimens, outcome CPR: IM progesterone versus vaginal or rectal
progesterone; and 6.2.4 Progesterone regimens, outcome CPR:
low dose vaginal progesterone versus high dose vaginal proges-
terone for publication bias as these three comparisons had more
than 10 included studies. We did this by making a funnel plot (see
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Figure 4; Figure 5). Figure 4 shows the majority of studies around
the pooled estimate, showing that different sizes of studies were
included. Although one study (Golan 1993) seemed to be out of
the expected pattern, we did not see asymmetry and therefore this
funnel plot indicated a small risk of publication bias. Figure 5
shows the majority of the studies around the pooled estimate with
the studies reasonably equally divided on both sides. There is quite
a large space at the lower side of the graph, which means that small
studies may not be published. Overall the funnel plot indicated
a small risk of publication bias. Figure 6 shows the majority of
the studies around the pooled estimate with all studies reasonably
equally divided on both sides. This funnel plot also showed that
small studies may not be published. Overall it indicated a small
risk of publication bias.
Figure 4. Funnel plot of comparison: 2 Progesterone versus hCG, outcome: 2.2 Clinical Pregnancy Rate.
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Figure 5. Funnel plot of comparison: 6 Progesterone regimens, outcome: 6.2 Clinical Pregnancy Rate.
Effects of interventions
See: Summary of findings for the main comparison Human
chorionic gonadotropin (hCG) versus placebo or no treatment for
assisted reproduction cycles; Summary of findings 2Progesterone
versus placebo or no treatment for assisted reproduction cycles;
Summary of findings 3 Progesterone versus hCG regimens for
assisted reproduction cycles; Summary of findings 4Progesterone
versus progesterone + estrogen for assisted reproduction cycles;
Summary of findings 5 Progesterone versus progesterone +
GnRH agonist for assisted reproduction cycles; Summary of
findings 6 Progesterone regimens for luteal phase support
All data were entered into six comparisons, separated into the six
previously stated different outcomes. We also analysed data in the
previously stated subgroupswith theCPRas outcome, as all studies
except five (Colwell 1991; Fatemi 2006; Kohls 2010; Serna 2008;
Tay 2005) reported this outcome.
1. hCG versus placebo or no treatment
1.1 Live birth rate
One study (Beckers 2000) with 6 events (3 in hCG group, 3 in
placebo group) in 38 participants: Peto OR of 2.25 (95% CI 0.37
to 13.80).
This showed no evidence of effect for this outcome. See Figure 6
for details of this comparison.
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Figure 6. Forest plot of comparison: 1 hCG versus placebo or no treatment, outcome: 1.1 Live Birth Rate.
1.2 Clinical pregnancy rate(CPR)
Five studies (Artini 1995; Beckers 2000; Belaisch-Allart 1990;
Kupferminc 1990; Torode 1987) with 140 events (75 in hCG
group, 65 in placebo group) in 746 participants: Peto OR of 1.30
(95% CI 0.90 to 1.88).
This showed no evidence of effect for this outcome. See Analysis
1.2 for details of this comparison.
1.3 Ongoing pregnancy rate
Three studies (Beckers 2000; Belaisch-Allart 1990; Kupferminc
1990) with 81 events (49 in hCG group, 32 in placebo group) in
527 participants: Peto OR of 1.75 (95% CI 1.09 to 2.81).
This suggested a significant effect in favour of hCG. See Analysis
1.3 for details of this comparison.
1.4 Miscarriage rate
Two studies (Beckers 2000; Kupferminc 1990) with 7 events (4
in hCG group, 3 in placebo group) in 140 participants: Peto OR
of 1.49 (95% CI 0.32 to 6.85).
This showed no evidence of effect for this outcome. See Analysis
1.4 for details of this comparison.
1.5 Ovarian hyperstimulation syndrome (OHSS)
One study (Belaisch-Allart 1990) with 38 events (30 in hCG
group, 8 in placebo group) in 387 participants: Peto OR of 3.62
(95% CI 1.85 to 7.06).
This result showed a significant effect in favour of placebo. As this
result was based on one study only it should be interpreted with
caution. See Analysis 1.5 for details of this comparison.
1.6 Multiple pregnancy
None of the studies reported this outcome.
1.7 Subgroup analysis 1: ovarian stimulation protocols (clinical preg-
nancy rate)
Five studies were included (Artini 1995; Beckers 2000; Belaisch-
Allart 1990; Kupferminc 1990; Torode 1987): Peto OR of 1.30
(95% 0.90 to 1.88).
This comparison showed no evidence of effect for the different
subgroups. See Analysis 1.7 for details of this comparison.
1.8 Subgroup analysis 2: patients with previously failed cycles
(clinical pregnancy rate)
No data were available for this subgroup analysis.
1.9 Subgroup analysis 3: duration of progesterone (clinical pregnancy
rate)
Not applicable.
1.10 Subgroup analysis 4: number of embryos transferred (clinical
pregnancy rate)
No data were available for this subgroup analysis.
2. Progesterone versus placebo or no treatment
2.1 Live birth rate
One study (Abate 1999a) with 17 events (15 in progesterone
group, 2 in placebo or no treatment group) in 156 participants:
Peto OR of 2.95 (95% CI 1.02 to 8.56).
This suggested a significant effect in favour of progesterone. See
Figure 7 for details of this comparison.
18Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 7. Forest plot of comparison: 1 Progesterone versus placebo or no treatment, outcome: 1.1 Live
Birth Rate.
2.2 Clinical pregnancy rate
Seven studies (Abate 1999; Abate 1999a; Artini 1995; Belaisch-
Allart 1987;Hurd 1996; Kupferminc 1990;Wong 1990)with 158
events (106 in progesterone group, 52 in placebo or no treatment
group) in 841 participants: Peto OR of 1.83 (95% CI 1.29 to
2.61).
This suggested a significant effect favouring progesterone. See
Analysis 2.2 for details of this comparison.
2.3 Ongoing pregnancy rate
Five studies (Abate 1999a; Belaisch-Allart 1987; Colwell 1991;
Hurd 1996; Kupferminc 1990)with 91 events (61 in progesterone
group, 30 in placebo or no treatment group) in 642 participants:
Peto OR of 1.87 (95% CI 1.19 to 2.94).
This suggested a significant effect favouring progesterone. See
Analysis 2.3 for details of this comparison.
2.4 Miscarriage rate
Three studies (Belaisch-Allart 1987; Colwell 1991; Kupferminc
1990) with 19 events (10 in progesterone group, 9 in placebo or
no treatment group) in 425 participants: Peto OR of 1.19 (95%
CI 0.47 to 2.99).
This showed no evidence of effect for this outcome. See Analysis
2.4 for details of this comparison.
2.5 Ovarian hyperstimulation syndrome (OHSS)
None of the studies reported this outcome.
2.6 Multiple pregnancy
One study (Colwell 1991) with 1 event (in progesterone group)
in 34 participants: Peto OR of 17.00 (95% CI 0.28 to 1027.28]
This showed no evidence of effect for this outcome. See Analysis
2.6 for details of this comparison.
2.7 Subgroup analysis 1: ovarian stimulation protocols
(clinical pregnancy rate)
Seven studies were included (Abate 1999; Abate 1999a; Artini
1995; Belaisch-Allart 1987; Hurd 1996; Kupferminc 1990;Wong
1990): Peto OR of 1.83 (95% CI 1.29 to 2.61).
Subgroup 2.7.3 human gonadotropins with or without GnRH
agonists showed a significant effect in favour of progesterone: Peto
OR of 1.90 (95% CI 1.21 to 2.99), which was strengthened when
we did not take the study without GnRH agonists (Kupferminc
1990) into account: Peto OR of 2.37 (95% CI 1.38 to 4.07). See
Analysis 2.7 for details of this comparison.
2.8 Subgroup analysis 2: patients with previously failed cycles
(clinical pregnancy rate)
No data were available for this subgroup analysis.
2.9 Subgroup analysis 3: duration of progesterone (clinical
pregnancy rate)
Seven studies were included (Abate 1999; Abate 1999a; Artini
1995; Belaisch-Allart 1987; Hurd 1996; Kupferminc 1990;Wong
1990): Peto OR of 1.83 (95% CI 1.29 to 2.61).
Subgroup1.9.2up to12weekswhenpregnant showed a significant
effect in favour of progesterone: Peto OR of 2.07 (95% CI 1.35
to 3.17). See Analysis 2.9 for details of this comparison.
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2.10 Subgroup analysis 4: number of embryos transferred
(clinical pregnancy rate)
No data were available for this subgroup analysis.
3. Progesterone versus hCG regimens
3.1 Live birth rate
Studies comparing progesterone with hCG regimens showed no
evidence of a difference between the groups for this outcome. See
Figure 8 for details of this comparison.
Figure 8. Forest plot of comparison: 3 Progesterone versus hCG regimens, outcome: 3.1 Live Birth Rate.
3.1.1 versus hCG
Two studies (Golan 1993; Ludwig 2001) with 15 events (4 in
progesterone group, 11 in hCG group) in 203 participants: Peto
OR of 0.41 (95% CI 0.14 to 1.18).
This showed no evidence of a difference between the groups.
3.1.2 versus progesterone + hCG
One study (Ludwig 2001) with 8 events (3 in progesterone group,
5 in progesterone + hCG group) in 132 participants: Peto OR of
0.52 (95% CI 0.12 to 2.16).
This showed no evidence of a difference between the groups.
3.2 Clinical pregnancy rate
Studies comparing progesterone with hCG regimens showed no
evidence of a difference between the groups for this outcome. See
Analysis 3.2 for details of this comparison.
3.2.1 versus hCG
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Ten studies (Albert 1991; Artini 1995; Golan 1993; Kupferminc
1990; Lam 2008; Loh 1996; Ludwig 2001; Martinez 2000; Ugur
2001; Vimpeli 2001) with 391 events (218 in progesterone group,
173 in hCG group) in 1448 participants: Peto OR of 1.14 (95%
CI 0.90 to 1.45).
This showed no evidence of a difference between the groups. See
Figure 16 for details of this comparison.
Because this comparison included 10 studies, we made a funnel
plot to determine the risk of publication bias (see Figure 4). This
is assessed in the section Selective reporting (reporting bias). We
concluded it showed a small risk of publication bias.
We did a sensitivity analysis for studies with an outlying result
(Golan 1993), see Table 1. This did not show a significant differ-
ence: Peto OR of 1.19 (95% CI 0.94 to 1.52).
3.2.2 versus progesterone + hCG
Seven studies (Caligara 2007; Fujimoto 2002; Geber 2007;
Ludwig 2001; Macrolin 1993; Ugur 2001; Wong 1990) with 342
events (169 in progesterone group, 173 in progesterone + hCG
group) in 1080 participants: Peto OR of 0.96 (95% CI 0.74 to
1.25).
This showed no evidence of a difference between the groups
3.3 Ongoing pregnancy rate
Studies comparing progesterone with hCG regimens showed no
evidence of a difference between the groups for this outcome. See
Analysis 3.3 for details of this comparison.
3.3.1 versus hCG
Three studies (Kupferminc 1990; Ludwig 2001; Tay 2005) with
100 events (67 in progesterone group, 33 in hCG group) in 413
participants: Peto OR of 1.09 (95% CI 0.66 to 1.80).
This showed no evidence of a difference between the groups.
3.3.2 versus progesterone + hCG
Two studies (Ludwig 2001; Macrolin 1993) with 85 events (44
in progesterone group, 41 in progesterone + hCG group) in 434
participants: Peto OR of 1.04 (95% CI 0.65 to 1.68).
This showed no evidence of a difference between the groups.
3.4 Miscarriage rate
Studies comparing progesterone with hCG regimens showed no
evidence of effect for this outcome. See Analysis 3.4 for details of
this comparison.
3.4.1 versus hCG
Five studies (Golan 1993; Kupferminc 1990; Lam 2008; Ludwig
2001; Martinez 2000) with 37 events (21 in progesterone group,
16 in hCG group) in 770 participants: Peto OR of 1.34 (95% CI
0.69 to 2.60).
This showed no evidence of a difference between the groups.
3.4.2 versus progesterone + hCG
One study (Ludwig 2001) with 8 events (4 in progesterone group,
4 in progesterone + hCG group) in 132 participants: Peto OR of
0.88 (95% CI 0.21 to 3.66).
This showed no evidence of a difference between the groups. We
felt that this study had a very high number of miscarriages. There-
fore the results between live birth and the clinical pregnancy and
ongoing pregnancy rates were not consistent.
3.5 Ovarian hyperstimulation syndrome (OHSS)
Studies comparing progesteronewith hCG regimens showed some
evidence of effect for this outcome but should be interpreted with
caution as there was a disagreement between the studies. See
Analysis 3.5 for details of this comparison.
3.5.1 versus hCG
Four studies (Albert 1991; Ludwig 2001; Martinez 2000; Ugur
2001)with 94 events (30 in progesterone group, 42 in hCGgroup)
in 706 participants: Peto OR of 0.63 (95% CI 0.38 to 1.03).
This showed no evidence of a difference between the groups.
3.5.2 versus progesterone + hCG
Three studies (Ludwig 2001; Macrolin 1993; Ugur 2001) with
55 events (18 in progesterone group, 37 in progesterone + hCG
group) in 713 participants: Peto OR of 0.45 (95% CI 0.26 to
0.79).
This suggested a significant effect in favour of progesterone.
Heterogeneity was detected, I2 = 76%. Ugur 2001 was the largest
study in this comparison with the most weight. We only had an
abstract for this study so it had a high risk of bias. All three studies
separated their participants into a high risk of OHSS and low
risk of OHSS group. Study results differed in their direction of
effect. Therefore this result, although it is significant, should be
interpreted very cautiously.
We did a sensitivity analysis for studies with outlying results, which
in this case were Ludwig 2001 and Ugur 2001, see Table 2. When
we deleted Ludwig 2001 the outcome became more significant:
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Peto OR of 0.26 (95% 0.13 to 0.51) and there was no heterogene-
ity, but without Ugur 2001 the outcome was no longer significant.
Therefore this result should be interpreted very cautiously.
3.6 Multiple pregnancy
Studies comparing progesterone with hCG regimens showed no
evidence of a difference between the groups for this outcome. See
Analysis 3.6 for details of this comparison.
3.6.1 versus hCG
One study (Ludwig 2001) with 4 events (1 in progesterone group,
3 in hCG group) in 268 participants: Peto OR of 0.40 (95% CI
0.05 to 2.88).
This showed no evidence of a difference between the groups.
3.6.2 versus progesterone + hCG
One study (Ludwig 2001) with 4 events (1 in progesterone group,
3 in progesterone + hCG group) in 132 participants: Peto OR of
0.32 (95% CI 0.04 to 2.30).
This showed no evidence of a difference between the groups.
3.7 Subgroup analysis 1: ovarian stimulation protocols,
progesterone versus hCG (clinical pregnancy rate)
No data were available for this subgroup analysis.
3.8 Subgroup analysis 1: ovarian stimulation protocols,
progesterone versus progesterone + hCG (clinical pregnancy
rate)
Four studies were included (Fujimoto 2002; Ludwig 2001;
Macrolin 1993; Wong 1990): Peto OR of 0.91 (95% CI 0.65 to
1.29.
This comparison showed no evidence of a difference between the
subgroups. See Analysis 3.8 for details of this comparison.
3.9 Subgroup analysis 2: patients with previously failed
cycles, progesterone versus hCG (clinical pregnancy rate)
No data were available for this subgroup analysis.
3.10 Subgroup analysis 2: patients with previously failed
cycles, progesterone versus progesterone + hCG (clinical
pregnancy rate)
No data were available for this subgroup analysis.
3.11 Subgroup analysis 3: duration of progesterone,
progesterone versus hCG (clinical pregnancy rate)
Six studies were included (Artini 1995; Golan 1993; Kupferminc
1990; Ludwig 2001; Martinez 2000; Vimpeli 2001): Peto OR of
1.10 (95% CI 0.81 to 1.51).
This comparison showed no evidence of a difference between the
subgroups. See Analysis 3.11 for details of this comparison.
3.12 Subgroup analysis 3: duration of progesterone,
progesterone versus progesterone + hCG (clinical pregnancy
rate)
No data were available for this subgroup analysis.
3.13 Subgroup analysis 4: number of embryos transferred,
progesterone versus hCG (clinical pregnancy rate)
No data were available for this subgroup analysis.
3.14 Subgroup analysis 4: number of embryos transferred,
progesterone versus progesterone + hCG (clinical pregnancy
rate)
No data were available for this subgroup analysis.
4. Progesterone versus progesterone + estrogen
After data extraction we found that different routes of estrogen ad-
ministration were used, with different dosages of estrogen. There-
fore we decided to use subgroups based on route of administra-
tion.
4.1 Live birth rate
One study (Lewin 1994)with 21 events (11 inprogesterone group,
10 in progesterone + estrogen group) in 100 participants: PetoOR
of 1.13 (95% CI 0.43 to 2.94).
This showed no evidence of effect. See Figure 9 for details of this
comparison.
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Figure 9. Forest plot of comparison: 4 Progesterone versus progesterone + estrogen, outcome: 4.1 Live
Birth Rate.
4.2 Clinical pregnancy rate
Seven studies (Ceyhan 2008; Drakakis 2007; Elgindy 2010;
Engmann 2008; Gorkemli 2004; Lewin 1994; Yanushpolsky
2010) with 596 events (326 in progesterone group, 270 in proges-
terone + estrogen group) in 1345 participants: Peto OR of 0.80
(95% CI 0.63 to 1.01).
This showed no evidence of effect. See Analysis 4.2 for details of
this comparison.
Subgroup 4.2.2: transdermal supplementation suggested a benefit
from progesterone + estrogen, with a significantly lower rate in the
progesterone-only group Peto OR of 0.50 (95% CI 0.31 to 0.82).
Subgroup 4.2.4: transdermal and oral also suggested a benefit from
progesterone + estrogen, with a significantly lower rate in the pro-
gesterone-only group; but it was based on only one study: Peto
OR of 0.33 (95% CI 0.12 to 0.94)
Elgindy 2010 was a three-arm study comparing progesterone, pro-
gesterone + oral estrogen and progesterone + vaginal estrogen. To
make sure we did not duplicate any data, we divided the data of
the progesterone-only arm by two so half of the progesterone-only
events and participants were reported under the subgroup ’oral’
and the other half of the progesterone-only events and participants
were reported under the subgroup ’vaginal’.
Heterogeneity was detected in the subgroups 4.2.2: transdermal,
I2 = 63%; and 4.2.3: vaginal, I2 = 82%. This resulted in hetero-
geneity between the subgroups (I2 = 65.9%). The main difference
between studies was the route of administration and the dose, but
the 95% CIs still overlapped. This result should be interpreted
very cautiously.
Gorkemli 2004 has an outlying result, which might be caused by
the higher dose and frequency of estrogen supplementation (100
µg daily versus 2 µg twice weekly or 50 µg every 4 days in the other
studies using the transdermal route). We did a sensitivity analysis
for studies with outlying results, see Table 3. This did not change
the result into a significant result.
4.3 Ongoing pregnancy rate
Five studies (Ceyhan 2008; Engmann 2008; Fatemi 2006; Serna
2008; Yanushpolsky 2010) with 408 events (247 in progesterone
group, 161 in progesterone + estrogen group) in 993 participants:
Peto OR of 1.00 (95% CI 0.77 to 1.31).
This showed no evidence of a difference between the groups.. See
Analysis 4.3 for details of this comparison.
We did a sensitivity analysis for studies with high risk of bias, based
on allocation concealment, see Table 4 for details.
4.4 Miscarriage rate
Six studies (Drakakis 2007; Elgindy 2010; Engmann 2008; Fatemi
2006; Yanushpolsky 2010) with 157 events (98 in progesterone
group, 59 in progesterone + estrogen group) in 1281 participants:
Peto OR of 1.01 (95% CI 0.70 to 1.45].
This showed no evidence of a difference between the groups. See
Analysis 4.4 for details of this comparison.
We found high heterogeneity in the subgroup 4.4.3: vaginal, I2 =
75% .Overall heterogeneity was I2 = 43%.
We did a sensitivity analysis for studies with high risk of bias, based
on allocation concealment. See Table 5 for details of the sensitivity
analysis without Fatemi 2006.
4.5 Ovarian hyperstimulation syndrome (OHSS)
One study (Ceyhan 2008) with 2 events (both in progesterone +
estrogen group) in 59 participants: PetoOR of 0.14 (95%CI 0.01
to 2.21).
This showed no evidence of a difference between the groups. See
Analysis 4.5 for details of this comparison.
4.6 Multiple pregnancy
None of the studies reported this outcome.
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4.7 Subgroup analysis 1: ovarian stimulation protocols
Seven studies were initially included (Ceyhan 2008; Drakakis
2007; Elgindy 2010; Engmann 2008; Gorkemli 2004; Lewin
1994; Yanushpolsky 2010). See Analysis 4.7. When these stud-
ies were pooled there was marked heterogeneity (I2=69%) among
studies using human gonadotrophins with or without GnRH ago-
nists (analysis 4.7.3). Gorkemli 2004 had an outlying result, pos-
sibly due to a difference in dose. Exclusion of Gorkemli 2004 re-
duced the I2 value in analysis 4.7.3 from 69% to 52% and the
overall I2 value in this subgroup analysis from 58% to 30%. There
was no evidence of effect (Peto OR 1.00, 95% CI 0.76 to 1.31).
No heterogeneity was detected between subgroups (i.e. analyses
4.7.1. to 4.7.4).
4.8 Subgroup analysis 2: patients with previously failed cycles
No data were available for this subgroup analysis.
4.9 Subgroup analysis 3: duration of progesterone
Seven studies were included (Ceyhan 2008; Drakakis 2007;
Elgindy 2010; Engmann 2008; Gorkemli 2004; Lewin 1994;
Yanushpolsky 2010). They were not pooled due to marked het-
erogeneity (I2=68%).
See Analysis 4.9 .
4.10 Subgroup analysis 4: number of embryos transferred
No data were available for this subgroup analysis.
5. Progesterone versus progesterone + GnRH agonist
5.1 Live birth rate
Three studies (Isik 2009; Isikoglu 2007; Qublan 2008) with 140
events (50 in progesterone group, 90 in progesterone + GnRH
agonist group) in 455 participants: PetoOR of 0.40 (95%CI 0.26
to 0.61).
This showed a benefit for progesterone + GnRH agonist, with sig-
nificantly fewer events in the progesterone group. However there
was marked heterogeneity for this analysis (I2=66%) and the result
should be interpreted with caution. See Figure 10 for details of
this comparison.
Figure 10. Forest plot of comparison: 5 Progesterone versus progesterone + GnRH agonist, outcome: 5.1
Live Birth Rate.
Subgroup 5.1.1: single dose includes one study (Isik 2009) with
39 events (13 in progesterone group, 26 in progesterone + GnRH
agonist group) in 154 participants: PetoOR of 0.36 (95%CI 0.17
to 0.77).
This showed a significant result in favour of progesterone +GnRH
agonist.
Subgroup 5.1.2: multiple dose included two studies (Isikoglu
2007; Qublan 2008) with 101 events (37 in progesterone group,
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64 in progesterone + GnRH agonist group) in 301 participants:
Peto OR of 0.42 (95% CI 0.2 to 0.70)..
This showed a significant result in favour of progesterone +GnRH
agonist. However there was marked heterogeneity for this analysis
(I2=82%) and the result should be interpreted with caution.
5.2 Clinical pregnancy rate
Six studies (Ata 2008; Isik 2009; Isikoglu 2007; Pirard 2006;
Qublan 2008; Tesarik 2006) with 664 events (302 in progesterone
group, 362 in progesterone + GnRH agonist group) in 1646 par-
ticipants: Peto OR of 0.74 [0.60, 0.90]
This suggested a significant result in favour of progesterone +
GnRH agonist. See Analysis 5.2 for details of this comparison.
We did a sensitivity analysis for studies with outlying results, see
Table 6 for results without Pirard 2006.
Subgroup 5.2.1: single dose included three studies with 542 events
(249 in progesterone group, 293 in progesterone + GnRH agonist
group) in 1324 participants: Peto OR of 0.75 (95% CI 0.60 to
0.93).
This showed a significant result in favour of progesterone +GnRH
agonist. Heterogeneity was detected in this subgroup (I2 = 69%).
All 95% confidence intervals overlapped but the result should be
interpreted with caution.
Subgroup 5.2.2: multiple dose included three studies with 122
events (53 in progesterone group, 69 in progesterone + GnRH
agonist group) in 322 participants: PetoOR of 0.67 (95%CI 0.42
to 1.07).
This showed a significant result in favour of progesterone +GnRH
agonist. Heterogeneity was detected in this subgroup (I2 = 67%).
All 95% confidence intervals overlapped but the results should be
interpreted with caution.
5.3 Ongoing pregnancy rate
Two studies (Ata 2008; Tesarik 2006) with 404 events (184 in
progesterone group, 220 in progesterone + GnRH agonist group)
in 1170 participants: Peto OR of 0.76 (95% CI 0.60 to 0.97). .
This suggested a significant effect in favour of progesterone +
GnRH agonists. See Analysis 5.3 for details of this comparison.
Heterogeneity was detected, I2 = 51%. However the 95% confi-
dence intervals for the two studies overlapped.
5.4 Miscarriage rate
One study (Qublan 2008) with 8 events (5 in progesterone group,
3 in progesterone + GnRH agonist group) in 120 participants:
Peto OR of 1.70 (95% CI 0.41 to 7.10).
This showed no evidence of a difference between the groups. See
Analysis 5.4 for details of this comparison.
5.5 Ovarian hyperstimualtion syndrome (OHSS)
None of the studies reported this outcome.
5.6 Multiple pregnancy
Two studies (Ata 2008; Isik 2009) with 107 events (50 in proges-
terone group, 57 in progesterone + GnRH agonist group) in 724
participants: Peto OR of 0.84 (95% CI 0.55 to 1.26).
This showed no evidence of effect. See Analysis 5.6 for details of
this comparison.
5.7 Subgroup analysis 1: ovarian stimulation protocols
(clinical pregnancy rate)
Six studies were included (Ata 2008; Isik 2009; Isikoglu 2007;
Pirard 2006; Qublan 2008; Tesarik 2006): Peto OR of 1.36 (95%
CI 1.11 to 1.66).
Subgroup 5.7.4: human gonadotropins with or without GnRH
antagonists suggested a significant effect in favour of GnRH ag-
onists: Peto OR of 0.74 (95% CI 0.60 to 0.90). See Analysis 5.7
for details of comparison.
As discussed before, this analysis seemed to indicate some hetero-
geneity, but all 95% confidence intervals overlapped.
5.8 Subgroup analysis 2: patients with previously failed cycles
(clinical pregnancy rate)
No data were available for this subgroup analysis.
5.9 Subgroup analysis 3: duration of progesterone (clinical
pregnancy rate)
Five studies were included (Ata 2008; Isik 2009; Isikoglu 2007;
Pirard 2006; Tesarik 2006): Peto OR of 0.78 (95% CI 0.63 to
0.96).
This suggested a significant result in favour of progesterone +
GnRH agonists. See Analysis 5.9 for details of this comparison.
5.10 Subgroup analysis 4: number of embryos transferred
(clinical pregnancy rate)
No data were available for this subgroup analysis.
6. Progesterone regimens
6.1 Live birth rate
See Figure 11 for details of this comparison.
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Figure 11. Forest plot of comparison: 6 Progesterone regimens, outcome: 6.1 Live Birth Rate.
26Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
6.1.1 Intramuscular (IM) versus oral
One study (Iwase 2008)with 7 events (3 in IMprogesterone group,
4 in oral progesterone group) in 40 participants: Peto OR of 0.71
(95% CI 0.14 to 3.57).
This showed no evidence of a difference between the groups.
We did a sensitivity analysis for studies with high risk of bias,
based on allocation concealment. See Table 7 for details of the
comparison without Iwase 2008.
6.1.2 IM versus vaginal or rectal
Four studies (Abate 1999a; Dal Prato 2008; Propst 2001; Zegers-
Hochschild 2000)with 346 events (167 in IMprogesterone group,
179 in vaginal or rectal progesterone group) in 1222 participants:
Peto OR of 1.17 (95% CI 0.91 to 1.51).
This showed no evidence of a difference between the groups.
Heterogeneity was detected, I2 = 60%.Dal Prato 2008 was a three-
arm study investigating IM progesterone versus vaginal gel 90 mg
daily versus vaginal gel 90 mg twice daily. We combined both
vaginal arms and compared themwith the IM arm. This third arm
in the original study had a higher dose of progesterone than in the
other studies. This might account for the heterogeneity.
6.1.3 Vaginal or rectal versus oral
Two studies (Chakravarty 2005; Pouly 1996)with 163 events (112
in vaginal or rectal progesterone group, 51 in oral progesterone
group) in 713 participants: Peto OR of 0.99 (95% CI 0.66 to
1.48).
This showed no evidence of a difference between the groups.
6.1.4 Low-dose vaginal (≤ 100 mg) versus high-dose vaginal
(> 100 mg)
Two studies (Dal Prato 2008; Doody 2009) with 528 events (185
in low dose group, 336 in high dose group) in 999 participants:
Peto OR of 0.99 (95% CI 0.79 to 1.24).
This showed no evidence of a difference between the groups..
Doody 2009 was a three-arm study comparing micronized pro-
gesterone vaginal gel 90 mg versus vaginal progesterone 100 mg
twice daily versus vaginal progesterone 100 mg three times daily.
We combined the two high-dose arms in this comparison.
6.1.5 Short protocol versus long protocol
One study (Goudge 2010) with 49 events (25 in short protocol
group, 24 in long protocol group) in 97 participants: Peto OR of
0.88 (95% CI 0.40 to 1.95).
This showed no evidence of a difference between the groups.
6.1.6 Micronized progesterone versus synthetic progesterone
Two studies (Chakravarty 2005; Iwase 2008) with 106 events (83
in micronized progesterone group, 23 in synthetic progesterone
group) in 470 participants: Peto OR of 0.90 (95% CI 0.52 to
1.56).
This showed no evidence of a difference between the groups.
We did a sensitivity analysis for studies with high risk of bias,
based on allocation concealment. See Table 8 for details of this
comparison without Iwase 2008.
6.2 Clinical pregnancy rate
See Analysis 6.2 for details of this comparison.
6.2.1 IM versus oral
Three studies (Iwase 2008; Licciardi 1999; Saucedo 2000) with
42 events (24 in IM progesterone group, 18 in oral progesterone
group) in 123 participants: Peto OR of 1.92 (95% CI 0.89 to
4.14).
This showed no evidence of a difference between the groups.
We did a sensitivity analysis for studies with high risk of bias,
based on allocation concealment. See Table 9 for details of the
comparison without Iwase 2008.
6.2.2 IM versus vaginalor rectal
Thirteen studies (Abate 1999a; Artini 1995; Dal Prato 2008;
Geusa 2001; Miller 2010; Perino 1997; Porcu 2003; Propst 2001;
Saucedo 2000; Saucedo 2003; Sumita 2003; Yanushpolsky 2010;
Zegers-Hochschild 2000) with 1098 events (548 in IM proges-
terone group, 550 in vaginal or rectal progesterone group) in 2932
participants: Peto OR of 1.14 (95% CI 0.97 to 1.33).
This showed no evidence of a difference between the groups.
Dal Prato 2008 was a three-arm study investigating IM proges-
terone versus vaginal gel 90 mg daily versus vaginal gel 90 mg
twice daily. We combined both vaginal arms and compared them
with the IM arm.
Because this comparison included more than 10 studies, we made
a funnel plot to determine the risk of publication bias (see Figure
5). This was assessed in the section ’Selective reporting (reporting
bias)’. We concluded that it showed a small risk of publication
bias.
We did a sensitivity analysis for studies with outlying results, see
Table 10 for details of this comparison without Perino 1997.
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6.2.3 Vaginal or rectal versus oral
Six studies (Chakravarty 2005; Friedler 1999; Ganesh 2011; Patki
2007; Pouly 1996; Saucedo 2000) with 801 events (484 in vaginal
or rectal progesterone group, 317 in oral progesterone group) in
2735 participants: Peto OR of 0.87 (95% CI 0.73 to 1.04).
This showed no evidence of a difference between the groups.
Heterogeneity was detected, I2 = 57%, which might have been
caused by Patki 2007 as it compared vaginal progesterone versus
vaginal progesterone + oral progesterone, although we did not find
a significant result in favour of high-dose vaginal progesterone
supplementation (see comparison 6.2.4: low dose vaginal versus
high dose vaginal). The two different routesmay have played a role
in this outlying result. Therefore this result should be interpreted
with caution.
6.2.4 Low-dose vaginal (≤ 100 mg) versus high-dose vaginal
(> 100 mg)
Twelve studies (Dal Prato 2008; Doody 2009; Dunstone 1999;
Ganesh 2011; Geber 2007a; Kleinstein 2005; Ludwig 2002;
Ng 2003; Ng 2007; Rodriguez-Pezino 2004; Stadtmauer 2010;
Strehler 1999) with 1846 events (840 in low dose group, 1006 in
high dose group) in 4973 participants: Peto OR of 1.04 (95% CI
0.92 to 1.17).
This showed no evidence of effect.
Doody 2009 was a three-arm study comparing micronized pro-
gesterone vaginal gel 90 mg versus vaginal progesterone 100 mg
twice daily versus vaginal progesterone 100 mg three times daily.
We combined the two high-dose arms in this comparison.
Because this comparison included more than 10 studies, we made
a funnel plot to determine the risk of publication bias (see Figure
5). This was assessed in the section Selective reporting (reporting
bias); we concluded it showed a small risk of publication bias.
We did a sensitivity analysis for studies with high risk of bias,
based on allocation concealment. See Table 11 for details about
this comparison without Ludwig 2002.
6.2.5 Short protocol versus long protocol
One study (Goudge 2010) with 61 events (32 in short protocol
group, 29 in long protocol group) in 97 participants: Peto OR of
0.99 (95% CI 0.43 to 2.24).
This showed no evidence of a difference between the groups.
6.2.6 Micronized progesterone versus synthetic progesterone
Four studies (Chakravarty 2005; Ganesh 2011; Iwase 2008; Patki
2007) with 698 events (426 in micronized progesterone group,
272 in synthetic progesterone group) in 2388 participants: Peto
OR of 0.79 (95% CI 0.65 to 0.96).
This suggested a significant result in favour of synthetic proges-
terone.
We did a sensitivity analysis for studies with high risk of bias,
based on allocation concealment. See Table 12 for details of this
comparison without Iwase 2008.
6.3 Ongoing pregnancy rate
See Analysis 6.3 for details of this comparison. There was marked
heterogeneity (I2=81%) for comparisons of IM versus vaginal/
rectal routes and the findings may not be reliable. There was also
heterogeneity (I2=63%) for comparisons of vaginal/rectal versus
oral routes, though confidence intervals overlapped.
6.3.1 IM versus oral
None of the studies reported this outcome.
6.3.2 IM versus vaginalor rectal
Four studies (Abate 1999a; Dal Prato 2008; Perino 1997;
Yanushpolsky 2010) with 410 events (204 in IM progesterone
group, 206 in vaginal or rectal progesterone group) in 1223 par-
ticipants: Peto OR of 1.34 (95% CI 1.05 to 1.61).
This suggested a significant result in favour of IM progesterone.
As noted above, marked heterogeneity was detected (I2 = 81%).
We did a sensitivity analysis for studies with outlying results, see
Table 13 for details of this comparison without Perino 1997.
6.3.3 Vaginal or rectal versus oral
Two studies (Friedler 1999; Pouly 1996)with 89 events (50 in vagi-
nal or rectal progesterone group, 39 in oral progesterone group)
in 346 participants: Peto OR of 1.45 (95% CI 0.89 to 2.34).
This showed no evidence of effect. As noted above, heterogeneity
was detected, I2 = 63%. The result was not significant and the
comparison included only two studies whose 95% confidence in-
tervals overlapped.
6.3.4 Low-dose vaginal (≤ 100 mg) versus high-dose vaginal
(> 100 mg)
Five studies (Dal Prato 2008; Doody 2009; Ludwig 2002;
Stadtmauer 2010; Tay 2005) with 1236 events (527 in low dose
group, 709 in high dose group) in 3034 participants: Peto OR of
0.99 (95% CI 0.85 to 1.15).
This showed no evidence of a difference between the groups..
Doody 2009 was a three-arm study comparing micronized pro-
gesterone vaginal gel 90 mg versus vaginal progesterone 100 mg
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twice daily versus vaginal progesterone 100 mg three times daily.
We combined the two high-dose arms in this comparison.
We did a sensitivity analysis for studies with high risk of bias,
based on allocation concealment. See Table 14 for details about
this comparison without Ludwig 2002.
6.3.5 Short protocol versus long protocol
One study (Goudge 2010) with 53 events (26 in short protocol
group, 27 in long protocol group) in 97 participants: Peto OR of
0.73 (95% CI 0.33 to 1.63).
This showed no evidence of effect.
6.3.6 Micronized progesterone versus synthetic progesterone
None of the studies reported this outcome.
6.4 Miscarriage rate
See Analysis 6.4 for details of this comparison.
6.4.1 IM versus oral
Three studies (Iwase 2008; Licciardi 1999; Saucedo 2000) with 5
events (3 in IM progesterone group, 2 in oral progesterone group)
in 123 participants: Peto OR of 0.60 (95% CI 0.10 to 3.56).
This showed no evidence of a difference between the groups.
Heterogeneity was detected (I2 = 54%), though all 95% confi-
dence intervals overlapped. All studies were small and Saucedo
2000 was an abstract only, with a high risk of bias. Therefore this
result should be interpreted with caution.
We did a sensitivity analysis for studies with high risk of bias,
based on allocation concealment. See Table 15 for details of the
comparison without Iwase 2008. We did a sensitivity analysis for
studies with outlying results, see Table 16 for details of the com-
parison without Licciardi 1999. In both sensitivity analyses the
results remained insignificant.
6.4.2 IM versus vaginal or rectal
Five studies (Dal Prato 2008; Miller 2010; Perino 1997; Saucedo
2000; Yanushpolsky 2010) with 126 events (55 in IM proges-
terone group, 71 in vaginal or rectal progesterone group) in 1324
participants: Peto OR of 0.85 [0.58, 1.25]
This showed no evidence of a difference between the groups.
We did a sensitivity analysis for studies with outlying results, see
Table 17 for details of this comparison without Saucedo 2000.
6.4.3 Vaginalor rectal versus oral
Four studies (Chakravarty 2005; Friedler 1999; Ganesh 2011;
Pouly 1996) with 109 events (76 in vaginal or rectal progesterone
group, 28 in oral progesterone group) in 2140 participants: Peto
OR of 1.18 [0.76, 1.85].
This showed no evidence of a difference between the groups.
Dal Prato 2008 was a three-arm study investigating IM proges-
terone versus vaginal gel 90 mg daily versus vaginal gel 90 mg
twice daily. We combined both vaginal arms and compared them
with the IM arm.
We did a sensitivity analysis for studies with outlying results, see
Table 18 for details of this comparison without Friedler 1999.
6.4.4 Low-dose vaginal (≤ 100 mg) versus high-dose vaginal
(> 100 mg)
Eight studies (Dal Prato 2008; Ganesh 2011; Geber 2007a;
Kleinstein 2005; Ludwig 2002;Ng 2007; Rodriguez-Pezino 2004;
Strehler 1999) with 103 events (45 in low dose group, 58 in high
dose group) in 2370 participants: Peto OR of 0.79 [0.53, 1.17]
This showed no evidence of a difference between the groups.
We did a sensitivity analysis for studies with high risk of bias,
based on allocation concealment. See Table 19 for details about
this comparison without Ludwig 2002.
6.4.5 Short protocol versus long protocol
None of the studies reported this outcome.
6.4.6 Micronized progesterone versus synthetic progesterone
Two studies (Chakravarty 2005; Ganesh 2011) with 86 events (66
in micronized progesterone group, 20 in synthetic progesterone
group) in 1793 participants: Peto OR of 1.16 [0.70, 1.91]
None of the studies reported this outcome.
6.5 Ovarian hyperstimulation syndrome (OHSS)
See Analysis 6.5 for details of this comparison.
6.5.1 IM versus oral
One study (Iwase 2008)with 2 events (1 in IMprogesterone group,
1 in oral progesterone group) in 40 participants: Peto OR of 1.00
(95% CI 0.06 to 16.58).
This showed no evidence of a difference between the groups.
We did a sensitivity analysis for studies with high risk of bias, based
on allocation concealment. See Table 20 for details.
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6.5.2 IM versus vaginal or rectal
None of the studies reported this outcome.
6.5.3 Vaginal or rectal versus oral
None of the studies reported this outcome.
6.5.4 Low-dose vaginal (≤ 100 mg) versus high-dose vaginal
(> 100 mg)
One study (Doody 2009) with 83 events (26 in low dose group,
57 in high dose group) in 1211 participants: Peto OR of 0.91
(95% CI 0.57 to 1.46).
This showed no evidence of a difference between the groups.
Doody 2009 was a three-arm study comparing micronized pro-
gesterone vaginal gel 90 mg versus vaginal progesterone 100 mg
twice daily versus vaginal progesterone 100 mg three times daily.
We combined the two high-dose arms in this comparison.
6.5.5 Short protocol versus long protocol
None of the studies reported this outcome.
6.5.6 Micronized progesterone versus synthetic progesterone
One study (Iwase 2008) with 2 events (1 in micronized proges-
terone group, 1 in synthetic progesterone group) in 40 partici-
pants: Peto OR of 1.00 (95% CI 0.06 to 16.58).
This showed no evidence of a difference between the groups.
We did a sensitivity analysis for studies with high risk of bias,
based on allocation concealment. See Table 21 for details of this
comparison without Iwase 2008.
6.6 Multiple pregnancy
See Analysis 6.6 for details of this comparison.
6.6.1 IM versus oral
Two studies (Iwase 2008; Licciardi 1999) with 14 events (10 in
IM progesterone group, 4 in oral progesterone group) in 83 par-
ticipants: Peto OR of 4.39 (95% CI 1.28 to 15.01).
This analysis favoured oral progesterone, with a significantly
higher rate of multiple pregnancies occurring in the IM proges-
terone group, but it included only two small studies so this result
should be interpreted with caution.
We did a sensitivity analysis for studies with high risk of bias,
based on allocation concealment. See Table 22 for details of the
comparison without Iwase 2008.
6.6.2 IM versus vaginalor rectal
One study (Zegers-Hochschild 2000) with 76 events (39 in IM
group, 37 in vaginal/rectal group) in 505 participants: Peto OR
of 0.97 (95% CI 0.60 to 1.59).
This showed no evidence of a difference between the groups.
6.6.3 Vaginalor rectal versus oral
One study (Pouly 1996) with 25 events (13 in vaginal or rectal
progesterone group, 12 in oral progesterone group) in 283 partic-
ipants: Peto OR of 1.13 (95% CI 0.50 to 2.58).
This showed no evidence of a difference between the groups.
6.6.4 Low -ose vaginal (≤ 100 mg) versus high-dose vaginal
(> 100 mg)
Four studies (Geber 2007a; Kleinstein 2005; Ng 2007; Strehler
1999) with 63 events (32 in lowdose group, 31 in high dose group)
in 905 participants: Peto OR of 0.95 (95% CI 0.57 to 1.58).
This showed no evidence of a difference between the groups.
6.6.5 Short protocol versus long protocol
Two studies (Goudge 2010; Kohls 2010) with 29 events (18 in
short protocol group, 11 in long protocol group) in 317 partici-
pants: Peto OR of 1.06 (95% CI 0.63 to 1.76).
This showed no evidence of a difference between the groups.
6.6.6 Micronized progesterone versus synthetic progesterone
None of the studies reported this outcome.
6.7 Subgroup analysis 1: ovarian stimulation protocols, IM
versus vaginal or rectal (clinical pregnancy rate)
Eleven studies were included (Abate 1999a; Artini 1995; Geusa
2001; Miller 2010; Perino 1997; Porcu 2003; Saucedo 2003;
Sumita 2003; Yanushpolsky 2010; Zegers-Hochschild 2000).
These studies were not pooled, as the forest plot showed differing
directions of effect and confidence intervals did not overlap. See
Analysis 6.7 for details of this comparison.
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6.8 Subgroup analysis 1: ovarian stimulation protocols, low-
dose vaginal (≤ 100 mg) versus high-dose vaginal (> 100 mg)
(clinical pregnancy rate)
Nine studies were included (Dal Prato 2008;Doody 2009;Ganesh
2011; Geber 2007a; Kleinstein 2005; Ng 2003; Ng 2007; Strehler
1999): Peto OR of 1.05 (95% CI 0.91 to 1.22).
This showed no evidence of a difference between these different
subgroups. See Analysis 6.8 for details of this comparison.
6.9 Subgroup analysis 2: patients with previously failed cycles
(clinical pregnancy rate)
No data were available for this subgroup analysis.
6.10 Subgroup analysis 3: duration of progesterone, IM versus
vaginal or rectal (clinical pregnancy rate)
Seven studies were included (Abate 1999a; Artini 1995; Dal Prato
2008; Perino 1997; Propst 2001; Sumita 2003; Yanushpolsky
2010). They were unsuitable for pooling, due to heterogeneity was
in both subgroups: I2 = 62% in the low-dose group, I2 = 87% in
the high-dose group, and also between subgroups (I2 = 72.2%).
See Analysis 6.10 for details of this comparison.
6.11 Subgroup analysis 3: duration of progesterone, vaginal
versus oral (clinical pregnancy rate)
Five studies were included (Chakravarty 2005; Friedler 1999;
Ganesh 2011; Patki 2007; Pouly 1996): PetoOR of 0.85 (95%CI
0.71 to 1.02). This showed no evidence of a difference between
the subgroups.
See Analysis 6.11 for details of this comparison.
6.12 Subgroup analysis 3: duration of progesterone, low-dose
vaginal (≤ 100 mg) versus high-dose vaginal (> 100 mg)
(clinical pregnancy rate)
Ten studies were included (Dal Prato 2008; Doody 2009; Ganesh
2011; Geber 2007a; Kleinstein 2005; Ludwig 2002; Ng 2003; Ng
2007; Stadtmauer 2010; Strehler 1999): Peto OR of 1.04 (95%
CI 0.92 to 1.17).
This showed no evidence of a difference between the subgroups.
See Analysis 6.12 for details of this comparison.
6.13 Subgroup analysis 4: number of embryos transferred
(clinical pregnancy rate)
No data were available for this subgroup analysis.
7. Funnel plots
For the comparisons with more than 10 included studies we con-
structed a funnel plot. Neither of the funnel plots (Figure 4; Figure
5) suggested publication bias.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Progesterone versus placebo/no treatment for assisted reproduction cycles
Patient or population: patients with assisted reproduction cycles
Settings:
Intervention: Progesterone versus placebo/no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Progesterone versus
placebo/no treatment
Live Birth Rate
Follow-up: 9 months
38 per 1000 104 per 1000
(39 to 253)
OR 2.95
(1.02 to 8.56)
156
(1 study)
⊕⊕©©
low1,2,3
Clinical Pregnancy Rate
Follow-up: 6 weeks
140 per 1000 230 per 1000
(174 to 298)
OR 1.83
(1.29 to 2.61)
841
(7 studies)
⊕⊕©©
low1,2,3
OHSS See comment See comment Not estimable 0
(0)
See comment
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was ’unclear’ therefore there might be limitations
2 Total number of events is less than 300
3 Number of studies is not sufficient to assess publication bias32
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Progesterone versus hCG regimens for assisted reproduction cycles
Patient or population: patients with assisted reproduction cycles
Settings:
Intervention: Progesterone versus hCG regimens
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Progesterone versus
hCG regimens
Live Birth Rate - versus
hCG
Follow-up: 9 months
103 per 1000 45 per 1000
(16 to 119)
OR 0.41
(0.14 to 1.18)
203
(2 studies)
⊕⊕©©
low1,2,3
Live Birth Rate - versus
progesterone + hCG
Follow-up: 9 months
81 per 1000 44 per 1000
(10 to 160)
OR 0.52
(0.12 to 2.16)
132
(1 study)
⊕⊕©©
low1,2,3
Clinical Pregnancy Rate
- versus hCG
Follow-up: 6 weeks
256 per 1000 282 per 1000
(236 to 333)
OR 1.14
(0.9 to 1.45)
1448
(10 studies)
⊕⊕⊕©
moderate1
Clinical Pregnancy Rate
- versus progesterone +
hCG
Follow-up: 6 weeks
320 per 1000 311 per 1000
(258 to 370)
OR 0.96
(0.74 to 1.25)
1080
(7 studies)
⊕⊕⊕©
moderate3,4
OHSS - versus hCG 126 per 1000 83 per 1000
(52 to 129)
OR 0.63
(0.38 to 1.03)
706
(4 studies)
⊕⊕⊕©
moderate1,2
OHSS - versus proges-
terone + hCG
105 per 1000 50 per 1000
(30 to 85)
OR 0.45
(0.26 to 0.79)
713
(3 studies)
⊕©©©
very low1,2,5
3
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*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was ’unclear’ therefore there might be limitations
2 Total number of events is less than 300
3 Number of studies is not sufficient to assess publication bias
4 Risk of bias was unclear or both high risk and low risk, there might be limitations
5 Heterogeneity = 71%
3
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Progesterone versus progesterone + estrogen for assisted reproduction cycles
Patient or population: patients with assisted reproduction cycles
Settings:
Intervention: Progesterone versus progesterone + estrogen
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Progesterone
versus progesterone +
estrogen
Live Birth Rate
Follow-up: 9 months
200 per 1000 220 per 1000
(97 to 424)
OR 1.13
(0.43 to 2.94)
100
(1 study)
⊕⊕©©
low1,2,3
Clinical Pregnancy Rate
Follow-up: 6 weeks
425 per 1000 372 per 1000
(318 to 430)
OR 0.8
(0.63 to 1.02)
1345
(7 studies)
⊕⊕©©
low3,4
OHSS 67 per 1000 10 per 1000
(1 to 137)
OR 0.14
(0.01 to 2.21)
59
(1 study)
⊕⊕©©
low2,3,5
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was ’unclear’ therefore there might be limitations
2 Total number of events is less than 300
3 Number of studies is not sufficient to assess publication bias3
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4 Although 95%CI overlap, heterogeneity is detected
5 Risk of bias was unclear or both high risk and low risk, there might be limitations
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
3
6
L
u
te
a
l
p
h
a
se
su
p
p
o
rt
fo
r
a
ssiste
d
re
p
ro
d
u
c
tio
n
c
y
c
le
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Progesterone versus progesterone + GnRH agonist for assisted reproduction cycles
Patient or population: patients with assisted reproduction cycles
Settings:
Intervention: Progesterone versus progesterone + GnRH agonist
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Progesterone
versus progesterone +
GnRH agonist
Live Birth Rate
Follow-up: 9 months
400 per 1000 215 per 1000
(153 to 292)
OR 0.41
(0.26 to 0.61)
455
(3 studies)
⊕⊕⊕©
moderate1,2
Clinical Pregnancy Rate
Follow-up: 6 weeks
438 per 1000 366 per 1000
(319 to 412)
OR 0.74
(0.6 to 0.9)
1646
(6 studies)
⊕⊕⊕©
moderate2,3
OHSS See comment See comment Not estimable 0
(0)
See comment
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Total number of events is less than 300
2 Number of studies is not sufficient to assess publication bias
3 Although 95%CI overlap, heterogeneity is detected37
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Progesterone regimens for luteal phase support
Patient or population:
Settings:
Intervention: Progesterone regimens
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Progesterone regimens
Live Birth Rate - IM ver-
sus Oral
Follow-up: 9 months
200 per 1000 151 per 1000
(34 to 472)
OR 0.71
(0.14 to 3.57)
40
(1 study)
⊕⊕©©
low1,2,3
Live Birth Rate - IM ver-
sus Vaginal/rectal
Follow-up: 9 months
267 per 1000 299 per 1000
(249 to 355)
OR 1.17
(0.91 to 1.51)
1222
(4 studies)
⊕©©©
very low1,2,3,4
Live Birth Rate - Vaginal/
rectal versus Oral
Follow-up: 9 months
229 per 1000 227 per 1000
(164 to 305)
OR 0.99
(0.66 to 1.48)
713
(2 studies)
⊕⊕©©
low2,3,5
Live Birth Rate - Low
dose vaginal versus high
dose vaginal
Follow-up: 9 months
356 per 1000 354 per 1000
(304 to 407)
OR 0.99
(0.79 to 1.24)
1485
(2 studies)
⊕⊕⊕©
moderate1,3
Live Birth Rate - Short
protocol versus longpro-
tocol
Follow-up: 9 months
522 per 1000 490 per 1000
(304 to 680)
OR 0.88
(0.4 to 1.95)
97
(1 study)
⊕⊕©©
low2,3,5
3
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Live Birth Rate - Mi-
cronized versus syn-
thetic
Follow-up: 9 months
232 per 1000 214 per 1000
(136 to 320)
OR 0.9
(0.52 to 1.56)
470
(2 studies)
⊕⊕©©
low2,3,5
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was unclear or both high risk and low risk, there might be limitations
2 Total number of events is less than 300
3 Number of studies is not sufficient to assess publication bias
4 Although 95%CI overlap, heterogeneity is detected
5 Risk of bias was ’unclear’ therefore there might be limitations
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D I S C U S S I O N
Summary of main results
This systematic review of all randomised controlled trials of luteal
phase support, from 1987 to 2011, had a broad range of subjects.
We therefore came up with six comparisons to make sure we in-
cluded as many studies as possible. Because we did not include
quasi-RCTs we had to exclude quite a few older studies, therefore
we have less evidence regarding the current standard luteal phase
protocols. For a complete overview see the ’Summary of findings’
tables (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6).
We can summarize the following results from our review.
Human chorionic gonadotropin (hCG) for luteal phase
support
Human chorionic gonadotropin (hCG) compared to placebo sug-
gested a significant result in favour of hCG for the ongoing preg-
nancy rate. The hCG is known to have a higher risk of OHSS.We
found this in two comparisons (1.5: hCG versus placebo or no
treatment; and 3.5.2: progesterone versus progesterone + hCG)
where the results showed a significant difference. Addition of hCG
to progesterone did not show any significant advantages or differ-
ences, except for the outcome OHSS. In that comparison proges-
terone was significantly favoured over progesterone + hCG; hCG
compared to progesterone showed no difference in effect.
Progesterone for luteal phase support
Progesterone had a significant positive effect on clinical pregnancy,
ongoing pregnancy and live birth rates. There were no significant
results when we compared progesterone with hCG.
Progesterone and estrogen for luteal phase support
Findings for progesterone and estrogen were inconsistent. Proges-
terone + oral estrogen did not have a significant effect on live birth
and pregnancy rates compared to progesterone alone, but both
transdermal and oral+transdermal estrogen supplementation sug-
gested a significant benefit from progesterone plus estrogen com-
pared to progesterone alone. Results for progesterone plus vaginal
estrogen versus progesterone alone were not statistically significant
but require very cautious interpretation as there was high hetero-
geneity (I2 =82%). There was no significant difference between
the groups for miscarriage or OHSS.
Progesterone and GnRH agonists for luteal phase support
A relatively newmethod of luteal phase support is GnRH agonists.
The pregnancy and live birth results were all significantly in favour
of progesterone +GnRHagonists. Therewere no significant results
for miscarriage and multiple pregnancy.
Different progesterone regimens
When we compared routes of progesterone administration, there
were no outstanding results. We found IM progesterone to have
more effect on the clinical pregnancy rate than oral and vaginal
or rectal progesterone, but none of these results were significant.
Vaginal progesterone is the most used formulation in Europe ac-
cording to a survey of 21 centres in Europe (Aboulghar 2008).
Sixteen centres used vaginal progesterone, three centres used IM
progesterone, one centre used oral progesterone and one hCG.
We found a lot of studies investigating Crinone 8% vaginal mi-
cronized progesterone gel. Therefore we conducted a comparison
investigating low-dose (≤ 100 mg) versus high-dose (> 100 mg)
vaginal progesterone. There was no evidence in favour of low or
high-dose vaginal progesterone.
The comparison and subgroup analysis regarding the duration of
progesterone administration gave differing results. In two compar-
isons (2.9: progesterone versus placebo or no treatment, and 6.10:
IM progesterone versus vaginal or rectal progesterone) the results
were significantly in favour of the short progesterone protocol,
but in subgroup analysis 5.9: progesterone versus progesterone +
GnRH agonist the results were significantly in favour of a long
progesterone protocol.
The results suggested a significant effect in favour of synthetic pro-
gesterone compared to micronized progesterone. The only syn-
thetic progesterone used was oral dydrogesterone.
The only significant result found regarding multiple pregnancy
was for the comparison of IMprogesteronewith oral progesterone.
It showed that IM progesterone causes more multiple pregnancies
than oral progesterone.
Pituitary desensitisation with GnRH agonists enhanced the sig-
nificant positive effect of progesterone compared to placebo or no
treatment. Comparing progesterone with progesterone + GnRH,
there was a significant result in favour of progesterone + GnRH
agonists when the cycle was down regulated with GnRH antago-
nists.
Overall completeness and applicability of
evidence
Most studies provided ’implantation rate’ as an outcome. For clin-
icians this result is not interesting as they would rather know the
pregnancy rate or live birth rate. For women the most important
result is live birth, which was only reported in a small number of
studies. Therefore it was difficult to find reassuring results for this
outcome. The outcome clinical pregnancy was reported in most
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of the reviews and did come up with a few significant results. To
investigate the safety of luteal phase support, we also looked at
the negative side effects, OHSS and multiple pregnancy. These
outcomes were not reported in all studies and therefore this re-
view might not give an accurate representation of these important
factors in luteal phase support.
Some of the studies we found investigated procedures or inter-
ventions influencing the luteal phase but did not investigate an
intervention used as luteal phase support. These studies are all re-
ported in the Characteristics of excluded studies. We also found
a few studies investigating luteal phase support which we could
not include in one of our comparisons. We therefore filed them
under Studies awaiting classification. Ding 2005 investigated IM
progesterone + IM estrogen versus IM progesterone + transder-
mal estrogen. They concluded that the IM estrogen protocol had
better results, which might have been due to the higher dose of
estrogen. In our comparison of progesterone versus progesterone
+ estrogen we did not find a better overall result with a higher dose
of estrogen. Esra 2010 investigated IM progesterone + estrogen in
three different doses. They concluded that addition of different
doses of estrogen did not affect pregnancy rates. Our comparison
of clinical pregnancy rates in progesterone versus progesterone +
estrogen showed a small effect in favour of estrogen supplementa-
tion although this was not significant. Mochtar 2006 investigated
the best moment to start luteal phase support, starting at the hCG
trigger, oocyte retrieval or embryo transfer. They concluded that
there might be a small clinically meaningful difference in preg-
nancy rates in favour of the group starting at embryo transfer al-
though the live birth rate was quite similar.
We only included first cycle data and four studies reported more
cycles than women (Erman Akar 2005; Lukaszuk 2005; Unfer
2004; Unfer 2004a). We contacted the authors but we have not
yet received a reply.
In our protocol we stated that we would include two other com-
parisons, urinary hCG versus recombinant hCG and single-dose
GnRH agonist versus placebo. We did not find any studies inves-
tigating these comparisons. It is unlikely that these comparisons
will be made in the future as hCG is an older method for luteal
phase support and is known for its high risk of OHSS. We do
not expect new trials to investigate the differences between urinary
and recombinant hCG. Nowadays progesterone is an accepted
method for luteal phase support and it is considered unethical not
to provide any form of luteal phase support. Therefore we do not
expect any new trials investigating the effect of GnRH agonists for
luteal phase support versus a placebo. For these reasons we chose
to remove these comparisons. To make sure we were as thorough
as possible, we came up with low-dose vaginal progesterone ver-
sus high-dose vaginal progesterone, short protocol progesterone
versus long protocol progesterone and progesterone versus proges-
terone + multiple dose GnRH agonist.
The included studies used different inclusion and exclusion criteria
but this was not a limitation for inclusion in our review.
In conclusion, we included all first cycles of randomised trials of
luteal phase support.We changed our comparisons after our search
to ensure we covered as much as possible. Most studies reported
pregnancy and implantation rates, but live birth and the negative
side effects of luteal phase support were poorly reported.
Quality of the evidence
This review has a huge number of included studies, 69 studies,
which investigated a lot of different interventions for luteal phase
support. Therefore our results are based on smaller numbers of
studies. The total number of included participants was 16,327
but, because of the variety of included studies per comparison, the
total number per comparison ranged from 30 to well over 5000
participants.
We found a high overall risk of bias because most studies did not
report their method of randomisation and allocation concealment
andwere therefore judged tohave anunclear assessment.We found
allocation concealment the most important and we did sensitivity
analyses for those studies with a high risk of bias for allocation
concealment, namely Fatemi 2006, Iwase 2008 and Ludwig 2002.
These sensitivity analysis did not have a significant effect on the
results. In only 10 studies the study authors reported that they
had used blinding, as it was found difficult by authors to conduct
blinding with the differences in dose, routes or intervention.
Only 16 studies reported live birth as an outcome. We feel this
outcome is more valuable than short-term outcomes like the clin-
ical pregnancy rate.
We also found heterogeneity in a number of comparisons and we
did a sensitivity analysis of these comparisons as well. In most
cases we were not able to find a clear reason and in almost all we
found that the confidence intervals overlapped. For those results,
especially the significant results with detected heterogeneity, the
findings should be interpreted with caution. Overall it is likely
that there might be some limitations in the evidence. We tried
to discover those limitations by doing sensitivity analyses but we
were not able to find valid reasons. This can also be seen in the
’Summary of findings tables’, where the overall quality is ’Low’,
sometimes even ’Very low’. ’Moderate’ is the best result of the
quality assessment in these tables.
Potential biases in the review process
All data were extracted by two review authors. MvdL extracted
data from all studies and MM and KB divided all studies between
them and thus each extracted data from half of the studies. These
results were compared byMvdL, who wrote the review. In case of a
disagreementCF acted as a third review author and determined the
final verdict. Usually this happened after consulting with MvdL.
This means MvdL had a big influence on these decisions, which
might have introduced bias.
Due to the large number of topics within the review, we might
not have discussed all topics in depth.
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We are quite sure we found all relevant studies but there might be
studies which were not yet published at the time of our search and
are published now, at the time of publication. As discussed above,
four studies did meet our inclusion criteria but included more
cycles than women (Erman Akar 2005; Lukaszuk 2005; Unfer
2004; Unfer 2004a). We contacted these authors but we did not
receive a reply, so these studies are not included.
Agreements and disagreements with other
studies or reviews
When we compared this review with the previous version (Daya
2004), we find a lot of similarities regarding the quality of included
studies. Although the previous review included quasi-randomised
trials, the overall quality of the present review is still poor. The
implications for research section in Daya 2004 stated that the
quality of studies, especially blinding, is important for further
research. In the more recent (after 2004) studies that we have
included, the quality of studies does indeed seem to be better,
although most of these studies did not use blinding. In Daya
2004 it was discussed that live birth was not often reported as an
outcome. This seems to be improved but is in most cases still not
the main outcome.
Regarding the results of Daya 2004, there are some agreements
and some disagreements between their findings and the results of
this review. As there are no new studies investigating hCG versus
placebo, we found the same results. In all comparisons investigat-
ing hCG we found that hCG has a higher risk of OHSS. This
was significant for hCG versus placebo and progesterone versus
progesterone + hCG.
In the previous review, and in this review, there was no significant
evidence found in favour of a particular route of administration.
Both versions of the review found no difference in effect between
different doses of vaginal progesterone.
This review suggests a significant result in favour of progesterone
+ estrogen, but this is based on only one study. Without this study
(Gorkemli 2004) the results do not show a difference between
progesterone and progesterone + estrogen.Daya 2004 also failed to
show a difference in effect between progesterone and progesterone
+ estrogen.
Both reviews found higher pregnancy rates for progesterone in
GnRH agonist stimulated cycles.
The main difference between the previous version and this review
seems to be the inclusion of the comparisons of micronized and
synthetic progesterone and progesterone + GnRH agonists for
luteal phase support.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review shows a significant effect in favour of progesterone for
luteal phase support, favouring synthetic progesterone over mi-
cronized progesterone. Overall, the addition of other substances
such as estrogen or hCG do not seem to improve outcomes. Ad-
ditionally, we found that hCG is associated with a significantly
higher risk of OHSS.
The route of progesterone administration does not seem to mat-
ter, although synthetic progesterone seems to give better results,
which in most cases was oral dydrogesterone. The dose of vaginal
micronized progesterone does not seem to improve the outcomes.
There is no agreement between the results for short or long pro-
tocol progesterone. The effect of progesterone in the luteal phase
after pituitary desensitisation with GnRH agonists seems to be
bigger. The only other significant results were found in the com-
parison of progesterone versus progesterone plus GnRH agonists.
These showed a result significantly favouring progesterone plus
GnRH agonists, with either single or multiple doses of GnRH ag-
onists. This means that the addition of GnRH agonist to proges-
terone has a bigger effect than progesterone alone. However these
results are based on a limited number of studies as this is a new
method for luteal phase support.
Overall, progesterone has a positive effect on pregnancy rates when
used as luteal phase support, with no difference in effect between
the different progesterone regimens; hCG should be avoided as it
gives a higher risk of OHSS. Addition of estrogen to progesterone
does not show, in general, a better effect than progesterone alone,
but addition of GnRH agonist to progesterone does show a better
effect than progesterone alone.
For now, progesterone is found to be the best method of luteal
phase support, favouring synthetic progesterone over micronized
progesterone with a small benefit. GnRH agonist addition is a
promising newmethod but the power of the evidence is not strong.
Implications for research
Out of the 69 included studies, only 10used blinding.Themethod
of blinding and specification of who was blinded were poorly re-
ported. To gain more high quality evidence, studies should be
properly blinded using a double-dummy design.
Only 15 studies reported live birth as an outcome. We feel this
outcome is more valuable than short-term outcomes such as clin-
ical pregnancy rate. Therefore researchers should use live birth as
the main outcome of their study.
Early studies were placebo controlled. Since research has shown
that luteal phase support has a positive effect on pregnancy out-
comes, it is unethical not to use luteal phase support. Therefore
we support the trend in more recent studies to compare different
kinds of support, doses or routes of administration. GnRH ago-
nist is relatively new as a method for luteal phase support but it
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shows promising results. Therefore, high quality randomised dou-
ble blind controlled trials should be conducted comparing GnRH
agonist support with progesterone.
A C K N OW L E D G E M E N T S
This review is an update of a previously withdrawn Cochrane
Review (Daya 2004). That review was withdrawn in 2008 because
of changes in the methodology of Cochrane systematic reviews.
We would like to thank the previous authors.
MDSG. Especially Marian Showell, Trial-Search Coordinator of
MDSG, for writing and running the search strings. Vanessa Jor-
dan, NZCochrane Fellow, for her help regarding the statistics and
heterogeneity, Jane Marjoribanks for her help in the editorial pro-
cess, Jane Clarke and Helen Nagels, Managing Editors of MDSG
and Julie Brown, systematic reviewer, for answering our questions
and the Obstetrics & Gynaecology Department of the University
of Auckland for their support.
Dr Luiz Eduardo Albuquerque andDrMario Tristán for their help
translating articles.
Prof Eman Elgindy for his constructive advice.
All original authors of the papers who took time to reply to our
queries.
R E F E R E N C E S
References to studies included in this review
Abate 1999 {published data only}
Abate A, Brigandi A, Abate FG, Manti F, Unfer V, Perino
M. Luteal phase support with 17alpha-hydroxyprogesterone
versus unsupported cycles in in vitro fertilization: a
comparative randomized study. Gynaecologic and Obstetric
Investigation 1999;48(2):78–80.
Abate 1999a {published data only}
Abate A, Perino M, Abate FG, Brigandi A, Costabile
L, Manti F. Intramuscular versus vaginal administration
of progesterone for luteal phase support after in vitro
fertilization and embryo transfer. A comparative
randomized study. Clinical and Experimental Obstetrics and
Gynecology 1999;26:203–6.
Aboulghar 2008 {published data only}
Aboulghar MA, Amin YM, Al-Inany HG, Aboulghar MM,
Mourad LM, Serour GI, et al.Prospective randomized study
comparing luteal phase support for ICSI patients up to the
first ultrasound compared with an additional three weeks.
Human Reproduction 2008;23(4):857–62.
Albert 1991 {published data only}
Albert J, Pfeifer S. Luteal phase hormone levels after in vitro
fertilization and embryo transfer (IVF-ET): a prospective
randomized trial of human chorionic gonadotropin (hCG)
vs. intramuscular (im) progesterone (P) for luteal phase
support following stimulation with gonadotropin-releasing
hormone agonist (GnRH-a) and human menopausal
gonadotropins (hMG) [abstract]. Fertility and Sterility.
1991:S18 (Abs # O-041).
Artini 1995 {published data only}
Artini PG, Volpe A, Angioni S, Galassi MC, Battaglia C,
Genazzani AR. A comparative, randomized study of three
different progesterone support of the luteal phase following
IVF/ET program. Journal of Endocrinological Investigation
1995;18:51–6.
Ata 2008 {published data only}
∗ Ata B, Yakin K, Balaban B, Urman B. GnRH agonist
protocol administration in the luteal phase in ICSI-ET
cycles stimulated with the long GnRH agonist protocol:
a randomized, controlled double blind study. Human
Reproduction 2008;23(3):668–73.
Urman B. Single dose gonadotropin-releasing hormone
(GnRH) agonist administration in the luteal phase of
GnRH antagonist stimulated ICSI-ET cycles. Directly
obtained from author, 17 March 2011. [: Clinicaltrials.gov:
NCT01007851]
Beckers 2000 {published data only}
Beckers NGM, Laven JSE, Eijkemans MJC, Fauser BCJM.
Follicular and luteal phase characteristics following early
cessation of gonadotrophin-releasing hormone agonist
during ovarian stimulation for in-vitro fertilization. Human
Reproduction 2000;15(1):43–9.
Belaisch-Allart 1987 {published data only}
∗ Belaisch-Allart J, Testart J, Fries N, Forman R G, Frydman
R. The effect of dydrogesterone supplementation in an IVF
programme. Human Reproduction 1987;2:183–5.
Belaisch-Allart J, Testart J, Fries N, Forman R, Hazout
A, Declerc l, et al.The effect of dydrogesterone and hCG
supplementation in an IVF program [abstract]. 5th World
Congress on In Vitro Fertilization and Embryo Transfer
Abstract Book. 1987:41 (Abs #PP-35).
Belaisch-Allart 1990 {published data only}
Belaisch-Allart J, De Mouzon J, Lapousterle C, Mayer M.
The effect of HCG supplementation after combined GnRH
agonist/HMG treatment in an IVF programme. Human
Reproduction 1990;5:163–6.
Caligara 2007 {published data only}
Caligara C, Carranza F, Ramos J, Rodriguez I, Gonzalez A,
Fernandez-Sanchez M. Luteal phase support in IVF patients
at low risk for OHSS: Progesterone vs. progesterone plus
43Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
HCG. A prospective randomized study. Fertility and
Sterility 2007;88:S163 (Abs#P-166).
Ceyhan 2008 {published data only}
Ceyhan ST, Basaran M, Kemal Duru N, Yilmaz A, Goktolga
U, Baser I. Use of luteal estrogen supplementation in
normal responder patients treated with fixed multidose
GnRH antagonist: a prospective randomized controlled
study. Fertility and Sterility 2008;89(6):1827–30.
Chakravarty 2005 {published data only}
Chakravarty BN, Shirazee HH, Dam P, Chattopadhyay R,
Ghosh S, Dam M, Goswami SK. A randomized prospective
study comparing dydrogesterone and intravaginal
micronised progesterone as luteal phase support in ART
cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126
(Abs #P-364).
∗ Chakravarty BN, Shirazee HH, Dam P, Goswami
SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus
intravaginal micronised progesterone as luteal phase support
in assisted reproductive technology (ART) cycles: Results
of a randomised study. Journal of Steroid Biochemistry and
Molecular Biology 2005;97(5):416–20.
Colwell 1991 {published data only}
Colwell KA, Tummon IS. Elevation of serum progesterone
with oral micronized progesterone after in vitro fertilization.
Journal of Reproductive Medicine 1991;36:170–2.
Dal Prato 2008 {published data only}
∗ Dal Prato L, Bianchi L, Cattoli M, Tarozzi N, Flamigni
C, Borini A. Vaginal gel versus intramuscular progesterone
for luteal phase supplementation: a prospective randomized
trial. Reproductive BioMedicine Online 2008;16(3):361–7.
Dal Prato L, Borini A, Bonu MA, Maccolini A, Cattoli M,
Flamigni C. Luteal support in IVF: i.m. versus intravaginal
progesterone. Human Reproduction. 2004 Suppl 1; Vol.
19:i69-70 (Abs #O-198).
Doody 2009 {published data only}
Doody KJ, Schnell VL, Foulk RA, Miller CE, Kolb BA,
Blake EJ, et al.Endometrin for luteal phase support in a
randomized, controlled, open-label, prospective in-vitro
fertilization trial using a combination of Menopur and
Bravelle for controlled ovarian hyperstimulation. Fertility
and Sterility 2009;91(4):1012–7.
Drakakis 2007 {published data only}
Drakakis P, Loutradis D, Vomvolaki E, Stefanidis
K, Kiapekou E, Anagnostou E, et al.Luteal estrogen
supplementation in stimulated cycles may improve the
pregnancy rate in patients undergoing in vitro fertilization/
intracytoplasmic sperm injection-embryo transfer.
Gynecological Endocrinology 2007;23(11):645–52.
Dunstone 1999 {published data only}
Dunstone T, Zosmer A, Hussain S, Tozer A, Paney N,
Wilson C et a l. A comparison between Cyclogest pessaries
and Crinone gel as luteal support in IVF-ET cycles
[abstract]. British Fertility Society Annual Meeting Abstract
Book. 1999:62 (Abs # FC21).
Elgindy 2010 {published data only}
Elgindy EA, El-Haieg DO. Does luteal estradiol
supplementation have a role in long agonist cycles? Does
luteal estradiol supplementation have a role in long agonist
cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88,
issue Suppl 1:164 (Abs #168).
∗ Elgindy EA, El-Haieg DO, Mostafa MI, Shafiek M. Does
luteal estradiol supplementation have a role in long agonist
cycles?. Fertility and Sterility 2010;93(7):2182–8.
Engmann 2008 {published data only}
Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier
D, Nulsen J. The effect of luteal phase vaginal estradiol
supplementation on the success of in vitro fertilization
treatment: a prospective randomized study. Fertility and
Sterility 2008;89(3):554–61.
Fatemi 2006 {published data only}
∗ Fatemi HM, Kolibianakis EM, Camus M, Tournaye
H, Donoso P, Papanikolaou E, et al.Addition of estradiol
to progesterone for luteal supplementation in patients
stimulated with GnRH antagonist/rFSH for IVF: A
randomized controlled trial. Human Reproduction 2006;21
(10):2628–32.
Fatemi HM, Kolibianakis EM, Camus M, Tournaye H, van
Steirteghem A, Devroey P. Progesterone Versus Progesterone
Combined With Estradiol as Luteal Support in Cycles
Stimulated With GnRH Antagonist/rec-FSH for IVF: A
Randomized Clinical Trial [abstract]. Fertility and Sterility.
2005; Vol. 84, issue Suppl 1:s322 (Abs #P-475).
Friedler 1999 {published data only}
Friedler S, Raziel A, Schachter M, Cohen O, Yaron
M, Tartakovsky L, et al.Characteristics of conceptional
and non-conceptional cycles after IVF using micronized
progesterone for luteal support: a comparative study of
vaginal or oral administration [abstract]. Abstract Book 1.
1998; Vol. 13, issue Abstract Book 1:161 (Abs # P-063).
∗ Friedler S, Raziel A, Schachter M, Strassburger D,
Bukovsky I, Ron-El R. Luteal support with micronized
progesterone following in-vitro fertilization using a down-
regulation protocol with gonadotrophin-releasing hormone
agonist: a comparative study between vaginal and oral
administration. Human Reproduction 1999;14(8):1944–8.
Fujimoto 2002 {published data only}
∗ Fujimoto A, Osuga Y, Fujiwara T, Yano T, Tsutsumi
O, Momoeda M et a l. Human chorionic gonadotropin
combined with progesterone for luteal support improves
pregnancy rate in patients with low late-midluteal estradiol
levels in IVF cycles. Journal of Assisted Reproduction and
Genetics 2002;19(12):550–4.
Fujimoto A, Osuga Y, Ooi N, Fujiwara T, Yano T, Taketani
Y. Addition of hCG to progesterone as a luteal support
improves pregnancy rates for patients with low mid-luteal
oestradiol levels in IVF and ICSI [abstract]. Human
Reproduction. 2001; Vol. 16, issue Suppl 1:143 (Abs #P-
143).
44Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ganesh 2011 {published data only}
Ganesh A, Chakravorty N, Mukherjee R, Goswami
S, Chaudhury K, Chakravarty B. Comparison of oral
dydrogesterone with progesterone gel and micronized
progesterone for luteal support in 1,373 women undergoing
in vitro fertilization: a randomized clinical study. Fertility
and Sterility 2011;95(6):1961–5. [DOI: 10.1016/
j.fertnstert.2011.01.148]
Geber 2007 {published data only}
Geber S, Maia L, Lauar I, Valle MP, Sampaio AC. Does
recombinant LH combined to progesterone for luteal phase
interfere in the outcome of assisted reproduction technique
cycles? [abstract]. Fertility and Sterility 2007;88 Suppl 1:25
(Abs #66).
Geber 2007a {published data only}
Geber S, Moreira ACF, De Paula SOC, Sampaio M.
Comparison of two different vaginal progesterone for luteal
phase support in cycles of assisted reproduction. Jornal
Brasileiro de Reproducao Assistida 2006;10(1):17–21.
Geber S, Moreira ACF, de Paula SOC, Sampaio M.
Comparison between two forms of vaginally administered
progesterone for luteal phase support in assisted
reproduction cycles. Reproductive BioMedicine Online 2007;
14(2):155–8.
Geusa 2001 {published data only}
Geusa S, Causio F, Marinaccio M, Stanziano A, Sarcina
E. Luteal phase support with progesterone in IVF/ET
cycles: a prospective, randomized study comparing vaginal
and intramuscular administration [abstract]. Human
Reproduction 2001;16 Suppl 1:145 (Abs # P-111).
Golan 1993 {published data only}
Golan A, Herman A, Soffer Y, Bukovsky I, Caspi
E, Ron-El R. Human chorionic gonadotrophin is a
better luteal support than progesterone in ultrashort
gonadotrophin-releasing hormone agonist/menotrophin
in-vitro fertilization cycles. Human Reproduction 1993;8:
1372–5.
Gorkemli 2004 {published data only}
Gorkemli H, Ak D, Akyurek C, Aktan M, Duman S.
Comparison of pregnancy outcomes of progesterone or
progesterone plus estradiol for luteal phase support in ICSI-
ET cycles. Gynecologic and Obstetric Investigation 2004;58
(3):140–4.
Goudge 2010 {published data only}
Goudge CS, Nagel TC, Damario MA. Duration of
progesterone-in-oil support after in vitro fertilization and
embryo transfer: A randomized, controlled trial. Fertility
and Sterility 2010;94(3):946–51.
Hurd 1996 {published data only}
Hurd W W, Randolph Jf J r, Christman G M, Ansbacher
R, Menge A C, Gell J S. Luteal support with both estrogen
and progesterone after clomiphene citrate stimulation for in
vitro fertilization. Fertility and Sterility 1996;66:587–92.
Isik 2009 {published data only}
Isik AZ, Caglar GS, Sozen E, Akarsu C, Tuncay G, Ozbicer
T, et al.Single-dose GnRH agonist administration in the
luteal phase of GnRH antagonist cycles: a prospective
randomized study. Reproductive BioMedicine Online 2009;
19(4):472–7.
Isikoglu 2007 {published data only}
Isikoglu M, Ozgur K, Oehninger S. Extension of GnRH
agonist through the luteal phase to improve the outcome of
intracytoplasmic sperm injection. Journal of Reproductive
Medicine 2007;52(7):639–44.
Iwase 2008 {published data only}
Iwase A, AndoH, Toda S, Ishimatsu S, Harata T, Kurotsuchi
S, et al.Oral progestogen versus intramuscular progesterone
for luteal support after assisted reproductive technology
treatment: A prospective randomized study. Archives of
Gynecology and Obstetrics 2008;277(4):319–24.
Kleinstein 2005 {published data only}
∗ Kleinstein J. Efficacy and tolerability of vaginal
progesterone capsules (Utrogest 200) compared with
progesterone gel (Crinone 8%) for luteal phase support
during assisted reproduction. Fertility and Sterility 2005;83
(6):1641–9.
Kleinstein, J. Efficacy of Utrogest 200 and Crinone 8%
for luteal phase support during ART: a comparative,
multicenter study [Abstract]. Human Reproduction. 2004;
Vol. 19:i123 (Abs #P-357).
Kohls 2010 {published and unpublished data}
Kohls G, Ruiz FJ, De La Fuente G, Toribio M, Martinez
M, Pellicer A, et al.Early progesterone cessation after in
vitro fertilization. Human Reproduction 2010;25 Suppl 1
(6):i249 Abstract no. P-344.
Kupferminc 1990 {published data only}
Kupferminc MJ, Lessing JB, Amit A, Yovel I, David MP,
Peyser MR. A prospective randomized trial of human
chorionic gonadotrophin or dydrogesterone support
following in-vitro fertilization and embryo transfer. Human
Reproduction 1990;5(3):271–3.
Lam 2008 {published data only}
Lam PM, Cheung MC, Cheung LP, Lok HI, Haines
CJ. Effects of early luteal-phase vaginal progesterone
supplementation on the outcome of in vitro fertilization
and embryo transfer. Gynecological Endocrinology 2008;24
(12):674–80.
Lewin 1994 {published data only}
Lewin A, Benshushan A, Mezker E, Yanai N, Schenker JG,
Goshen R. The role of estrogen support during the luteal
phase of in vitro fertilization-embryo transplant cycles: a
comparative study between progesterone alone and estrogen
and progesterone support. Fertility and Sterility 1994;62:
121–5.
Licciardi 1999 {published data only}
Licciardi F, Kwiatkowski A, Noyes N, Berkeley AS, Krey
LL, Grifo JA. Oral versus intramuscular progesterone for in
vitro fertilization: a prospective randomized study. Fertility
and Sterility 1999;71:614–8.
Loh 1996 {published data only}
Loh SKE, Leong NKY. Luteal phase support in IVF-cycles
- is intramuscular progesterone the therapy of choice?
45Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[abstract]. Fertility Society of Australia XV Annual Meeting
Abstract Book (Abs #O24). 1996.
Ludwig 2001 {published data only}
Ludwig M, Finas A, Bals-Pratsch M, Felberbaum RE,
Schopper B, Al-Hasani S, et al.Prospective, randomized
study to evaluate the pregnancy rate using HCG, vaginal
progesterone (Utrogest), or a combination of both for
luteal-phase support: preliminary results [abstract]. Human
Reproduction. 1999; Vol. 14 Suppl 1:2-3 (Abs # O-004).
∗ Ludwig M, Finas A, Katalinic A, Strik D, Kowalcek
I, Schwartz P et a l. Prospective, randomized study to
evaluate the success rates using hCG, vaginal progesterone
or a combination of both for luteal phase support. Acta
Obstetricia et Gynecologica Scandinavica 2001;80:574–82.
Ludwig 2002 {published data only}
LudwigM, Schwartz P, Babahan B, Katalinic A, Bals-Pratsch
M, Diedrich K. Progesterone gel (Crinone 8%) is more
comfortable than progesterone suppositories (Utrogest) for
luteal phase support and results in comparable pregnancy
rates: results of a prospective, randomized study [abstract].
Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P-S210).
∗ Ludwig M, Schwartz P, Babahan B, Katalinic A, Weiss
JM, Felberbaum R et a l. Luteal phase support using
either Crinone 8% or Utrogest: results of a prospective,
randomized study. European Journal of Obstetrics and
Gynaecology 2002;103:48–52.
Schwartz P, LudwigM, Babahan B, Katalinic A, Bals-Pratsch
M, Felberbaum R, et al.Luteal phase support using either
progesterone gel (Crinone 8%) or progesterone suppositories
(Utrogest): results of a prospective, randomized study
[abstract]. Human Reproduction 2000;15(Abstract Book 1):
43-4 (Abs #O-111).
Macrolin 1993 {published data only}
Macrolin G, Buvat J, Guittard C, Herbaut JC, Louvet AL,
Dehaene JL. [Fécondation in vitro après agoniste de la
LHRH: comparison randomisée de soutiens lutéaux par
progestérone vaginale seule ou associee a la gonadotrophine
chorionique]. Contraception Fertilité Sexualité 1993;21(5):
434.
Martinez 2000 {published data only}
Martinez F, Coroleu B, Parera N, Alvarez M, Traver JM,
Boada M et a l. Human chorionic gonadotropin and
intravaginal natural progesterone are equally effective for
luteal phase support in IVF. Gynaecological Endocrinology
2000;14:316–20.
Miller 2010 {published data only}
Miller CE, Doody KJ, Zbella E, Webster B, Bush M, Scobey
J. Efficacy of vaginal progesterone inserts (Endometrin)
compared to intramuscular progesterone in oil for luteal
support in IVF patients. Fertility and Sterility 2010;94
Suppl 1(4):20-1 Abstract no. O-68.
Ng 2003 {published data only}
Ng EHY, Miao B, Cheung W, Ho PC. A randomised
comparison of side effects and patient inconvenience of two
vaginal progesterone formulations used for luteal support in
in vitro fertilisation cycles. European Journal of Obstetrics
Gynecology and Reproductive Biology 2003;111:50–4.
Ng 2007 {published data only}
Ng EHY, Chan CCW, Tang OS, Ho PC. A randomized
comparison of side effects and patient convenience between
Cyclogest suppositories and Endometrin tablets used for
luteal phase support in IVF treatment. European Journal of
Obstetrics Gynecology and Reproductive Biology 2007;131(2):
182–8.
Patki 2007 {published data only}
Patki A, Pawar VC. Modulating fertility outcome in assisted
reproductive technologies by the use of dydrogesterone.
Gynecological Endocrinology 2007;23 Suppl 1:68–72.
Perino 1997 {published data only}
Perino M, Brigandi A, Abate FG, Costabile L, Balzano
E, Abate A. Intramuscular versus vaginal progesterone in
assisted reproduction: a comparative study. Clinical and
Experimental Obstetrics and Gynecology 1997;24:228–31.
Pirard 2006 {published data only}
Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal
phase support in assisted reproduction technique cycles:
Results of a pilot study. Human Reproduction 2006;21(7):
1894–900.
Porcu 2003 {published data only}
Porcu E. Intramuscular versus vaginal progesterone in
assisted reproduction [abstract]. Fertility and Sterility.
2003; Vol. 80:S131 (Abs # P-32).
Pouly 1996 {published data only}
∗ Pouly JL, Bassil S, Frydman R, Hedon B, Nicollet B,
Prada Y et a l. Luteal support after in-vitro fertilization:
Crinone 8%, a sustained release vaginal progesterone gel,
versus Utrogestan, an oral micronized progesterone. Human
Reproduction 1996;11:2085–9.
Pouly JL, Bassil S, Frydman R, Hedon B, Nicollet B, Prada
Y, et al.Luteal phase support after vaginal progesterone:
comparative study with micronized oral progesterone.
Contraception, Fertilité, Sexualité 1997;25:596–601.
Propst 2001 {published data only}
∗ Propst AM, Hill JA, Ginsburg ES, Hurwitz S, Politch J,
Yanushpolsky EH. A randomized study comparing Crinone
8% and intramuscular progesterone supplementation in
in vitro fertilization-embryo transfer cycles. Fertility and
Sterility 2001;76:1144–9.
Propst AM, Hill JA, Politch J, Yanushpolsky EH. A
prospective, randomized study comparing Crinone and
intramuscular progesterone supplementation in IVF/ET
cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30-1
(Abs #O-084).
Qublan 2008 {published data only}
Qublan H, Amarin Z, Al-Quda M, Diab F, Nawasreh
M, Malkawi S, et al.Luteal phase support with GnRH-a
improves implantation and pregnancy rates in IVF cycles
with endometrium of [less-than or equal to]7 mm on day of
egg retrieval. Human Fertility 2008;11(1):43–7.
46Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rodriguez-Pezino 2004 {published data only}
Rodriguez-Pezino J, Saucedo-de la Llata E, Batiza-Resendiz
V, Galache-Vega P, Santos-Haliscak R, Hernandez-Ayup S,
et al.Vaginal progesterone in assisted reproduction. Human
Reproduction. Berlin, Germany, 2004; Vol. 19 Suppl 1:
i51.
Saucedo 2000 {published data only}
Saucedo-de la Llata E, Galache VP, Hernandez AS, Santos
HR, Arenas ML, Patrizio P. Randomized trial of three
different forms of progesterone supplementation in ART:
preliminary results [abstract]. Fertility and Sterility 2000;74
Suppl 1:S150 (Abs # P-175).
Saucedo 2003 {published data only}
Saucedo-de la Llata E, Batiza V, Arenas L, Santos R, Galache
P, Hernandez-Ayup S, et al.Progesterone for luteal support:
randomized, prospective trial comparing vaginal and i.m.
administration [abstract]. Fertility and Sterility 2003;18
Suppl 1:130 (Abs # P-382).
Serna 2008 {published data only}
Serna J, Cholquevilque JL, Cela V, Martinez-Salazar J,
Requena A, Garcia-Velasco JA. Estradiol supplementation
during the luteal phase of IVF-ICSI patients: a randomized,
controlled trial. Fertility and Sterility 2008;90(6):2190–5.
Stadtmauer 2010 {published data only}
Stadtmauer LA, Reape KZ, Shu H. Luteal supplementation
with a weekly progesterone vaginal ring in infertile women
undergoing in vitro fertilization (IVF). Fertility and Sterility.
Denver, CO United States, 2010; Vol. 94 Suppl 1:244.
Strehler 1999 {published data only}
Strehler E, Abt M, El-Danasouri I, Sterzik K. Transvaginal
administration of micronized progesterone does not differ
to progesterone gel application in the efficacy of luteal phase
support in IVF cycles [abstract]. 11th World Congress of
In Vitro Fertilization and Human Reproductive Genetics
Abstract Book. 1999:287 (Abs # P-243).
Sumita 2003 {published data only}
Sumita S, Sofat S Sr. Intra muscular versus intra vaginal
progesterone as luteal phase and early pregnancy support
in patients undergoing IVF-ET [abstract]. Fertility and
Sterility 2003;80 Suppl 3:134-5 (Abs # P-44).
Tay 2005 {published data only}
Tay PYS, Lenton EA. The impact of luteal supplement
on pregnancy outcome following stimulated IVF cycles.
Medical Journal of Malaysia 2005;60(2):151–7.
Tesarik 2006 {published data only}
Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N,
Mendoza C. Beneficial effect of luteal-phase GnRH agonist
administration on embryo implantation after ICSI in both
GnRH agonist- and antagonist-treated ovarian stimulation
cycles. Human Reproduction 2006;21(10):2572–9.
Torode 1987 {published data only}
Torode HW, Porter RN, Vaughan JI, Saunders DM. Luteal
phase support after in vitro fertilisation: a trial and rationale
for selective use. Clinical Reproduction and Fertility 1987;5:
255–61.
Ugur 2001 {published data only}
Ugur M, Yenicesu O, Ozcan S, Keles G, Gokmen O. A
prospective randomized study comparing hCG, vaginal
micronized progesterone and a combination regimen for
luteal phase support in an in-vitro fertilization programme
[abstract]. Fertility and Sterility 2001;76 Suppl 1:118 (Abs
# P-19).
Vimpeli 2001 {published data only}
Vimpeli T, Tinkanen H, Huhtala H, Ronnberg L, Kujansuu
E. Salivary and serum progesterone concentrations during
two luteal support regimens used in in vitro fertilization
treatment. Fertility and Sterility 2001;76:847–8.
Wong 1990 {published data only}
Wong YF, Loong EPL, Mao KR, Tam PPL, Panesar NS,
Neale E, et al.Salivary oestradiol and progesterone after in
vitro fertilization and embryo transfer using different luteal
support regimens. Reproduction Fertility and Development
1990;2:351–8.
Yanushpolsky 2010 {published data only}
Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky
C, Hornstein M. Compared to Crinone, intramuscular
progesterone (IMP) delays menstrual bleeding but does not
improve pregnancy rates or outcomes in IVF/ET cycles.
Fertility and Sterility. 2009; Vol. 92 Suppl 1:243.
∗ Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C,
Hornstein M. Crinone vaginal gel is equally effective and
better tolerated than intramuscular progesterone for luteal
phase support in in vitro fertilization-embryo transfer cycles:
A prospective randomized study. Fertility and Sterility 2010;
94(7):2596–9.
Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C,
Hornstein M. Patterns of luteal phase bleeding in in vitro
fertilization cycles supplemented with Crinone vaginal gel
and with intramuscular progesterone - Impact of luteal
estrogen: Prospective, randomized study and post hoc
analysis. Fertility and Sterility 2011;95(2):617–20.
Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C,
Hornstein MD. Comparison of Crinone 8% intravaginal
gel and intramuscular progesterone supplementation for in
vitro fertilization/embryo transfer in women under age 40:
interim analysis of a prospective randomized trial. Fertility
and Sterility 2008;89(2):485–7.
Zegers-Hochschild 2000 {published data only}
∗ Zegers-Hochschild F, Balmaceda J P, Fabres C, Alam V,
Mackenna A, Fernández E et a l. Prospective randomized
trial to evaluate the efficacy of a vaginal ring releasing
progesterone for IVF and oocyte donation. Human
Reproduction 2000;15(10):2093–7.
Zegers-Hochschild F, Balmaceda JP, Fabres C, Alam V,
Mackenna A, Fernandez E, et al.Efficacy and acceptability of
a vaginal ring releasing progesterone for in-vitro fertilization
and oocyte donation [abstract]. 1998; Vol. 13, issue
Abstract Book 1:118-9 (Abs #O-231).
References to studies excluded from this review
47Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Abu-Musa 2008 {published data only}
Abu-Musa A, Usta I, Nassar A, Hajami F, Hannoun A.
Effect of 17alpha-hydroxyprogesterone caproate before
embryo transfer on the outcome of in vitro fertilization and
embryo transfer: a randomized trial. Fertility and Sterility
2008;89(5):1098–102.
Abu-Musa 2008a {published data only}
Abu-Musa A, Usta I, Nassar A, Hajami F, Hannoun A.
Effect of 17alpha-hydroxyprogesterone caproate before
embryo transfer on the outcome of in vitro fertilization and
embryo transfer: a randomized trial. Fertility and Sterility
2008;89(5):1098–102.
Allahbadia 2004 {published data only}
Allahbadia GN, Kaur K, Kadam K, Virk S, Gandhi G,
Gosrani S. The comparison of pregnancy outcomes of
intramuscular progesterone versus oral dydrogesterone for
luteal phase support in donor egg IVF recipient cycles.
Fertility and Sterility 2004;82 Suppl 2:194.
Allen 2004 {published data only}
Allen C, Harrison RF. Luteal support progesterone
vaginal gel v pessary: clinical/endocrine outcome. Human
Reproduction 2004;19 Suppl:i125–6.
Alsanie 2005 {published data only}
Alsanie A, Kadoch I, Phillips S, Lapensee L, Hemmings R,
Bissonnette F. Adding estrogen to progesterone in luteal
phase support in vitro fertilization-embryo transfer (IVF-
ET) cycles produces pregnancies with higher quantitative
beta human chorionic gonadotropins (beta hCG). Fertility
and Sterility 2005;84 Suppl:155.
Anserini 2001 {published data only}
Anserini P, Costa M, Remorgida V, Sarli R, Guglielminetti E,
Ragni N. Luteal phase support in assisted repoductive cycles
using either vaginal (Crinone 8) or systemic (Prontogest)
progesterone: results of a prospective randomized study.
Minerva Ginecologica 2001;53:297–301.
Anthony 1993 {published data only}
Anthony F W, Smith E M, Gadd S C, Masson G M,
Chard T, Perry L. Placental protein 14 secretion during in
vitro fertilization cycles with and without human chorionic
gonadotropin for luteal support. Fertility and Sterility 1993;
59:187–91.
Araujo 1994 {published data only}
Araujo E Jr, Bernardini L, Frederick JL, AschRH, Balmaceda
JP. Prospective randomized comparison of human chorionic
gonadotropin versus intramuscular progesterone for luteal-
phase support in assisted reproduction. Journal of Assisted
Reproduction and Genetics 1994;11(2):74–8.
Araujo Filho 1996 {published data only}
de Araujo Filho E, Asch RH, de Araujo E, Luz OA,
Balmaceda JP. Prospective and randomized trial comparing
human chorionic gonadotropin and intramuscular
progesterone for luteal phase support in assisted fertilization
[Estudo prospectivo e randomizado comparando
gonadotrofina coriônica humana e progesterona
intramuscular para suporte da fase lútea em reproduçao
assistida]. Revista Brasileira de Ginecologia e Obstetrica 1996;
18(2):131–7.
Baber 1988 {published data only}
Baber R J, Kuan R, Porter R N, Saunders D M. Early
pregnancy support in an in vitro fertilization program: does
human chorionic gonadotropin reduce the miscarriage rate?
. Asia-Oceania Journal of Obstetrics and Gynaecology 1988;
14:453–5.
Beckers 2006 {published data only}
Beckers NGM, Platteau P, Eijkemans MJ, Macklon NS,
de Jong FH, Devroey P, et al.The early luteal phase
administration of estrogen and progesterone does not
induce premature luteolysis in normo-ovulatory women.
European Journal of Endocrinology 2006;155(2):355–63.
Belaisch-Allart 1988 {published data only}
Belaisch-Allart J, de Mouzon J. Effect of luteal phase
supplementation in an IVF programme after ovarian
stimulation by LH-RH analogs. Multicentric analysis
[Effet de la supplementation de la phase luteale dans un
programme de fecondation in vitro apres stimulation
de l’ovulation par les agonistes du LHRH. Etude
multicentrique]. Contraception, Fertilite, Sexualite 1988;16
(7):654–6.
Ben-Nun 1990 {published data only}
Ben-Nun I, Ghetler Y, Jaffe R, Siegal A, Kaneti H, Fejgin
M. Effect of preovulatory progesterone administration on
the endometrial maturation and implantation rate after in
vitro fertilization and embryo transfer. Fertility and Sterility
1990;53:276–81.
Berjis 2008 {published data only}
Berjis K, Sarem A, Moaya M, Mohamad Alayha N. The
comparative assessment of intramuscular progesterone and
intravaginal progesterone to support luteal phase in IVF
cycle [Farsi]. Medical Sciences Journal of the Islamic Azad
University of Tehran Medical Unit 2008;18(1):9.
Blake 2010 {published data only}
Blake EJ, Norris PM, Dorfman SF, Longstreth J, Yankov
VI. Single and multidose pharmacokinetic study of a vaginal
micronized progesterone insert (Endometrin) compared
with vaginal gel in healthy reproductive-aged female
subjects. Fertility and Sterility 2010;94(4):1296–301.
Buvat 1988 {published data only}
∗ Buvat J, Marcolin G, Herbaut J C, Dehaene J L, Verbecq
P, Fourlinnie J C. A randomized trial of human chorionic
gonadotropin support following in vitro fertilization and
embryo transfer. Fertility and Sterility 1988;49:458–61.
Macrolin G, Buvat J, Herbaut JC, Louvet AL, Dehaene
JL, Renouard O. Luteal phase support with HCG - can
it be of any benefit following in vitro fecundation (IVF)?
A controlled randomized study covering 116 cycles [Le
soutien de la phase lutéale par HCG a–t–il de l’intérêt après
fécondation in vitro?]. Gynecologie 1988;39:163–6.
Buvat 1990 {published data only}
Buvat J, Marcolin G, Guittard C, Dehaene JL, Herbaut
JC, Louvet AL. Luteal support after administration of an
LHRH analog for in vitro fertilization. Superiority of
48Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
vaginal progesterone in comparison with oral progesterone
[Soutien lutéal après analogue de la gonadoréline pour
fécondation in vitro. Supériorité de la progestérone vaginale
sur la progestérone orale]. La Presse Médicale 1990;19:527.
Buvat J, Marcolin G, Guittard C, Herbaut JC, Louvet AL,
Dehaene JL. Luteal phase support after LHRH-agonist
for in vitro fertilization (IVF): vaginal progesterone is
superior to oral progesterone and as much effective as
human chorionic gonadotropin (hCG) [Soutien lutéal
après LHRH–agonistes pour fécondation in vitro: la
progestérone vaginale est supérieure à la progestérone orale,
et aussi efficace que la gonadotrophine chorionique (hCG)].
Contraception Fertilite Sexualite 1990;18:616–7.
∗ Buvat J, Marcolin G, Guittard C, Herbaut JC, Louvet
AL, Dehaene JL. Luteal support after luteinizing hormone-
releasing hormone agonist for in vitro fertilization:
superiority of human chorionic gonadotropin over oral
progesterone. Fertility and Sterility 1990;53:490–4.
Buvat J, Mercolin G, Guittard C, Dehaene JL, Verbecq
P, Renouard O, et al.Chorionic gonadotropin support of
the luteal phase following in vitro fertilization and embryo
transfer. Randomized comparison wih oral progesteronein
protocols using triptoreline [Soutien de la phase lutéal
par la gonadotrophine chorionique après fécondation in
vitro et transfert d’embryon. Comparaison randomisée
à la progestérone per os dans les protocoles utilitsant la
triptoréline]. La Presse Médicinale 1989;18:539.
Casini 2003 {published data only}
Casini ML, Unfer V, Costabile L, Gerli S, Agostini R, Di
Renzo GC. Oral versus i.m. progesterone supplementation
in IVF-embryo transfer cycles: a randomized study
[abstract]. Human Reproduction 2003;18 Suppl 1:106 (Abs
# P-307).
Chang 2008 {published data only}
Chang Sheng-Ping. Comparison of Crinone 8%
Intravaginal Gel and Intramuscular Progesterone for Luteal
Support in In Vitro Fertilization. Journal of the Chinese
Medical Association 2008;71(8):381–5.
Chang 2009 {published data only}
Chang HJ, Lee JR, Jee BC, Suh CS, Kim SH. Cessation of
gonadotropin-releasing hormone antagonist on triggering
day: an alternative method for flexible multiple-dose
protocol. Journal of Korean Medical Science 2009;24(2):
262–8.
Chantilis 1999 {published data only}
Chantilis S J, Zeitoun K M, Patel S I, Johns D A, Madziar
V A, McIntire D D. Use of Crinone vaginal progesterone
gel for luteal support in in vitro fertilization cycles. Fertility
and Sterility 1999;72:823–9.
Check 2010 {published data only}
Check J H, Dietterich C, Cohen R, Choe J K, Amui
J, Brasile D. Increasing the dosage of progesterone (P)
supplemention from the mid-luteal phase in women not
attaining a mid-luteal homogeneous hyperechogenic
(HH) pattern with sonography improves pregnancy rates
(PRS) following frozen embryo transfer (ET). Clinical and
Experimental Obstetrics and Gynecology 2010;37(1):13–4.
Claman 1992 {published data only}
Claman P, Domingo M, Leader A. Luteal phase support
in in-vitro fertilization using gonadotrophin releasing
hormone analogue before ovarian stimulation: a prospective
randomized study of human chorionic gonadotrophin
versus intramuscular progesterone. Human Reproduction
1992;7(4):487–9.
Daya 2009 {published data only}
Daya S. Luteal support: progestogens for pregnancy
protection. Maturitas 2009;65 Suppl 1:29–34.
Ding 2005 {published data only}
Ding J, Rana N, Dmowski W. Comparative Effectiveness of
two Luteal Phase Support Protocols for IVF. Fertility and
Sterility 2005;84 Suppl 1:349.
Erman Akar 2005 {published data only}
Erman Akar M, Kursun S, Taskin O, Simsek M, Kaba
M, Uner M. Intravaginal progesterone gel vs 17oe
hydroxyprogesterone caproate in ICSI embryo transfer
cycles: A prospective randomized study. Fertility and
Sterility 2005;84 Suppl 1:320.
Escriba 2006 {published data only}
Escriba MJ, Bellver J, Bosch E, Sanchez M, Pellicer
A, Remohi J. Delaying the initiation of progesterone
supplementation until the day of fertilization does not
compromise cycle outcome in patients receiving donated
oocytes: a randomized study. Fertility and Sterility 2006;86
(1):92–7.
Farhi 2000 {published data only}
Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H,
Levran D. Estradiol supplementation during the luteal phase
may improve the pregnancy rate in patients undergoing
in vitro fertilization-embryo transfer cycles. Fertility and
Sterility 2000;73:761–6.
Farrag 2008 {published data only}
Farrag A, Costantini A, Manna C, Grimaldi G.
Recombinant HCG for triggering ovulation increases the
rate of mature oocytes in women treated for ICSI. Journal of
Assisted Reproduction and Genetics 2008;25(9-10):461–6.
Feliciani 2004 {published data only}
Feliciani E, Ferraretti AP, Balicchia B, Grieco N, Magli
MC, Gianaroli. A prospective randomised study comparing
the effect of intravaginal progesterone and intramuscular
progesterone in frozen/thawed embryo transfer (FET)
cycles. Human Reproduction 2004;82:i51.
Garcia-Velasco 2009 {published data only}
Garcia-Velasco J, Motta L, Lopez A, Mayoral M, Cerrillo
M, Pellicer A, Pacheco A. Estradiol/progesterone vs low
dose hCG luteal phase support in GnRH agonist triggered
ART cycles: A pilot study. Human Reproduction 2010;25
Suppl 1:i86 (Abs #O-224).
∗ Garcia-Velasco JA, Quea G, Piro M, Mayoral M, Ruiz M,
Toribio M, et al.Letrozole administration during the luteal
phase after ovarian stimulation impacts corpus luteum
function: a randomized, placebo-controlled trial. Fertility
and Sterility 2009;92(1):222–5.
49Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ghanem 2009 {published data only}
Ghanem M, Sadek E, Helal A, Gamal A, Eldiasty E, Bakre
NI, Houssen M. The effect of luteal phase support protocol
on luteal phase serum estradiol and progesterone and cycle
outcome in ICSI cycles: a randomized trial [Abstract].
Human Reproduction. 2008; Vol. 23, issue Suppl 1:i124
(Abs #P-307).
∗ Ghanem ME, Sadek EE, Elboghdady LA, Helal AS,
Gamal A, Eldiasty A, et al.The effect of luteal phase support
protocol on cycle outcome and luteal phase hormone profile
in long agonist protocol intracytoplasmic sperm injection
cycles: a randomized clinical trial. Fertility and Sterility
2009;92(2):486–93.
Gibbons 1998 {published data only}
Gibbons W E, Toner J P, Hamacher P, Kolm P. Experience
with a novel vaginal progesterone preparation in a donor
oocyte program. Fertility and Sterility 1998;69:96–101.
Griesinger 2006 {published data only}
Griesinger G, Diedrich K. Vaginal progesterone for
luteal phase support in assisted reproduction [Die
vaginale Anwendung von natürlichem Progesteron als
Lutealphasenunterstützung nach IVF und Embryotransfer].
Geburtsh Frauenheilk 2006;66:655–64.
Herman 1990 {published data only}
Herman A, Ron-El R, Golan A, Raziel A, Soffer Y, Caspi
E. Pregnancy rate and ovarian hyperstimulation after luteal
human chorionic gonadotropin in in vitro fertilization
stimulated with gonadotropin-releasing hormone analog
and menotropins. Fertility and Sterility 1990;53:92–6.
Herman 1996 {published data only}
Herman A, Raziel A, Nachum H, Strassburger D, Soffer
Y, Bukovsky Y, et al.The benefits of midluteal addition of
human chorionic gonadotrophin in IVF using a down-
regulation protocol and luteal support with progesterone
[abstract]. Human Reproduction 1995;10(Abstract Book 2):
63 (Abs #127).
∗ Herman A, Raziel A, Strassburger D, Soffer Y, Bukovsky
I, Ron-El R. The benefits of mid-luteal addition of
human chorionic gonadotrophin in in-vitro fertilization
using a down-regulation protocol and luteal support with
progesterone. Human Reproduction 1996;11:1552–7.
Ho 2008 {published data only}
Ho CH, Chen SU, Peng FS, Chang CY, Yang YS. Luteal
support for IVF/ICSI cycles with Crinone 8% (90 mg)
twice daily results in higher pregnancy rates than with
intramuscular progesterone. Journal of the Chinese Medical
Association 2008;71(8):386–91.
Humaidan 2010 {published data only}
Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding
Andersen C. 1,500 IU human chorionic gonadotropin
administered at oocyte retrieval rescues the luteal phase
when gonadotropin-releasing hormone agonist is used for
ovulation induction: a prospective, randomized, controlled
study. Fertility and Sterility 2010;93(3):847–54.
Hutchinson-Williams 1990 {published data only}
Hutchinson-Williams KA, DeCherney AH, Lavy G,
Diamond MP, Naftolin F, Lunenfeld B. Luteal rescue in
in vitro fertilization-embryo transfer. Fertility and Sterility
1990;53:495–9.
Jee 2010 {published data only}
Jee BC, Suh CS, Kim SK, Kim YB, Moon SY. Effects of
estradiol supplementation during the luteal phase of in vitro
fertilization cycles: a meta-analysis. Fertility and Sterility
2010;93(2):428–36.
Johnson 1999 {published data only}
Johnson M R, Okokon E, Collins W P, Sharma V, Lightman
S L. The effect of human chorionic gonadotropin and
pregnancy on the circulating level of relaxin. Journal of
Clinical Endocrinology and Metabolism 1999;72:1042–7.
Kahraman 2010 {published data only}
∗ Kahraman S, Karagozoglu SH, Karlikaya G. The
efficiency of progesterone vaginal gel versus intramuscular
progesterone for luteal phase supplementation in
gonadotropin-releasing hormone antagonist cycles: a
prospective clinical trial. Fertility and Sterility 2010;94(2):
761–3.
Karagozoglu H, Kahraman S, Karlikaya G, Kavrut M,
Ersahin A. The efficiency of vaginal gel vs intramuscular
progesterone for luteal phase support in GnRH antagonist
cycles: A prospective, randomized trial. Human
Reproduction. 2009; Vol. 24 Suppl 1:i109-10 (Abs #O-
273).
Koper 2008 {published data only}
The Corifollitropin Alfa Dose-finding Study Group. A
randomized dose-response trial of a single injection of
corifollitropin alfa to sustain multifollicular growth during
controlled ovarian stimulation. Human Reproduction 2008;
23(11):2484–92.
Krause 2006 {published data only}
Krause BT, Ohlinger R. Safety and efficacy of low dose hCG
for luteal support after triggering ovulation with a GnRH
agonist in cases of polyfollicular development. European
Journal of Obstetrics Gynecology and Reproductive Biology
2006;126(1):87–92.
Krischker 1998 {published data only}
Krischker U, Poehl M, Bichler K, Feichtinger W. Different
methods of luteal phase support in an in vitro fertilization
(IVF) program [abstract]. Fertility and Sterility 1998;70
Suppl 1:327 (Abs # P-639).
Lam 2003 {published data only}
Lam PM, Cheung LP, Haines CJ. Early luteal phase
progesterone supplementation and IVF-ET outcome
[abstract]. Reproduction 2003;Abstract Series #30:51 (Abs
# P2).
Lan 2007 {published data only}
Lan VTN, Tuan P, Canh L, Tuong H, Howles CM.
Comparison of the efficacy and tolerability of two
formulations of vaginal progesterone for luteal phase
support in frozen embryo transfer cycles. Fertility and
Sterility 2007;88 Suppl 1:164 (Abs #169).
50Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Leeton 1985 {published data only}
Leeton J, Trounson A, Jessup D. Support of the luteal phase
in in vitro fertilization programs: results of a controlled
trial with intramuscular proluton. Journal of In Vitro
Fertilization and Embryo Transfer 1985;2:166–9.
Lightman 1999 {published data only}
Lightman A, Kol S, Itskovitz-Eldor J. A prospective
randomized study comparing intramuscular with
intravaginal natural progesterone in programmed thaw
cycles. Human Reproduction 1999;14:2596–9.
Lukaszuk 2005 {published data only}
Lukaszuk K, Liss J, Lukaszuk M, Maj B. Optimization
of estradiol supplementation during the luteal phase
improves the pregnancy rate in women undergoing in vitro
fertilization-embryo transfer cycles. Fertility and Sterility
2005;83(5):1372–6.
Mahadevan 1985 {published data only}
Mahadevan M M, Leader A, Taylor P J. Effects of low-dose
human chorionic gonadotropin on corpus luteum function
after embryo transfer. Journal of In Vitro Fertilization and
Embryo Transfer 1985;2:190–4.
Marianowski 2000 {published data only}
Marianowski P, Radwanska E. Intramuscular vs vaginal
progesterone for luteal support in cycles of in vitro
fertilization. Ginekologia Polska 2000;71:1064–70.
Martins 2010 {published data only}
Martins WdP. Suporte da fase lutea. Femina 2010;38(5):
271.
McBain 1987 {published data only}
McBain J C, Clarke G A, Molloy D, Yeates J, Johnston
W I H, McKenna M. A randomized trial of progesterone
support following ovarian stimulation with clomiphene
hMG for IVF and GIFT [abstract]. 5th World Congress on
In Vitro Fertilization and Embryo Transfer Abstract Book.
1987:75 (Abs # PP-126).
Mochtar 1996 {published data only}
Mochtar M H, Hogerzeil H V, Mol B W J. Progesterone
alone versus progesterone combined with HCG as
luteal support in GnRHa/HMG induced IVF cycles: a
randomized clinical trial. Human Reproduction 1996;11:
1602–5.
Moraloglu 2008 {published data only}
Moraloglu O, Kilic S, Karayalcin R, Yuksel B, Tasdemir N,
Isik A, et al.Comparison of GnRH agonists and antagonists
in normoresponder IVF/ICSI in Turkish female patients.
Advances in Therapy 2008;25(3):266–73.
Nader 1988 {published data only}
Nader S, Berkowitz A S, Ochs D, Held B, Winkel C
A. Luteal-phase support in stimulated cycles in an in
vitro fertilization/embryo transfer program: progesterone
versus human chorionic gonadotropin. Journal of In Vitro
Fertilization and Embryo Transfer 1988;5:81–4.
Nikkanen 1992 {published data only}
Nikkanen V, Kresanov I, Makinen J, Vuorento T. The effect
of luteal support with human chorionic gonadotrophin or
progesterone on the daily progesterone profile after different
types of ovarian stimulation. Human Reproduction 1992;7:
333–6.
Ozcimen 2004 {published data only}
Ozcimen EE, Ugur M, Ozcimen N, Yilmaz Z. Is luteal
phase support with hCG or vaginal micronised progesterone
beneficial in non-IVF gonadotropin induction of ovulation?
. Fertility and Sterility 2004;82 Suppl 2:142.
Papanikolaou 2010 {published data only}
Papanikolaou E, Werpoest W, Fatemi H, Polyzos N,
Humaidan P, Tarlatzis B, et al.Recombinant LH as luteal
supplementation method after agonist triggering in IVF. A
proof of concept study [abstract]. Human Reproduction.
2010; Vol. 25:i167-8 (Abs #P-134).
∗ Papanikolaou EG, Fatemi H, Kyrou D, Polyzos NP,
Humaidan P, Tarlatzis B, Devroey P, Tournaye H. Higher
birth rate after recombinant hCG triggering compared with
urinary-derived hCG in single-blastocyst IVF antagonist
cycles: a randomized controlled trial. Fertility and Sterility
2010;94(7):2902–4.
Pirard 2005 {published data only}
Pirard C, Donnez J, Loumaye E. GnRH agonist as novel
luteal support: results of a randomized, parallel group,
feasibility study using intranasal administration of buserelin.
Human Reproduction 2005;20(7):1798–804.
Polson 1992 {published data only}
Polson DW, Rogers PAW, Krapez JA, Leeton JF. Vaginal
progesterone as luteal phase support in an IVF/GIFT
programme. European Journal of Obstetrics Gynecology and
Reproductive Biology 1992;46(1):35–8.
Schwarzler 2003 {published data only}
Schwarzler P, Abendstein BJ, Klingler A, Kreuzer E,
Rjosk HK. Prevention of severe ovarian hyperstimulation
syndrome (OHSS) in IVF patients by steroidal ovarian
suppression - A prospective randomized study. Human
Fertility 2003;6(3):125–9.
Simunic 2007 {published data only}
Simunic V, Tomic V, Tomic J, Nizic D. Comparative study
of the efficacy and tolerability of two vaginal progesterone
formulations, Crinone 8% gel and Utrogestan capsules,
used for luteal support. Fertility and Sterility 2007;87(1):
83–7.
Singh 2010 {published data only}
Singh T, Majumdar A. Supplementation of gonadotrophin
releasing hormone (GnRH) agonist during the luteal
phase improves the pregnancy outcome in intrauterine
insemination (IUI) cycles, when compared with
human chorionic gonadotrophin (hCG). Journal fur
Reproduktionsmedizin und Endokrinologie. Munich,
Germany, 2010:277 (Abs 15-7).
Smith 1989 {published data only}
Smith E M, Anthony F W, Gadd S C, Masson GM. Trial of
support treatment with human chorionic gonadotrophin in
the luteal phase after treatment with buserelin and human
menopausal gonadotrophin in women taking part in an in
vitro fertilisation programme. BMJ 1989;298:1483–6.
51Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Smitz 1988 {published data only}
Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen
C, et al.The luteal phase and early pregnancy after combined
GnRH-agonist/HMG treatment for superovulation in IVF
or GIFT. Human Reproduction 1988;3(5):585–90.
Smitz 1992 {published data only}
∗ Smitz J, Devroey P, Faguer B, Bourgain C, Camus M,
van Steirteghem A. A prospective randomized comparison
of intramuscular or intravaginal natural progesterone as
a luteal phase and early pregnancy supplement. Human
Reproduction 1992;7:168–75.
Smitz J, Devroey P, Faguer B, Bourgain C, Camus M, van
Steirteghem AC. A randomized prospective study comparing
supplementation of the luteal phase and early pregnancy
by natural progesterone administered by intramuscular or
vaginal route [Etude prospective randomisee comparant
la supplementation de la phase luteale et de la grossesse
debutante par la progesterone naturelle administree par
voie intra–musculaire ou vaginale]. Revue Francaise de
Gynecologie et d Obstetrique 1992;87(10):507–516.
Smitz 1993 {published data only}
Smitz J, Bourgain C, Van Waesgerghe L, Camus M,
Devroey P, Van Steirteghem AC. A prospective randomized
study on oestradiol valerate supplementation in addition
to intravaginal micronized progesterone in buserelin and
HMG induced superovulation. Human Reproduction 1993;
8:40–5.
Sordal 1993 {published data only}
Sordal T, Kahn J A, Sunde A, von Düring V, Molne
K. A prospective randomized study comparing natural
progesterone administered intramuscularly and vaginal
micronized progesterone for luteal support [abstract].
Human Reproduction 1993;8 Suppl 1:39 (Abs # 99).
Stadtmauer 2009 {published data only}
Stadtmauer L, Harrison DD, Boyd J, Bocca S, Oehninger S.
Pilot study evaluating a progesterone vaginal ring for luteal-
phase replacement in donor oocyte recipients. Fertility and
Sterility 2009;92(5):1600–5.
Tay 2003 {published data only}
Tay PY, Lenton EA. Inhibition of progesterone secretion
by oestradiol administered in the luteal phase of assisted
conception cycles. Medical Journal of Malaysia 2003;58(2):
187–95.
Trounson 1986 {published data only}
Trounson A, Howlett D, Rogers P, Hoppen H O. The effect
of progesterone supplementation around the time of oocyte
recovery in patients superovulated for in vitro fertilization.
Fertility and Sterility 1986;45:532–5.
Unfer 2004 {published data only}
Unfer V, Casini M, Costabile L, Gerli S, Baldini D, Di
Renzo GC. 17 alpha-hydroxyprogesterone caproate versus
intravaginal progesterone in IVF-embryo transfer cycles: a
prospective randomized study. Reproductive BioMedicine
Online 2004;9(1):17–21.
Unfer 2004a {published data only}
Unfer V, Casini ML, Gerli S, Costabile L, Mignosa M, Di
Renzo GC. Phytoestrogens may improve the pregnancy rate
in in vitro fertilization-embryo transfer cycles: a prospective,
controlled, randomized trial. Fertility and Sterility 2004;82
(6):1509–13.
Valentino 2004 {published data only}
Valentino V, Artini P G, Ruggiero M, Parisen Toldin M R,
Cristello F, et al.A randomised comparison of effects and
patient inconvenience of two progesterone supplementation
used in in vitro fertilisation cycles. Gynaecological
Endocrinology 2004;18 Suppl 1:358 (Abs # P-170).
van Steirteghem 1988 {published data only}
van Steirteghem AC, Smitz J, Camus M, Van Waesberghe
L, Deschacht J, Khan I, et al.The luteal phase after in-vitro
fertilization and related procedures. Human Reproduction
1988;3:161–4.
Var 2011 {published data only}
Var T, Aysin Tonguc E, Doganay M, Gulerman C, Gungor
T, Mollamahmutoglu L. A comparison of the effects of
three different luteal phase support protocols on in vitro
fertilization outcomes: a randomized clinical trial.. Fertility
and Sterility 2011;95:985–9.
Wang 2009 {published data only}
Wang LJ, Huang FJ, Kung FT, Lin PY, Chang SY, Lan KC.
Comparison of the efficacy of two vaginal progesterone
formulations, Crinone 8% gel and Utrogestan capsules,
used for luteal support in blastocyst stage embryo transfers.
Taiwanese Journal of Obstetrics & Gynecology 2009;48(4):
375–9.
Wilcox 2001 {published data only}
Wilcox J, Nelson JR, Potter D, Frederick J, Feinman M,
Batzofin J. Comparison of different luteal phase support
protocols for frozen embryo transfer (FET) [abstract].
Fertility and Sterility 2001;76 Suppl 1:124 (Abs # P-37).
Ye 2009 {published data only}
Ye H, Huang GN, Zeng PH, Pei L. IVF/ICSI outcomes
between cycles with luteal estradiol (E2) pre-treatment
before GnRH antagonist protocol and standard long GnRH
agonist protocol: A prospective and randomized study.
Journal of Assisted Reproduction and Genetics 2009;26(2-3):
105–11.
Yigit 2002 {published data only}
Yigit N, Halicigil C, Basaran M, Aksu T, Yarali H. Crinone
and i.m. progesterone yield comparable pregnancy rates
following ICSI and embryo transfer [title only]. Human
Reproduction 2002;17(Abstract Book 1):201 (Abs # R-624).
Yovich 1984 {published data only}
Yovich JL, Stanger JD, Yovich JM, Tuvik AI. Assessment
and hormonal treatment of the luteal phase of in vitro
fertilization cycles. Australian & New Zealand Journal of
Obstetrics & Gynaecology 1984;24:125–30.
Yovich 1985 {published data only}
Yovich J L, McColm S C, Yovich J M, Matson P L. Early
luteal serum progesterone concentrations are higher in
pregnancy cycles. Fertility and Sterility 1985;44:185–9.
52Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yovich 1991 {published data only}
Yovich JL, Rohini Edirisinghe W, Cummins JM. Evaluation
of luteal support therapy in a randomized controlled study
within a gamete intrafallopian transfer program. Fertility
and Sterility 1991;55:131–9.
References to studies awaiting assessment
Esra 2010 {published data only}
Esra T, Var T, Citil A, Dogan M, Cicek N. Estradiol
supplementation in luteal phase: How much matter?.
Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:
i307–8.
Gallardo 2004 {published data only}
Gallardo LE, Ayón P, Neuspiller F. [Estudio de dos vías
diferentes de administración de progesterona micronizada
en reproducción asistida]. Ginecología y Obstetricia de
México 2004;72(8):407–10.
Humaidan 2006 {published data only}
Humaidan P, Bungum L, Bungum M, Andersen CY. Rescue
of corpus luteum function with peri-ovulatory HCG
supplementation in IVF/ICSI GnRH antagonist cycles in
which ovulation was triggered with a GnRH agonist: a pilot
study. Reproductive BioMedicine Online 2006;13(2):173–8.
Jung 2010 {published data only}
Jung YH, Kim YY, Kim MH, Cho JD. The best luteal phase
support protocol for patients who had E2 levels <1500 pg/
ml on the hCG day in a long GnRH agonist cycles. Fertility
and Sterility 2010;94 Suppl 1(4):177.
Mochtar 2006 {published data only}
Mochtar MH, Van Wely M, Van der Veen F. Timing luteal
phase support in GnRH agonist down-regulated IVF/
embryo transfer cycles. Human Reproduction 2006;21(4):
905–8.
Paredes 2004 {published data only}
Paredes Chavez FC, Barros Delgadillo JC, Ochoa Rueda
SS, Barroso Villa G, et al.[Papel de los estrógenos en el
soporte de la fase lútea en ciclos de fertilización in vitro con
transferencia de embriones]. Ginecología y Obstetricia de
México 2004;72(12):645–55.
Shamma 1992 {published data only}
Shamma F, Haj-Hassan L, Penzias A, Gutmann J, Leykin
L, Jones E. Luteal phase support in in vitro fertilization
embryo transfer (IVF-ET) - a prospective randomized trial
[abstract]. American Fertility Society 48th Annual Meeting
Abstract Book. 1992:S140-1 (Abs # P-074).
Silverberg 2010 {published data only}
Silverberg K, Vaughn TC, Hansard L, Burger N, Minter T.
Progesterone vaginal gel vs. intramuscular progesterone
in oil for luteal support in IVF: a large, prospective trial
[abstract]. Fertility and Sterility. 2010; Vol. Suppl 1:21
(Abs # O-69).
Additional references
Balasch 2004
Balasch J. The role of FSH and LH in ovulation induction:
current concepts and the contribution of recombinant
gonadotropins. In: Gardner DK, Weissman A, Howles
and Shoham V editor(s). Textbook of Assisted Reproductive
Techniques. Laboratory and Clinical Perspectives. 2nd
Edition. London and New York: Taylor & Francis, 2004:
541–565.
CDC 2009
Centers for Disease Control and Prevention ASfRM, Society
for Assisted Reproductive Technology 2007. Assisted
Reproductive Technology Success Rates: National Summary
and Fertility Clinic Reports, Atlanta. US Department of
Health and Human Services, Centres for Disease Control
and Prevention 2009.
Chan 2003
Chan CC, Ng EH, Chan MM, Tang OS, Lau EY, Yeung
WS, et al.Bioavailability of hCG after intramuscular or
subcutaneous injection in obese and non-obese women.
Human Reproduction 2003;18(11):2294–7.
Choavaratana 2004
Choavaratana R, Manoch D. Efficacy of oral micronized
progesterone when applied via vaginal route. Journal of the
Medical Association of Thailand 2004;87(5):455–8.
de Mouzon 2010
de Mouzon J, Goossens V, Bhattacharya S, Castilla
JA, Ferraretti AP, Korsak V, et al.Assisted reproductive
technology in Europe, 2006: results generated from
European registers by ESHRE. Human Reproduction 2010;
25(8):1851–62.
Edwards 1980
Edwards RG, Steptoe PC, Purdy JM. Establishing full-term
human pregnancies using cleaving embryos grown in vitro.
British Journal of Obstetrics and Gynaecology 1980;87(9):
737–56.
Farquhar 2010
Farquhar C, Roberts H. Introduction to Obstetrics and
Gynaecology. Third Edition. Auckland: Department of
Obstetrics & Gynaecology, The University of Auckland,
2010.
Fatemi 2009
Fatemi HM. The luteal phase after 3 decades of IVF: what
do we know?. Reproductive Biomedicine Online 2009;19(4):
4331.
Higgins 2011
Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1 [updated
March 2011]. The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
Kerin 1981
Kerin JF, Broom TJ, Ralph MM, Edmonds DK, Warnes
GM, Jeffrey R, et al.Human luteal phase function following
oocyte aspiration from the immediately preovular graafian
follicle of spontaneous ovular cycles. British Journal of
Obstetrics and Gynaecology 1981;88(10):1021–8.
53Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mannaerts 1998
Mannaerts BM, Geurts TB, Odink J. A randomized
three-way cross-over study in healthy pituitary-suppressed
women to compare the bioavailability of human chorionic
gonadotrophin (Pregnyl) after intramuscular and
subcutaneous administration. Human Reproduction 1998;
13(6):1461–4.
Messinis 2009
Messinis IE, Messini CI, Dafopoulos K. Luteal-phase
endocrinology. Reproductive Biomedicine Online 2009;19
(4):4314.
Miyake 1979
Miyake A, Aono T, Kinugasa T, Tanizawa O, Kurachi K.
Suppression of serum levels of luteinizing hormone by
short- and long-loop negative feedback in ovariectomized
women. Journal of Endocrinology 1979;80(3):353–6.
Mochtar 2007
Mochtar MH, Van der Veen F, Ziech M, van Wely M,
Musters A. Recombinant Luteinizing Hormone (rLH) for
controlled ovarian hyperstimulation in assisted reproductive
cycles. Cochrane Database of Systematic Reviews 2007, Issue
2. [DOI: 10.1002/14651858.CD005070.pub2.]
Pabuccu 2005
Pabuccu R, Akar ME. Luteal phase support in assisted
reproductive technology. Current Opinion in Obstetrics and
Gynecology 2005;17(3):277–81.
Saal 1991
SaalW,GlowaniaHJ,HengstW,Happ J. Pharmacodynamics
and pharmacokinetics after subcutaneous and intramuscular
injection of human chorionic gonadotropin. Fertility and
Sterility 1991;56(2):225–9.
Schindler 2009
Schindler AE. Progestational effects of dydrogesterone in
vitro, in vivo and on the human endometrium. Maturitas
2009;65(1):S3–11.
Smitz 1992a
Smitz J, Erard P, Camus M, Devroey P, Tournaye H,
Wisanto A, et al.Pituitary gonadotrophin secretory capacity
during the luteal phase in superovulation using GnRH-
agonists and HMG in a desensitization or flare-up protocol.
Human Reproduction 1992;7(9):1225–9.
Tavaniotou 2003
Tavaniotou A, Devroey P. Effect of human chorionic
gonadotropin on luteal luteinizing hormone concentrations
in natural cycles. Fertility and Sterility 2003;80(3):654–5.
Tesarik 2004
Tesarik J, Hazout A, Mendoza C. Enhancement of embryo
developmental potential by a single administration of
GnRH agonist at the time of implantation. Human
Reproduction 2004;19(5):1176–80.
Wang 2009a
Wang YA, Chambers GM, et al.Assisted reproductive
technology in Australia and New Zealand 2007. Assisted
reproductive technology series no 13 Cat no PER 47
Canberra: AIHW 2009.
Wikland 1995
Wikland M, Borg J, Forsberg AS, Jakobsson AH, Svalander
P, Waldenstrom U. Human Chorionic-Gonadotropin Self-
Administered by the Subcutaneous Route to Induce Oocyte
Maturation in an in-Vitro Fertilization and Embryo-
Transfer Program. Human Reproduction 1995;10(7):
1667–70.
References to other published versions of this review
Daya 2004
Daya S, Gunby J. Luteal phase support in assisted
reproduction cycles. Cochrane Database of Systematic Reviews
2004, Issue 3. [DOI: 10.1002/14651858]
∗ Indicates the major publication for the study
54Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abate 1999
Methods Randomized placebo controlled trial.
Participants Women undergoing first time IVF/ET for tubal factor infertility, age <38 (n=86)
Interventions Pituitary desensitization (PD) and controlled ovarian hyperstimulation (COH): GnRH
agonist, 400µg sc twice daily and FSH
ET: day +2, max 4 embryos transferred.
LPS: 17 alpha-hydroxyprogesterone 341mg im every 3 days vs saline im every 3 days.
From day before ET until pregnancy test (day +14)
Outcomes Pregnancy (not defined).
Notes No reply from author in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients [...] were randomly allocated.”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Abate 1999a
Methods Randomized placebo controlled trial.
Participants Women undergoing IVF/ET for tubal occlusion, age 25-35y (n=156)
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Abate 1999a (Continued)
Interventions PD/COH: GnRH agonist im and FSH.
ET: day +2, max 4 embryos transferred.
LPS: progesterone 50mg imdaily vs progesterone 90mg vaginal gel daily vs saline solution
every 3 days. All from day before ET (+1) until hCG test (+16)
Outcomes Biochemical pregnancy (small transitory increase in ß-hCG levels, followed by a decrease
within a week), clinical pregnancy (gestational sac or serum hCG≥1400mIU), ongoing
pregnancy (20 weeks gestational), live birth
Notes No reply from author in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “They were randomly treated”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Aboulghar 2008
Methods Randomized controlled trial.
Participants Women who have a clinical pregnancy after ICSI with im progesterone or vaginal pro-
gesterone as luteal phase support, mean age 30 (n=257)
Interventions PD/COH: GnRH agonist
LPS: vaginal progesterone 600 mg or progesterone 50 mg IM until first US vs aginal
progesterone 600 mg or progesterone 50 mg IM until 3 weeks after first US
Outcomes Miscarriage (up to 20 weeks gestation)
Notes
56Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Aboulghar 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Dark, sealed envelopes contained the intervention
(continuation or stoppage of LPS) were created by a
third party not involved in the allocation process. Ran-
domization was performed by picking one envelope for
each patients from sequentially numbered envelopes.”
Allocation concealment (selection bias) Low risk Dark, sealed envelopes created by third party.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patient was informed about the allocated arm”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Albert 1991
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET (n=57).
Interventions PD/COH: GnRH agonist and hMG.
LPS: hCG 2,500 IU 4 times vs progesterone 50mg im at day of ET, then 12.5mg im
daily
Outcomes Clinical pregnancy (not defined), OHSS.
Notes Only abstract available.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were treated in a prospective, randomized fash-
ion”
Method of randomization not reported.
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Albert 1991 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes not reported.
Artini 1995
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET for tubal factor, oligospermia or unexplained infertility,
mean age 33 (n=176)
Interventions COH: GnRH agonist im and FSH.
ET: day +2.
LPS: progesterone 50mg im daily vs progesterone 100mg daily in vaginal cream vs hCG
2000IU im every 3 days vs no supplementation
Outcomes Viable pregnancy (not defined).
Notes No reply from author in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly divided”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
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Artini 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Ata 2008
Methods Randomized controlled trial.
Participants Women undergoing ART with at least one embryo available for transfer, mean age 31
(n=570)
Interventions COH: GnRH agonist 0.1mg sc from 21st day of preceding cycle + rFSH
ET: day +3, max 3 embryos transferred.
LPS: progesterone 90mg vaginal gel daily + 0.1 mg GnRH agonist (triptorelin) sc at day
+9 vs progesterone 90mg vaginal gel daily + saline sc at day +9
Outcomes Clinical pregnancy (fetus with heartbeat at 6 weeks gestation), ongoing pregnancy (be-
yond 20th week of gestation), multiple pregnancy (gestation with more than one fetus)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Womenwere randomized according to a computer gen-
erated randomization list prepared by the chief investi-
gator. Study subjects were randomized in blocks of 10.
Opaque envelopes, which were numbered and sealed,
containing the allocation information were given to the
hospital pharmacy.”
Allocation concealment (selection bias) Low risk Numbered, sealed, opaque enveloped were given to hos-
pital pharmacy
“The allocation code was broken upon completion of
the 20th gestational week of the last pregnant subject.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both the nurse injecting the study medication and the
women receiving injections were blinded for allocation.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Outcome assessors who performed the pregnancy tests
and ultrasonographic examinations to determine if the
patient was pregnant were also blinded for allocation.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons for withdrawal reported.
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Ata 2008 (Continued)
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Beckers 2000
Methods Randomized controlled trial, 3 different pituitary desensitization protocols whether com-
bined with LPS
Participants Women undergoing IVF for tubal or male factor, age <39, mean age 32 (n=38). Women
with ovarian hyperresponse (estradiol >8000 pmol/l) were excluded from analysis
Interventions PD/COH: GnRH agonist 0.1mg sc from cycle day 1 until trigger vs GnRH agonist 0.
1mg sc from cycle day 1 until 3rd day of hMG stimulation vs GnRH agonist 0.1mg sc
from cycle day 1 until hCG trigger. Followed by hMG for COH
ET: day 4, max 2 embryos transferred.
LPS: hCG 1500 IU im on day of oocyte retrieval, +2, +4, +6 vs no treatment vs no
treatment
Outcomes Pregnancy (positive urine test), ongoing pregnancy, live birth and miscarriage. Multiple
pregnancy rate is mentioned, but not defined per group
Notes Author contacted in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized on the same day
(i.e. day 1 of the treatment cycle) by means
of sealed envelopes for one of the three
treatment groups A, B or C (20 patients
each)”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reason withdrawals reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
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Belaisch-Allart 1987
Methods Randomized placebo controlled trial.
Participants Women undergoing IVF (87% for tubal factor), mean age 33 (n=286)
Interventions PD/COH: Clomiphene + hMG or pure FSH or FSH + hMG or oral contraceptive pill
+ clomiphene-hMG
ET: mean 2.2 embryos transferred.
LPS: Oral dydrogesterone 10mg 3x daily vs oral placebo 3x daily. Both from oocyte
retrieval for 21 days
Outcomes Pregnancy (not defined), ongoing pregnancy, miscarriage.
Notes Author contacted in 2004, unable to provide any information.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The treatment was allocated according to a
double-blind randomized list.”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind randomized list”
Not specified.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind randomized list”
Not specified.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Belaisch-Allart 1990
Methods Multi-centre (12), randomized placebo controlled trial.
Participants Women undergoing IVF for tubal sterility (50%), serum estradiol on day of ET <2,500
pg/ml, mean age 33 (n=387)
Interventions PD/COH: GnRH agonist in long (67%) or short protocol + hMG.
ET: mean 3 embryos transferred, up to >4.
LPS: hCG 1500 IU vs placebo. Both on day of ET and 4 days after ET
Outcomes Pregnancy (not defined), ongoing pregnancy rate, OHSS.
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Belaisch-Allart 1990 (Continued)
Notes 2 Authors employed by Organon. Author contacted in 2004, unable to provide any
information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A double-blind, randomized list in each
centre.”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double blind, not specified.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double blind, not specified.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Caligara 2007
Methods Randomized controlled trial.
Participants Women undergoing IVF with 10 or less oocytes retrieved and a max estradiol level of
2500 pg/ml at hCG trigger
Interventions LPS: vaginal progesterone 200 mg two times daily vs vaginal progesterone 200 mg two
times daily plus hCG 1000 IU sc on day +4, +7 and +10. Progesterone from day after
oocyte retrieval
Outcomes Pregnancy rate (not defined).
Notes Only abstract available. Author contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization.
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Caligara 2007 (Continued)
Allocation concealment (selection bias) Low risk By phone call to unrelated department
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding used.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding used.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes not reported.
Ceyhan 2008
Methods Randomized controlled trial.
Participants Women undergoing IVF, excluding endometriosis, polycystic ovarian syndrome and
severe male factor, age < 36, mean 31 (n=60)
Interventions PD/COH: GnRH antagonist 0.25mg daily from day 6 until day of trigger + rFSH.
ET: day 3 or 5, mean 2 embryos transferred.
LPS: Vaginal progesterone 600 mg daily vs vaginal progesterone 600 mg daily + estrogen
transdermal 100ug/d estradiol release, twice weekly. Both from day of oocyte retrieval
until 8 weeks gestation when pregnant
Outcomes Pregnancy rate (serumß-hCG>10mIU/mL), clinical pregnancy (intrauterine gestational
sac), ongoing pregnancy (intrauterine gestational sac and fetal heartbeat after 13th week
amenorrhoea), OHSS
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Sample randomization performed by a computer”
Allocation concealment (selection bias) Low risk “Central consultation was used for allocation of pa-
tients”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “no blinding was used during follow-up”
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Ceyhan 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “no blinding was used during follow-up”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reason withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Chakravarty 2005
Methods Randomized controlled trial.
Participants Women undergoing IVF/ICSI-ET, excluding women with PCOS, advanced en-
dometriosis, dense pelvic adhesions genital tuberculosis or previous failed IVF/ICSI cy-
cles. Age 25-42 (n=430)
Interventions PD/COH: GnRH agonist 1 mg sc + r-FSH 150-200 IU sc.
ET: day 2, average of 3 embryos transferred.
LPS: micronized vaginal progesterone 200 mg 3x daily vs oral dydrogesterone 10 mg
twice daily. Both from day of ETuntil ß-hCG test or up to 12 weeks when pregnant
Outcomes Clinical pregnancy (not defined), miscarriage and viable delivery rate
Notes No reply from author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patients were randomly selected”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
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Colwell 1991
Methods Randomized controlled trial.
Participants Women undergoing IVF, excluding women with luteal phase <12 days in previous cycles,
mean age 33 (n=39)
Interventions PD/COH: clomiphene citrate 100mg oral from day 5 until 9+ hMG
ET: day +2, mean 2.6 embryos transferred, ET in only 55% of women
LPS: progesterone 200mg oral 4 times daily vs no supplementation
Outcomes Ongoing pregnancy (not defined), multiple pregnancy.
Notes No reply from author in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subjects were randomly assigned”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All RIAs were performed by personnel blinded to the
group assignment of each subject”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons for withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Dal Prato 2008
Methods Randomized controlled trial.
Participants Women undergoing IVF for idiopathic, tubal or male factor, grade I-II endometriosis
and no more then 3 previous cycles, mean age 33 (n=412)
Interventions PD/COH: long protocol GnRH agonist + FSH.
IVF/ET: Age <35: 2 embryos transferred, age >35: 3 embryos transferred
LPS: progesterone 50 mg im daily vs vaginal progesterone gel 90 mg once daily vs vaginal
progesterone gel 90 mg twice daily. All from oocyte retrieval for 15 days or until first US
when pregnant
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Dal Prato 2008 (Continued)
Outcomes Live birth (one or more live babies), clinical pregnancy (one or more gestational sacs)
, ongoing pregnancy, miscarriage (pregnancy loss after US confirmation of embryo im-
plantation and before 12 weeks)
Notes Author contacted.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization list was provided by an external
statistician and the treatment sequence given to the in-
vestigator using sealed envelopes containing the name
of one of the three medications”
Allocation concealment (selection bias) Low risk “Dark envelopes were used so their content could not
be seen against bright light. Each envelope and alloca-
tion was sequentially numbered to prevent patients from
being randomized out of sequence. Envelopes were not
allowed to be opened in advance
and were opened only by a nurse not involved in the
trial.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “No blinding procedure was planned for this study due
to the complex management of the blinding procedures
with two different routes of administration”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “No blinding procedure was planned for this study due
to the complex management of the blinding procedures
with two different routes of administration”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reason withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Doody 2009
Methods Multi-centre (25) randomized controlled trial.
Participants Women undergoing IVF, excluding women who had a history of recurrent (≥3 spon-
teneous abortions) pregnancy loss, abnormal uterine bleeding of undetermined origin,
or a history of either poor response to gonadotrophin or two previous cancelled cycles,
mean age 33 (n=1211)
Interventions PD/COH: long protocol GnRH agonist + hMG (Menopur) + FSH (Bravelle)
ET: max 3, mean 2.4 embryos transferred.
LPS: progesterone vaginal capsules 100 mg 2x daily vs progesterone vaginal capsules 100
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Doody 2009 (Continued)
mg 3x daily vs progesterone vaginal gel
Outcomes Ongoing pregnancy (fetal heart movement at 6 weeks), clinical pregnancy (gestational
sac), live birth
Notes 2 Authors are employees of Ferring Pharmaceuticals, one author receives grant support
from Ferring Pharmaceuticals, acts as a consultant for Ferring Pharmaceuticals, Ethicon
Endo Surgery, Ethicon Women’s Health and Urology, Smith & Nephew, Galil Medical,
and Boston Scientific, and serves on speakers bureaus for Boston Scientific, Ferring
Pharmaceuticals, Ethicon Endo Surgery, and Ethicon Women’s Health and Urology
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Allocation to treatment group was per-
formed by a telephone-based electronic in-
teractive voice response system, which en-
sured an equal number of patients per treat-
ment group across the study centers and
stratification factors.”
Allocation concealment (selection bias) Low risk Telephone-based electronic interactive
voice response system
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Study drug was administered on an open-
label basis”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The study was assessor-blinded; the per-
son who performed the transvaginal ultra-
sound examinations to confirm clinical and
ongoing pregnancy was blinded to the pa-
tient’s treatment group assignment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawals reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Drakakis 2007
Methods Randomized controlled trial.
Participants Women undergoing IVF/ICSI for tubal factor,male infertility, anovulation, endometrio-
sis and unexplained infertility, mean age 35 (n=76)
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Drakakis 2007 (Continued)
Interventions PD/COH: GnRH agonist 100 µg intranasal 5 times daily from day 21 preceeding cycle
for 15-24 days + r-FSH
LPS: progesterone 100 µg oral 3x daily + vaginal progesterone capsules 200 mg 3x daily
until pregnancy test + estradiol valerate oral 2mg + 0.5 mg norgesterel 3x daily for 15
days + estradiol hemihydrate 50 µg transdermal patch every 4 days vs progesterone 100
µg oral 3x daily + vaginal progesterone capsules 200 mg 3x daily until pregnancy test
Outcomes Clinical pregnancy, miscarriage.
Notes No reply from author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were divided randomly into two groups ac-
cording to the protocol used.”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Dunstone 1999
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET (n=38).
Interventions LPS: progesterone 400mg vaginal pessaries twice daily vs progesterone 90mg vaginal gel
daily. Both from night before oocyte retrieval until pregnancy test
Outcomes Clinical pregnancy (fetal heartbeat at ultrasound)
Notes No reply from author in 2004. Only abstract available.
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Dunstone 1999 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Women undergoing IVF-ET treatment were randomly
assigned”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Preliminary results are available for 38 women of a
planned total of 100.”
Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes not reported.
Elgindy 2010
Methods Randomized controlled trial.
Participants Women undergoing their first ICSI cycle for male factor infertility, mean age 29 (n=270)
Interventions PD/COH: GnRH agonist 0.1 mg sc from midluteal phase of the pretreatment cycle +
r-FSH + hMG
ET: day 2, mean 3 embryos transferred.
LPS: progesterone 100 mg im daily vs progesterone 100 mg im daily + E2 valerate 2 mg
orally 3x daily vs progesterone 100 mg im daily + E2 valerate 2 mg vaginally 3x daily
Outcomes Clinical pregnancy (not defined).
Notes No reply from author.
Risk of bias
Bias Authors’ judgement Support for judgement
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Elgindy 2010 (Continued)
Random sequence generation (selection
bias)
Low risk “Study participants were randomized into three groups,
90 women each, using the block randomization tech-
nique.”
Allocation concealment (selection bias) Low risk “Two hundred seventy identical sealed envelopes were
prepared by one of the investigators (M.I.M.) and kept
in the unit pharmacy.When the woman was eligible and
agreed to participate, she was instructed to select only
one envelope only once to determine the group to which
she was assigned. The randomization key was kept with
the pharmacy director and was not opened until after
statistical analysis”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcome reported.
Engmann 2008
Methods Ranomized controlled trial.
Participants Women undergoing first cycle of IVF, excluding women with high risk of OHSS, mean
age 35 (n=166)
Interventions PD/COH: GnRH agonist or antagonist or microdose GnRH agonist and rFSH or FSH
+ u-hMG.
ET: day 3, mean 2.5 embryos transferred.
LPS: progesterone 50 mg im daily vs progesterone 50 mg im daily + estradiol 2 mg
vaginally 2x daily. Both from oocyte retrieval until pregnancy test or fetal heartbeat when
pregnant
Outcomes Clinical pregnancy (gestational sac and positive heartbeat), ongoing pregnancy (beyond
12 weeks), miscarriage
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Engmann 2008 (Continued)
Random sequence generation (selection
bias)
Low risk “They were randomly assigned to either group in a ratio
of 1:1 by means of computer-generated random numbers
on the day of ET. To ensure similar distribution of pa-
tients with low peak serum E2 concentration in the two
groups, separate randomization schedules were drawn up
for women with peak E2 levels on the day of hCG ad-
ministration of%1200 pg/mL and for those with levels
>1200 pg/mL by the use of stratified randomized blocks.
”
Allocation concealment (selection bias) Low risk “Selection into the groups was performed by a research
nurse using a series of consecutively numbered sealed
opaque envelopes (one for each category of peak serum
E2 level), so the sequence of allocation was concealed.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The study was not blinded because the patients as well
as the clinicians were aware of the treatment group.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “The study was not blinded because the patients as well
as the clinicians were aware of the treatment group.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons for withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Fatemi 2006
Methods Randomized controlled trial.
Participants Women undergoing IVF or ICSI/ET, excluding women with PCO, endometriosis >
grade 2, TESE and need for pre-implantation genetic diagnosis. Mean age 32 (n=201)
Interventions PD/COH: GnRH antagonist 0.25 mg daily from day 6+ rFSH.
ICSI or IVF/ET: Day 3, 1 or 2 embryos transferred.
LPS: natural micronized progesterone vaginal capsules 200mg 3x daily vs natural mi-
cronized progesterone vaginal capsules 200mg 3x daily + oral E2 valerate 2mg twice
daily. From day after oocyte retrieval until 7 weeks of gestation
Outcomes Ongoing pregnancy (beyond 12 weeks), early pregnancy loss (initially positive hCG test,
failed to develop beyond 12 weeks)
Notes Author contacted.
Risk of bias
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Fatemi 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “According to a computer-generated not concealed ran-
domization list prior to initiation of stimulation.”
Allocation concealment (selection bias) High risk Not concealed randomization list.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding used.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding used.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reason of withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Other bias High risk Only abstract available.
Friedler 1999
Methods Randomized controlled trial.
Participants Women undergoing ICSI/ET for male factor infertility with >1 embryo available and a
serum oestradiol >2500 pg/ml on day of hCG, mean age 31 (n=64)
Interventions PD/COH: GnRH agonist + hMG.
ICSI/ET: day 2, max 3 embryos transferred except in older women (>38 yrs) or in cases
of recurrent failures of implantation
LPS: micronized progesterone 200mg oral 4 times daily vs micronized progesterone 100
mg vaginal 2 times daily. Both from day +1 after ET until serum test (+14)
Outcomes Pregnancy (not defined), ongoing pregnancy, miscarriage.
Notes No reply from author in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “The patients included in this study were prospectively
randomized by order of embryo transfer”
Method of randomization not reported.
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Friedler 1999 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Fujimoto 2002
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET, including only women with lowmid-luteal serum estradiol
in a previous cycle, mean age 35 (n=114)
Interventions PD/COH: long protocol GnRH agonist 300µg intranasal 3x daily + hMG
ET: day 2 or 3, max 3 embryos transferred.
LPS: progesterone 25 mg injection once daily from day after oocyte retrieval vs proges-
terone 25 mg injection once daily from day after oocyte retrieval + hCG 3000 IU im on
days 1, 4, 7 after ET
Outcomes Pregnancy (gestational sac)
Notes Study investigates progesterone as luteal phase support in 436 women. Women who fail
to conceive (n=114) are included in a second cycle in which they are randomized to
receive either progesterone or progesterone + hCG. Only women undergoing the second
cycle are included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “They were randomly treated”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
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Fujimoto 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcome reported.
Ganesh 2011
Methods Randomized controlled trial.
Participants Women undergoing IVF/ICSI, excluding women with baseline FSH >12 IU and ade-
nomyosis, mean age 32 (n=1363)
Interventions PD/COH: GnRH agonist 500 µg sc daily + r-FSH.
ET: day 2, average of 3 embryos transferred.
LPS: dydrogesterone 10 mg oral daily vs micronized progesterone vaginal gel 90 mg
daily vs micronized progesterone vaginal capsules 200mg 3x daily. All from ET until 12
weeks gestation
Outcomes Clinical pregnancy (viable fetus on US), ongoing pregnancy (viable fetus at 12 weeks
gestation), miscarriage
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Sequentially numbered sealed envelopes were prepared
and provided by the study coordinator, according to ran-
dom-number tables.”
Allocation concealment (selection bias) Low risk Sequentially numbered sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Single-blinding was achieved by keeping the person
enrolling participants, study investigators, ultrasound
technicians, and clinicians unaware of the type of pro-
tocol used.” Method of blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Only the statisticians had access to the unblinded data.
A double-blind study protocol was not possible because
the drug delivery method in the three groups was differ-
ent”
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Ganesh 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawal reported.
Selective reporting (reporting bias) High risk Ongoing pregnancy results are not reported, but are re-
ported in the protocol
Geber 2007
Methods Randomized controlled trial.
Participants Women undergoing ART (n=150).
Interventions PD/COH: GnRH agonist or antagonist + r-FSH.
ET: mean 3 embryos transferred.
LPS: vaginal progesterone daily (dose not reported) + rLH on day 5, 8, 11 and 14 vs
vaginal progesterone daily (dose not reported)
Outcomes Clinical pregnancy (not defined).
Notes Only abstract available. Author contacted.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly allocated on the day of embryo
transfer”
By sealed envelopes.
Allocation concealment (selection bias) Low risk Sequentially numbered opaque sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Clinicians blinded, a non participant (nurse) gave the
medicine
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Researchers blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes not reported.
Dose progesterone not reported.
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Geber 2007a
Methods Randomized controlled trial.
Participants Women undergoing IVF/ICSI-ET with serum FSH concentrations <15IU/l on day 3
of menstrual cycle, mean age 35 (n=122)
Interventions PD/COH: GnRH agonist 3.6mg sc + r-FSH sc.
IVF/ICSI-ET: day 3 or 5, 1 to 4 mean 3.4 embryos transferred
LPS: micronized progesterone vaginal capsules 200mg 3x daily vs micronized proges-
terone vaginal gel 90 mg daily. Both from day after oocyte retrieval for 13 days or 12
weeks when pregnant
Outcomes Pregnancy (fetal heartbeat), miscarriage, multiple pregnancy
Notes Author contacted.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly allocated (sealed envelopes)
into two groups.”
Allocation concealment (selection bias) Low risk Sequentially numbered opaque sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Clinicians blinded, a non participant (nurse) gave the
medicine
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Researchers blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “A total of 122 patients were allocated to each group
and all completed the study.”
Selective reporting (reporting bias) Low risk Planned outcome data is reported.
Geusa 2001
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET, excluding women with systemic or endocrine pathologies,
age <42 yrs (n=300)
Interventions PD/COH: GnRH agonist + rFSH.
LPS: progesterone 90mg vaginal gel daily vs progesterone 50mg im daily. Both starting
at oocyte retrieval
76Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Geusa 2001 (Continued)
Outcomes Clinical pregnancy (not defined).
Notes Only abstract available. No reply from author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “All 318 patients were randomized”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes not reported.
Golan 1993
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET for male factor infertility, mechanical or unexplained in-
fertility, mean age 33 (n=56)
Interventions PD/COH: GnRH agonist + hMG.
IVF/ET: max 4 embryos transferred.
LPS: hCG 1000 or 2500 IU im every 3 days, 4 times vs progesterone 100mg im daily.
Both from day of ET
Outcomes Clinical pregnancy (gestational sac), miscarriage, OHSS.
Notes Author contacted in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
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Golan 1993 (Continued)
Random sequence generation (selection
bias)
Unclear risk Patients were prospectively randomized”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reason withdrawal reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Gorkemli 2004
Methods Randomized controlled trial.
Participants Women undergoing IVF/ICSI (n=266).
Interventions PD/COH: GnRH agonist 1mg/ml sc from day 21 from mensturation + r-FSH or r-
FSH/hMG
ET: day 2 or 3, mean 3.5 embryos transferred.
LPS: progesterone vaginal capsules 200 mg 3x daily vs progesterone vaginal capsules 200
mg 3x daily + estradiol transdermal 100 µg daily. Both from oocyte retrieval for 14/15
days, when preganant progesterone until 10 weeks gestation
Outcomes Clinical pregnancy (fetal heart), ongoing pregnancy, miscarriage
Notes First cycle data obtained from author (only clinical pregnancy)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated randomization”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
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Gorkemli 2004 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcome reported.
Goudge 2010
Methods Randomized controlled trial.
Participants Women undergoing their first IVF/ET cycle for any indication, mean age 32 (n=97)
Interventions PD/COH: GnRH agonist 0.5 mg sc daily + oral contraceptive.
IVF/ET: mean 2 embryos transferred.
LPS: progesterone-in-oil 50 mg im daily from oocyte retrieval until US at 5 or 6 weeks
vs progesterone-in-oil 50 mg im daily from oocyte retrieval until 11 days after ET
Outcomes Live birth, clinical pregnancy, ongoing pregnancy, multiple pregnancy (all not defined)
Notes No reply from author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomization was accomplished using sequentially
numbered, opaque, sealed envelopes.”
Method of randomization not reported.
Allocation concealment (selection bias) Low risk Sequentially numbered, opaque, sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
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Hurd 1996
Methods Randomized cross-over study.
Participants Women undergoing IVF-ET, excluding women with a history of anovulation, unrespon-
sive to CC or when their ovaries were not accessible for vaginal retrieval of oocytes, mean
age 34 (n=56)
Interventions PD/COH: CC 100 mg oral.
ET: day 2, mean 2.2 embryos transferred.
LPS: none versus vaginal progesterone suppositories 100 mg 2x daily from embryo
transfer + E2 2 mg oral 3x daily from oocyte retrieval. Both until pregnancy test or until
8th week when pregnant
Outcomes Clinical pregnancy (gestational sac), multiple pregnancy, miscarriage, ongoing preg-
nancy, OHSS
Notes Contacted in 2004, only first cycle data used.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “..., she was randomized”
Method of randomization not reported.
Allocation concealment (selection bias) Low risk “using a sealed opaque envelope techniquewith blocked
allocation”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Isik 2009
Methods Randomized controlled trial.
Participants Women undergoing ICSI/ET, excluding donor, freeze/thaw and/or TESA cycles, mean
age 35 (n=154)
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Isik 2009 (Continued)
Interventions PD/COH: GnRH antagonist + FSH.
LPS: Micronized progesterone 600 mg 3x daily vaginal capsules from oocyte retrieval for
17 days + single-dose hCG 1500 IU sc on day +8 + single dose GnRH agonist 0.5 mg
sc on day +6 vs micronized progesterone 600 mg 3x daily vaginal capsules from oocyte
retrieval for 17 days + single-dose hCG 1500 IU sc on day +8
Outcomes Live birth, clinical pregnancy (fetal heartbeat), multiple pregnancy
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated random table was used for ran-
domization and performed on the day of embryo trans-
fer by a nurse to assign participants to their groups.”
Allocation concealment (selection bias) Low risk By a nurse.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The clinicians and the laboratory staff were blinded to
groups.”
Participant blinding not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The clinicians and the laboratory staff were blinded to
groups.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Isikoglu 2007
Methods Randomized controlled trial.
Participants Women undergoing ICSI, mean age 30 (n=181).
Interventions PD/COH: GnRH agonist 0.5 mg sc daily from 21st day of preceding cycle + FSH
ET: max 4, mean 2.8 embryos transferred.
LPS: progesterone 50 mg im daily vs progesterone 50 mg im daily + GnRH agonist 0.
25 mg sc daily for 12 days
Outcomes Live birth, clinical pregnancy (fetal cardiac activity).
Notes Author contacted.
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Isikoglu 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized at initiation of stimulation
by a computer-generated list”
Allocation concealment (selection bias) Low risk Via onsite computer system utilising locked files.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The embryologists were blind to this randomization
process”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Iwase 2008
Methods Randomized controlled trial.
Participants Women undergoing IVF/ICSI for tubal factor, male factor or unexplained infertility,
mean age 33 (n=40)
Interventions PD/COH: long or short protocol GnRH agonist + hMG.
ET: day 2, max 3 embryos transferred.
LPS: chlormadione acetate 6 mg oral 2x daily vs progesterone im 25 mg daily from day
2 to 6, 50 mg daily from day 7 to 14. Both until pregnancy test, when pregnant 125 mg
hydroxyprogesterone caproate weekly until 6 or 7 weeks gestation
Outcomes Live birth, clinical pregnancy (fetal heart activity) and OHSS
Notes No reply from author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “According to a randomization table generated using
computer software into two groups of 20 patients each”
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Iwase 2008 (Continued)
Allocation concealment (selection bias) High risk “The random allocation sequence was concealed until
the interventions were assigned.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Kleinstein 2005
Methods Multicenter (17) randomized controlled trial.
Participants Women undergoing first IVF/ICSI cycle, successful transfer of 2 or 3 embryos,normal
smear in past 12 months, age ≥18 and ≤35, mean age 30 (n=430)
Interventions PD/COH: long GnRH agonist protocol + hMG or FSH.
ET: 2 (74.4%) or 3 embryos transferred.
LPS: progesterone vaginal capsules 200 mg 3x daily vs progesterone vaginal gel 90 mg
daily. Both from ET until pregnancy or 12 weeks gestation when pregnant
Outcomes Clinical pregnancy (amniotic sac), ongoing pregnancy (12 weeks of gestation, with fetal
heart activity)
Notes Supported by Dr Kade, Besins Pharma GmbH
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The patients were randomly assigned to
one of the treatments with the aid of a ran-
domization code. The randomization code
(Blocking-Factor 10) was generated by a
computer program.”
Allocation concealment (selection bias) Low risk “The trial investigators received consecu-
tively numbered envelopes corresponding
to the envisaged number to be recruited.
An envelope was allowed to be opened in
chronological sequence to assign treatment
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Kleinstein 2005 (Continued)
group only after successful transfer.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open, phase III RCT.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open, phase III RCT.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers and reasons for withdrawal re-
ported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Kohls 2010
Methods Randomized controlled trial.
Participants Women with gestational sac at first ultrasound, mean age 35 (n=220)
Interventions PD/COH: GnRH analogue.
LPS: vaginal progesterone 200 mg 2x daily until first ultrasound vs vaginal progesterone
200 mg 2x daily until 3 weeks after ultrasound
Outcomes Miscarriage rate (not defined).
Notes Author contacted.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization list.
Allocation concealment (selection bias) Low risk Computerized allocation.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding used.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding used.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawal reported.
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Kohls 2010 (Continued)
Selective reporting (reporting bias) Low risk Results directly obtained from author.
Kupferminc 1990
Methods Randomized placebo controlled trial, allocation computer-generated, using sealed en-
velopes, partially blinded, power calculation done
Participants Women undergoing IVF/ET formechanical, male factor or unexplained infertility,mean
age 33 (n=156)
Interventions PD/COH: hMG from day 3 of menses.
ET: day 2, mean 2.8 embryos transferred.
LPS: dydrogesterone 10mg oral 3 times daily from ET for 14 days vs oral placebo vs
hCG 2,500 IU im on day 3, 6 and 10
Outcomes Clinical pregnancy (gestational sac), ongoing pregnancy (beyond 1st trimester) and mis-
carriage
Notes Author contacted in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patients were randomized into one of
three treatment groups.”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The current prospective blind study...”
Method of blinding not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The current prospective blind study...”
Method of blinding not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
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Lam 2008
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET with a normal uterine cavity, excluding women using vagi-
nal progesterone for LPS, age <40, mean age 34 (n=197)
Interventions PD/COH: long GnRH agonist protocol 600µg intranasal for at least 14 days + hMG
or r-FSH
IVF/ET: day 3, mean 2.2 embryos transferred.
LPS: micronized progesterone 200 mg 3x daily vaginal capsules from oocyte retrieval
until ET + hCG 2000 IU on day of oocyte retrieval, +3, +6 and +9 vs hCG 2000 IU im
on day of oocyte retrieval, +3, +6 and +9
Outcomes Pregnancy (positive urine pregnancy test), miscarriage.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization was performed by a computer-gen-
erated program.”
Allocation concealment (selection bias) Low risk “Sealed opaque envelopes were used for allocation.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Both investigators and the participants were not
blinded of the intervention groups.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Both investigators and the participants were not
blinded of the intervention groups.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reason withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Lewin 1994
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET for mechanical infertility, mean age 33 (n=100)
Interventions PD/COH: 3 ampoules hMG a day and GnRH agonist 0.5 mg/day sc.
ET: max 4 embryos transferred.
LPS: progesterone 50 mg im from ET vs progesterone 50 mg im + estradiol valerate 2
mg oral daily
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Lewin 1994 (Continued)
Outcomes Clinical pregnancy (not defined), live birth.
Notes No reply from author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly allocated”
Method of allocation not mentioned.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Licciardi 1999
Methods Randomized controlled trial, allocation by randomization table
Participants Women undergoing IVF/ET, age <40 years, mean 35 yrs (n=43).
Interventions PD/COH: GnRH agonist and FSH im or hCG or a combination of both
ET: day 3, mean 3.4 embryos transferred.
LPS: progesterone 50mg im daily vs micronized progesterone 200mg 3 times daily. Both
from day after oocyte retrieval
Outcomes Clinical pregnancy (gestational sac), multiple pregnancy, miscarriage
Notes No reply from author in 2004, study is terminated early for ethical reasons: differences
in implantation rates were highly statistically significant
Risk of bias
Bias Authors’ judgement Support for judgement
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Licciardi 1999 (Continued)
Random sequence generation (selection
bias)
Low risk “Patients were assigned to receive either IM
or oral progesterone supplementation ac-
cording to a randomization table”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Loh 1996
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET (n=156). 8% of randomized cycles did not result in ET
(numbers by group not provided)
Interventions PD/COH: “standard GnRH agonist” protocol.
LPS: im progesterone vs hCG.
Outcomes Pregnancy (not defined).
Notes Only abstract available. No reply from author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized at recruitment”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
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Loh 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes not reported.
Ludwig 2001
Methods Randomized controlled trial.
Participants Women undergoing IVF or ICSI, excluding women with abdominal discomfort on day
of ET and estradiol levels >5000 pg/ml, mean age 32 (n=413)
Interventions PD/COH: long protocol GnRH agonist + r-FSH or hMG.
ET: mean 2.7 embryos transferred.
LPS: Low risk catagory (<12 oocytes retrieved and estradiol on day of ovulation induction
<2.500 pg/ml); hCG 5000 IU on daty of ET and day +3, 2500 IU on day +6 vs hCG
5000 IU on day of ET + progesterone vaginal capsules 200 mg 3x daily vs progesterone
vaginal capsules 200 mg 3x daily
High risk catagory (≥12 oocytes retrieved and estradiol on day of ovulation induction
≥2.500 pg/ml); hCG 5000 IU on day of ET + progesterone vaginal capsules 200 mg 3x
daily vs progesterone vaginal capsules 200 mg 3x daily
Outcomes Clinical pregancy (positive fetal heart beat), ongoing pregnancy (delivery of live born or
stillborn baby >500 g or delivery of live born baby <500 g), miscarriage
Notes Because the high risk category is quasi-randomized, the data of these arms is not included
in the meta analysis. Author contacted in 2004
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subsequently randomized according to a randomiza-
tion list.”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
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Ludwig 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Ludwig 2002
Methods Randomized controlled trial, allocation by computer-generated open list
Participants Women undergoing IVF or ICSI/ET, age <40 mean age 31 (n=126). Patients with
oestradiol levels <2000pg/ml on day of hCG trigger were not selected
Interventions PD/COH: long protocol GnRH agonist or multiple dose antagonist + FSH or hMG
ET: mean 2.8 embryos transferred.
LPS: progesterone in capsules 200mg 3 times daily vaginally vs progesterone in gel 90mg
daily. Both from evening before ET until menses or pregnancy test
Outcomes Clinical pregnancy (positive fetal heartbeat on US), ongoing pregnancy (>12 weeks),
miscarriage
Notes Additional information obtained in 2004 from handout provided at poster presentation
Funded by an unconditional grant from Wyeth Pharma GmbH
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized on an individ-
ual basis by use of an open computerized
randomization list.”
Allocation concealment (selection bias) High risk Open randomization list.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
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Ludwig 2002 (Continued)
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Macrolin 1993
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET, excluding women with OHSS, repeated implantation fail-
ure, or estradiol >2700 pg/mL, age <38 yrs (n=302)
Interventions PD/COH: GnRHa in a long or short protocol + hMG.
ET: max 3 (41%) or 2 embryos transferred.
LPS: vaginal micronized progesterone 400 mg daily from the day after oocyte retrieval
vs vaginal micronized progesterone 400 mg daily from the day after oocyte retrieval +
hCG 1500 IU every other day 3 time from ET
Outcomes Clinical pregnancy, OHSS, ongoing pregnancy (13 weeks).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomisée’
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
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Martinez 2000
Methods Randomized controlled trial, sample size calculation based on OHSS rates
Participants Womenundergoing IVF/ICSIwith normal ovarian response,mean age 33, BMI between
21 and 27, no history of OHSS (n=310)
Interventions PD/COH: GnRH agonist 0.2 mL sc and FSH or hMG.
ET: day 2, when possible at least 3 embryos transferred.
LPS: progesterone 100 mg 3 times daily vaginally for 10 days from ET vs hCG 2,500
IU im on days +2, +4 and +6 after oocyte retrieval
Outcomes Clinical pregnancy (gestational sac), miscarriage, multiple pregnancy, OHSS
Notes Author contacted in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomly allocated (according to a com-
puter-generated random assignment table)
”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Miller 2010
Methods Multicenter randomized controlled trial, number of centres not reported
Participants Women undergoing IVF with GnRH antagonist downregulation, mean age 33 (n=165)
Interventions PD/COH: GnRH antagonist + Menopur or r-FSH.
ET: mean 2.3 embryos transferred.
LPS: progesterone vaginal capsules (Endometrin) vs progesterone IM
Outcomes Ongoing pregnancy, miscarriage.
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Miller 2010 (Continued)
Notes Only abstract available. No reply from author.
Support from Ferring Pharmaceuticals Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “With randomization prior to stimulation”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Amulticenter, randomized, open-label ex-
ploratory study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Amulticenter, randomized, open-label ex-
ploratory study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Ng 2003
Methods Randomized controlled trial, sample size calculation based on rate of perineal irritation
(primary outcome of study)
Participants Women undergoing ICVF/ICSI with high risk of OHSS because of E2 level on day of
hCG administration >10,000 pmol/l or >15 oocytes obtained (n=60)
Interventions PD/COH: GnRH agonist long protocol
ET: max 3 embryos transferred
LPS: progesterone suppositories (Cyclogest) 400mg 2 times daily vaginally vs proges-
terone gel (Crinone 8%) 90mg once daily vaginally. Both for 14 days from day of ET
Outcomes Clinical pregnancy (not defined).
Notes Author contacted.
Risk of bias
Bias Authors’ judgement Support for judgement
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Ng 2003 (Continued)
Random sequence generation (selection
bias)
Low risk “They were randomized according to a
computer-generated randomization list in
sealed envelopes”
Allocation concealment (selection bias) Unclear risk Sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Ng 2007
Methods Randomized controlled trial.
Participants Women undergoing IVF/ICSI with long protocol GnRH agonist, mean age 35 (n=132)
Interventions PD/COH: GnRH agonist 150 µg intranasal 4x daily from mid-luteal phase preceeding
cycle + hMG
ET: max 3 embryos, mostly 2 embryos transferred.
LPS: progesterone vaginal suppositories 400 mg 2x daily vs progesterone vaginal capsules
100 mg 2x daily. Both from ET for 14 days
Outcomes Clinical pregnancy (1 ormore gestational sacs), ongoing pregnancy (beyond 10-12 weeks
gestation), miscarriage, multiple pregnancy
Notes Author contacted.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “They were randomized according to a computer-gen-
erated randomization list in sealed envelopes”
Allocation concealment (selection bias) Unclear risk Sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
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Ng 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Patki 2007
Methods Randomized placebo controlled trial, “dose-finding study” consisting of 2 phases. Phase 1
investigates 20mg dydrogesterone vs placebo, phase 2 investigates 30mg dydrogesterone
vs placebo
Participants Women undergoing ART divided into groups with low or high risk of OHSS, down
regulation by long protocol GnRH agonist, excluding all other protocols (Phase 1: n=
404, Phase 2: n=555)
Interventions Phase 1:
PD/COH: long protocol GnRH agonist.
LPS: micronized progesterone vaginal capsules 600 mg daily + dydrogesterone 20 mg
daily oral vs micronized progesterone vaginal capsules 600 mg daily from day of oocyte
retrieval + placebo
Phase 2:
PD/COH: long protocol GnRH agonist.
LPS: micronized progesterone vaginal capsules 600 mg daily from day of oocyte retrieval
+ dydrogesterone 30 mg daily oral vs micronized progesterone vaginal capsules 600 mg
daily from day of oocyte retrieval + placebo
All progesterone from day of oocyte retrieval, dydrogesterone or placebo from day of ET
all until pregnancy test or continued when pregnant
Outcomes Pregnancy (intrauterine viable pregnancy).
Notes Phase 1 investigates vaginal progesterone + oral dydrogesterone versus vaginal proges-
terone + placebo. This does not fit in any of our comparisons and therefore phase 1 is
excluded.
Both phases included an extra group, which both examined patients in a donor oocyte
program and were therefore not included in our data analysis
Author contacted.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized”
Method of randomization not reported.
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Patki 2007 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patient receives either intervention or
placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcome reported.
Perino 1997
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET for the first time for tubal factor infertility, age <38, mean
age 31 (n=300)
Interventions PD/COH: GnRH agonist + FSH.
ET: day 2, max 4 embryos transferred.
LPS: micronized progesterone 50mg im daily vs natural progesterone 200mg vaginally
daily. Both from day before ET until pregnancy test
Outcomes Clinical pregnancy (not defined), ongoing pregnancy (term), miscarriage (not defined)
Notes No reply from author in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly allocated”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
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Perino 1997 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Pirard 2006
Methods Randomized controlled trial.
Participants Women undergoing IVF/ICSI-ET with indications for ART, median age between 29
and 37 (n=23)
Interventions PD/COH: hMG/FSH
IVF/ICSI-ET: day 3, 1 or 2 embryos transferred.
LPS:
Group A: trigger 10,000 IU hCG followed by vaginal micronized progesterone 200 mg
3x daily vs
Group B: 200 µg GnRH agonist (buserelin) intranasal (IN) followed by 100 µg IN every
2 days vs
Group C: 200 µg GnRH agonist (buserelin) IN followed by 100 µg IN daily vs
Group D: 200 µg GnRH agonist (buserelin) IN followed by 100 µg IN twice daily vs
Group E: 200 µg GnRH agonist (buserelin) IN followed by 100 µg IN 3x daily
Outcomes Clinical pregnancy (ongoing pregnancy with amniotic sac and a fetal heartbeat)
Notes Intervention groups B and C were discontinued prematurely as they caused a short luteal
phase. Patients in this groups received a further sealed envelope with new allocation
instructions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomization list was computer-generated by an
independent statistician”
Allocation concealment (selection bias) Low risk “Treatment allocation instructions were placed in indi-
vidually sealed envelopes to be opened at the centre in
chronological order, on the day of ovulation trigger.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Open, parallel group, pilot study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Open, parallel group, pilot study”
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Pirard 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Porcu 2003
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET (n=224).
Interventions PD/COH: GnRH agonist.
LPS: natural progesterone 50mg im daily vs micronized progesterone 200mg vaginally
daily
Outcomes Pregnancy per transfer (not defined).
Notes No reply from author in 2004. Only abstract available.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly allocated”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes not reported.
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Pouly 1996
Methods Multi-centre (6) randomized controlled trial.
Participants Women undergoing IVF/ET for tubal, idiopathic or endometriosis related infertility,
age <38, mean age 32 (n=283)
Interventions PD/COH: GnRH agonist + hMG.
ET: mean 3 embryos transferred.
LPS: progesterone 90mg vaginal gel daily vs micronized progesterone 100mg oral one in
morning, two in evening. Both from day after ET for 14 days or 30 in case of pregnancy
Outcomes Clinical pregnancy (gestational sac or β-hCG >1000 IU), miscarriage, multiple preg-
nancy, ongoing pregnancy (13 weeks)
Notes Author contacted in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer generated random assignment
schedule for each centre”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal is reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Propst 2001
Methods Randomized controlled trial, sample size calculation based on LBR
Participants Women undergoing IVF or ICSI/ET, no cryopreserved ET or donor recipients were
included, mean age 35 (n=201)
Interventions PD/COH: GnRHa in 76%, rest had different protocols.
IVF (64%), ICSI (36%)/ET: 79% on day 3, mean 3.5 embryos transferred, 21% on day
5, 2 embryos transferred.
LPS: progesterone gel 90mg vaginally once daily vs progesterone 50mg im daily. Both
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Propst 2001 (Continued)
from day after oocyte retrieval until pregnancy test, +10 weeks in case of pregnancy
Outcomes Clinical pregnancy (gestational sac), miscarriage (loss of clinical pregnancy before 20
weeks of gestation), live birth
Notes Recruitement was terminated after interim results showed high rate of early bleeding in
Crinone group
Crinone 8% was provided by Serono Laboratories, Inc., Randolph, Massachusetts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomized by permuted blocks of four
in sealed envelopes”
Allocation concealment (selection bias) Unclear risk Sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Open-label study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Open-label study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Qublan 2008
Methods Randomized placebo controlled trial.
Participants Women undergoing IVF/ICSI-ET, excluding PCO, endometriosis, hydrosalpinx throm-
bophilia, abnormal uterine cavity, women receiving any other form of hormonal treat-
ment and women with ≥ 3 previous cycles. Age between 19 and 36, mean age 29 (n=
120)
Interventions PD/COH: long protocol GnRH agonist + hMG.
IVF/ICSI-ET: day 3, 1-3 embryos transferred.
LPS: progesterone pessaries (Cyclogest) + GnRH agonist triptorelin 0.1 mg sc on day of
oocyte retrieval, day of ET and day +3 vs progesterone pessaries (Cyclogest) + placebo
(solvent) on day of oocyte retrieval, day of ET and day +3
Outcomes Clinical pregnancy (positive fetal heartbeat), miscarriage, live birth rate
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Qublan 2008 (Continued)
Notes Dosage/frequency of Cyclogest usage not mentioned.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was accomplished by using a
selection from a table of random numbers avail-
able in a standard statistics textbook.”
Allocation concealment (selection bias) Low risk “Allocation to the groups was concealed from
both researchers and patients. The randomiza-
tion sequence was placed into sealed, numbered
opaque envelopes that were only opened once
the consent form was signed.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded by using placebo in control group.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 234 Patients recruited, 120 analysed, no reasons
for withdrawal reported
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Other bias High risk Dosage/frequency of Cyclogest usage not men-
tioned.
Rodriguez-Pezino 2004
Methods Randomized controlled trial.
Participants Women undergoing IVF (n=124).
Interventions PD/COH: GnRH antagonist 0.25 mg sc + rFSH + LH + hCG.
ET: day 3.
LPS: vaginal progesterone gel 90 mg daily vs vaginal progesterone capsules (Utrogestan)
200mg twice daily vs vaginal progesterone suppositories 200mg daily. All from oocyte
retrieval
Outcomes Pregnancy (not defined), miscarriage.
Notes Only abstract available. No reply from author.
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Rodriguez-Pezino 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Were randomised”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Objective states same outcome as reported outcome.
Saucedo 2000
Methods Randomized controlled trial.
Participants Women undergoing ART (n=60).
Interventions ET: Day 3, average of 3 embryos transferred.
LPS: progesterone 400mg oral daily vs progesterone vaginal gel 90mg daily vs proges-
terone 50mg im daily
Outcomes Clinical pregnancy (not defined).
Notes Only abstract available. No reply from author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Prospectively randomized”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
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Saucedo 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes not reported.
Saucedo 2003
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET, mean age 35 (n=86).
Interventions PD/COH: GnRH agonist + r-FSH.
ET: day 3.
LPS: progesterone 50mg im daily vs vaginal progesterone gel 90mg daily. Both from day
of oocyte retrieval
Outcomes Pregnancy (not defined).
Notes Only abstract available. No reply from author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
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Saucedo 2003 (Continued)
Selective reporting (reporting bias) High risk Only abstract available.
Serna 2008
Methods Randomized controlled trial.
Participants Women undergoing IVF/ICSI-ET with at least 2 good quality embryos available for ET,
age <42, excluding women with FSH >12 IU/L, liver or renal disease, alcoholism, drug
abuse, abnormal thyroid function tests or hyperprolactinaemia, mean age 34 (n=160)
Interventions PD/COH: long protocol GnRH agonist or GnRH antagonist + r-FSH
IVF/ICSI-ET: 2 embryos transferred.
LPS: vaginal progesterone 200 mg 2x daily + transdermal E2 10µg daily vs vaginal
progesterone 200 mg 2x daily. Progesterone from oocyte retrieval until 10th week of
gestation, E2 from ET until 10th week of gestation
Outcomes Ongoing pregnancy (>12 weeks gestation), miscarriage (positive test, failed to develop
>12 weeks)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated randomnumber list was created,
and patients were included consecutively.”
Allocation concealment (selection bias) Low risk “Sequence was concealed-opaque consecutively num-
bered envelopes-until intervention was assigned; a study
nurse generated the allocation sequence, enrolled the
participants, and assigned participants to their group.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
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Stadtmauer 2010
Methods Multi-centre randomized controlled trial.
Participants Women undergoing ART aged 18-42 (n=1297).
Interventions PD/COH: long down regulation protocol GnRH agonist.
ET: day 3 or 5.
LPS: progesterone weekly vaginal ring vs progesterone vaginal gel 90 mg daily. Borth
from ET until 12 weeks when pregnant
Outcomes Clinical pregnancy (gestational sac and fetal heart beat).
Notes Only abstract available. No reply from author.
Supported by Teva Pharmaceuticals T&D.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “After 1:1 randomization”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Single-blind”, not defined.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Single-blind”, not defined.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Other bias High risk Only abstract available.
Strehler 1999
Methods Randomized controlled trial.
Participants Women undergoing IVF, mean age 32 (n=99).
Interventions PD/COH: short GnRH agonist protocol + hMG.
IVF/ET: day 2, mean 2.8 embryos transferred.
LPS: progesterone vaginal gel 90mg daily vs progesterone vaginal suppositories 200mg
3 times daily. Both from oocyte retrieval until 8th week of pregnancy
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Strehler 1999 (Continued)
Outcomes Clinical pregnancy (fetal sac), miscarriage and multiple pregnancy
Notes Only abstract available.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were prospectively randomized”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Correct blinding was used for researchers”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes reported.
Sumita 2003
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET, mean age 34 (n=100).
Interventions PD/COH: GnRH agonist + FSH.
IVF/ET: 2 embryos transferred.
LPS: progesterone 50 mg im daily vs vaginal micronized progesterone 600 mg daily,
both from day of oocyte retrieval until 12th week of pregnancy
Outcomes Clinical pregnancy (not defined).
Notes Additional information obtained in 2004 from poster presentation, only abstract avail-
able. No reply from author
Risk of bias
Bias Authors’ judgement Support for judgement
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Sumita 2003 (Continued)
Random sequence generation (selection
bias)
Unclear risk “A randomized prospective trial”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes not reported.
Tay 2005
Methods Randomized controlled trial.
Participants Women undergoing IVF for tubal disease, male factor, ovulatory dysfunction, en-
dometriosis or unexplained infertility, excluding women with pre-ovulatory estradiol
concentration ≥15000 pmol/l and/or total oocyte number ≥15. Age is between 21-41,
mean 32.4 (n=168)
Interventions PD/COH: long protocol stimulated IVF regimens.
IVF/ET: mean 2.3 embryos transferred.
LPS:
Group 1: natural progesterone 200 mg rectally twice daily vs
Group 2: natural progesterone vaginal gel 90 mg daily vs
Group 3: natural progesterone vaginal capsules, 200 mg once, twice or 3x daily vs
Group 4: hCG 1500 IU sc on day 4 and 7 after oocyte retrieval
All progesterone supplements were administered from day 4 until 14 days after oocyte
retrieval
Outcomes Expected live birth rate (>14 weeks gestation).
Notes 5 Egg donor cycles and 5 natural cycle frozen embryo replacement cycles were recruited
as controls. None of them conceived and non were given any form of luteal support.
These are not included in out data analysis. No reply from author
Risk of bias
Bias Authors’ judgement Support for judgement
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Tay 2005 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Subjects were randomised on the day of embryo trans-
fer”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Tesarik 2006
Methods Randomized placebo controlled trial. Including 2 separate patient groups; patients un-
dergoing a GnRH agonist protocol and patients undergoing a GnRH antagonist proto-
col, this is subjectively decided depending on clinical context
Participants Women undergoing ICSI/ET excluding women with age >40 and non-obstructive
azoospermia requiring testicular sperm retrieval, mean age in agonist group 35, in an-
tagonist group 31 (Agonist: n=283, Antagonist: n=289)
Interventions Agonist:
PD/COH:GnRHagonist, triptorelin, 0.1mg sc daily starting in luteal phase of preceding
cycle, reduced to 0.05 mg after first bleeding + r-FSH and hMG
ET: day 3, mean 2.2 embryos transferred.
LPS: single-dose GnRH agonist 0.1 mg 6 days after ICSI (3 days after ET) vs placebo
Antagonist:
PD/COH: r-FSH + hMG from day 2 of menstrual bleeding, followed by withdraw of a
contraceptive pill. GnRH antagonist 0.25 mg sc daily from started on day 5 until trigger
ET: day 3, mean 2.3 embryos transferred.
LPS: single-dose GnRH agonist 0.1 mg 6 days after ICSI (3 days after ET) vs placebo
All women received vaginal micronized progesterone 400 mg and E2 valerate 4 mg daily
from oocyte retrieval for 17 days and a injection of 250 µg human r-hCG on day of
embryo transfer
Outcomes Live birth, clinical pregnancy (not defined), ongoing pregnancy (not defined)
Notes
Risk of bias
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Tesarik 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was done with the use of
a computer-generated randomization list.”
Allocation concealment (selection bias) Low risk “Sealed envelopes with treatment alloca-
tion instructions were opened on the day
of embryo transfer by a nurse who assigned
participants to their groups.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The doctor and the biological team per-
forming the ARTwere blinded to group as-
signment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The doctor and the biological team per-
forming the ARTwere blinded to group as-
signment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers and reasons withdrawal reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Torode 1987
Methods Randomized placebo controlled trial.
Participants Women undergoing IVF (n=131).
Interventions PD/COH: clomiphene citrate + hMG.
ET: day 2.
LPS: hCG 1500 IU every other day vs placebo.
Outcomes Pregnancy (not defined).
Notes No reply from author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly allocated”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
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Torode 1987 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons withdrawal reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
Ugur 2001
Methods Randomized controlled trial.
Participants Women undergoing IVF with high and normal risk developing OHSS (n=375)
Interventions High risk:
PD/COH: GnRH agonist.
LPS: vaginal micronized progesterone 400 mg daily vs vaginal micronized progesterone
400 mg daily + hCG 3,000 IU on day 7
Low risk:
PD/COH: GnRH agonist.
LPS: vaginal micronized progesterone 400 mg daily vs hCG 1500 IU every 3 days vs
vaginal micronized progesterone 400 mg daily + hCG 1500 IU every 3 days
Outcomes Pregnancy (not defined).
Notes Only abstract available.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly allocated”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
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Ugur 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Only abstract available.
Planned outcomes not reported.
Vimpeli 2001
Methods Randomized controlled trial.
Participants Women undergoing IVF, excluding women with PCO, previous case of OHSS or >20
oocytes (n=89)
Interventions PD/COH: GnRH agonist + hMG.
LPS: hCG 1500 IU im on day 3, 6 and 9 after oocyte retrieval vs vaginal micronize
natural progesterone 200 mg 3 times daily. from day of oocyte retrieval for 2 weeks, or
4 when pregnant
Outcomes Pregnancy (not defined).
Notes No reply in 2004.
Supported by a grant from Organon, the Netherlands.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patients were randomly assigned”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Unclear risk Planned outcomes not reported.
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Wong 1990
Methods Randomized controlled trial.
Participants Women undergoing IVF/ET for tubal factor (n=30).
Interventions PD/COH: clomiphene citrate + hMG.
ET: day 2.
LPS: progesterone 50mg im daily from day 2 until 11 vs progesterone 50mg im daily
from day 2 until 11 + hCG 1500 IU alternate days from day 5 to 15 vs no luteal support
Outcomes Pregnancy (not defined).
Notes No reply from author in 2004.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly allocated”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) High risk Given outcome (pregnancy) not stated in method sec-
tion.
Yanushpolsky 2010
Methods Randomized controlled trial.
Participants Women undergoing IVF with fewer than 3 prior unsuccessful cycles, mean age 34 (n=
407)
Interventions ET: mean 2.1 embryos transferred.
LPS: progesterone 50 mg im daily from day after oocyte retrieval vs progesterone vaginal
gel 90 mg daily from 48 hrs after oocyte retrieval. In both arms 51 women received E2
3 mg oral daily
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Yanushpolsky 2010 (Continued)
Outcomes Pregnancy (not defined), failed pregnancy (chemical pregnancy + sponteneous abortion
+ ectopic pregnancy)
Notes Author contacted, the article published in Fertility & Sterility 2011 contains a retrospec-
tive analysis of women receiving LPS with E2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized with equal probability to re-
ceive either [...]”
Computer generated randomization.
Allocation concealment (selection bias) Low risk Via onsite computer system utilising locked files.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding used.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding used.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Zegers-Hochschild 2000
Methods Multicentre (3) randomized controlled trial, including 2 different studies: IVF-embryo
transfer trial and oocyte donation trial. Only the IVF-ET trial is included in the review
Participants Women undergoing ICSI/IVF-ET (n=505).
Interventions PD/COH: GnRH agonist + hMG.
ET: day 2 or 3, mean 3.7 embryos transferred.
LPS: 1 gram progesterone vaginal ring versus 50 mg progesterone IM daily
Outcomes Clinical pregnancy (gestational sac), multiple gestation (2 or more gestational sacs visu-
alised 5 weeks after embryo transfer), live birth
Notes Laboratorios Silesia S.A. provided the vaginal rings.
Risk of bias
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Zegers-Hochschild 2000 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “On day of oocyte retrieval patient were
randomly allocated...”
Method of randomization not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal not reported.
Selective reporting (reporting bias) Low risk Planned outcomes reported.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abu-Musa 2008 This RCT investigated the role of 17a-hydroxyprogesterone caproate given prior to embryo transfer
to decrease uterine contractions and therefore improve implantation rates
Abu-Musa 2008a This RCT investigated the role of 17a-hydroxyprogesterone caproate given prior to embryo transfer
to decrease uterine contractions and therefore improve implantation rates
Allahbadia 2004 This comparative study investigated pregnancy outcomes of IM progesterone (n=94) versus oral dy-
drogesterone (n=30) for luteal phase support in cycles using donated eggs
Allen 2004 This RCT included ZIFT cycles only (n=99).
Alsanie 2005 This retrospective case control study compared serumhCG levelswhenusing progesterone and estrogen
(n=15) vs progesterone alone (n=15) for luteal phase support in IVF-ET cycles
Anserini 2001 This is a quasi-RCT.
Anthony 1993 This is a quasi-RCT.
Araujo 1994 ThisRCT investigated IVF andZIFTcycles, but did not describe the distributionof these interventions.
Authors previously contacted in 2004
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(Continued)
Araujo Filho 1996 Study does not report the percentage of ZIFT cycles.
Baber 1988 This study was excluded in the previous version of this review as in this RCT, allocation to hCG or no
treatment only included women with a positive pregnancy test, thus the treatment was not truly luteal
phase support
Beckers 2006 This RCT investigated high doses of steroids administered after the LH surge in normo-ovulatory
volunteers in order to investigate if this gives rise to endocrine changes and a shortening of the luteal
phase
Belaisch-Allart 1988 This is an interim analysis of 295 cases out a total of 525 women. Data is about 451 transfers, author
contacted in 2004, not able to provide any information
Ben-Nun 1990 This study was excluded in the previous version of this review as it is not a randomized trial - compared
i.m. progesterone to historical controls receiving no progesterone. Treatment was given only for 6 days
around the time of oocyte retrieval
Berjis 2008 This study only includes rapid-ZIFT procedures.
Blake 2010 This pharmacokinetic study, does not include patients undergoing ART
Buvat 1988 This is a quasi-RCT.
Buvat 1990 This is a quasi-RCT.
Casini 2003 This study was excluded in the previous version of this review because in this RCT some women
contributed more than one cycle to the study (n=201 women, 436 cycles). The author was unable to
provide first cycle data
Chang 2008 Not a randomized trial - review about intramuscular progesterone for luteal phase support in IVF
Chang 2009 Not a randomized trial - retrospectively analyzed outcomes of IVF cycles with GnRH antagonist
administration on ovulation triggering day
Chantilis 1999 This study was excluded in the previous version of this review as it is not a randomized trial - compared
vaginal progesterone to historical controls using i.m. progesterone
Check 2010 This RCT investigated the dosage of progesterone supplementation in frozen embryo transfers only
(n=408)
Claman 1992 This RCT includes IVF/ETcycles (n=121) rather than women (n=unknown), author contacted in
2004 and was not able to provide first cycle data
Daya 2009 Not a randomized trial - review about progestogens for luteal support
Ding 2005 This RCT in excluded because it contains more cycles (n=114) than women (n=95). No reply from
author
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(Continued)
Erman Akar 2005 This RCT is excluded because it contains more cycles (n=115) than women (n=95). No reply from
author
Escriba 2006 This RCT investigated the initiation of progesterone supplementation in donated oocyte transfers only
(n=300)
Farhi 2000 This study was excluded in the previous version of this review because in this RCT some women
contributed more than one cycle to the study (n=271 women, 285 cycles)
Farrag 2008 This RCT investigated the use of recombinant hCG to induce final oocyte maturation in ICSI cycles
Feliciani 2004 This RCT compared the effect of intravaginal (n=14) and i.m. progesterone (n=14) in frozen/thawed
embryo transfers only
Garcia-Velasco 2009 This RCT investigated the effect of letrozole administered during the luteal phase after oocyte retrieval
in oocyte donors only
Ghanem 2009 This study is quasi-randomised as randomisation was performed using a sequential allocation method
Gibbons 1998 This study was excluded in the previous version of this review as this RCT compared vaginal and IM
progesterone only in women receiving donated oocytes (n=72)
Griesinger 2006 Not a randomized trial - review.
Herman 1990 This is a quasi-RCT.
Herman 1996 This is a quasi-RCT.
Ho 2008 Not a randomized trial - retrospective case control study.
Humaidan 2010 This RCT is excluded as it investigates only one dose of hCG as a trigger, not a luteal phase support
study
Hutchinson-Williams 1990 This study was excluded in the previous version of this review as it is not a randomized trial - the
treatment group was “randomly” selected, but the control group was retrospectively selected and age-
matched to the treatment group
Jee 2010 Not a randomized trial - meta-analysis.
Johnson 1999 This study was excluded in the previous version of this review as this RCT compared hCG with
no treatment, with primary objective of measuring relaxin levels during the luteal phase. Complete
pregnancy outcomes by groups were not reported
Kahraman 2010 This is a quasi-RCT.
Koper 2008 This randomized trial investigated the dose-response relationship of corifollitropin alfa to initiate
multifollicular development for the first 7 days of controlled ovarian stimulation
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(Continued)
Krause 2006 This RCT investigated the efficiency and safety of different luteal support regimes in non-IVF cycles
(n=36)
Krischker 1998 This study was excluded in the previous version of this review as this RCT compared progesterone
i.m., 2 types of oral progesterone, and hCG, using long GnRHa (n=30) or ultrashort GnRHa (n=
273). Pregnancy rates by group were provided, but the numbers of transfers in each group were not.
Attempts to contact authors were unsuccessful
Lam 2003 This study was excluded in the previous version of this review as this RCT compared hCG plus vaginal
progesterone administered only between oocyte retrieval and embryo transfer with hCG alone (n=102)
. This was the only study found making this comparison
Lan 2007 This RCT compared the efficacy and tolerability of two formulations of vaginal progesterone, Crinone
8% (n=100) and Utrogestan (n=100) in frozen embryo transfers only
Leeton 1985 This is a quasi-RCT.
Lightman 1999 This is a quasi-RCT.
Lukaszuk 2005 This RCT is excluded because it contains more cycles (n=231) than women (n=166). No reply from
author
Mahadevan 1985 This is a quasi-RCT.
Marianowski 2000 This study was excluded in the previous version of this review as it is not a randomized trial - compared
IM and vaginal progesterone with allocation by the woman’s preference (n=79)
Martins 2010 Not a randomized trial - review about luteal phase support.
McBain 1987 This is a quasi-RCT.
Mochtar 1996 This study was excluded in the previous version of this review because in this RCT some women
contributed more than one cycle to the study (n=98 women, 176 cycles). An attempt was made to
contact the authors, but no reply received
Moraloglu 2008 This study compared the effect of GnRH agonist (n=48) and GnRH antagonist (n=45) use in two
matched groups of women undergoing IVF/ICSI
Nader 1988 This study was excluded in the previous version of this review as this RCT compared progesterone to
hCG, but was excluded because some women contributed more than one cycle to the study (n=17
women, 20 cycles). The author was unable to provide first cycle data
Nikkanen 1992 This is a quasi-RCT.
Ozcimen 2004 This cross-over study investigated the effect of luteal phase support in non-IVF gonadotropin induction
of ovulation
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Papanikolaou 2010 This RCT compares recombinant hCG (n=59) versus urinary hCG (n=60) as a final oocyte maturation
trigger
Pirard 2005 This randomized trial includes IUI only.
Polson 1992 This is a quasi-RCT.
Schwarzler 2003 This study was excluded in the previous version of this review because in this RCT some women
contributed more than one cycle to the study (n=603 women, 945 cycles)
Simunic 2007 Not a randomized trial - cohort study investigating the efficacy and tolerability of Crinone 8% gel vs
Utrogestan capsules
Singh 2010 This randomized trial investigated the supplementation of GnRH agonists during the luteal phase in
IUI only
Smith 1989 This is a quasi-RCT.
Smitz 1988 Study does not report the percentage of GIFT cycles.
Smitz 1992 Study includes >20% GIFT/ZIFT cycles.
Smitz 1993 This is a quasi-RCT.
Sordal 1993 This study was excluded in the previous version of this review as this RCT compared progesterone i.
m., 2 doses of vaginal progesterone and no treatments (n=40), but pregnancy rates by group were not
provided. Attempts to contact the author were unsuccessful
Stadtmauer 2009 This randomized trial compared the effect of progesterone in a vaginal ring (n=10) vs progesterone
vaginal gel (n=10) in donor oocytes
Tay 2003 This study divided their population in 2 groups; group A underwent GnRH-a/r-FSH ovarian stim-
ulation followed by IVF, group B underwent CC/r-FSH ovarian stimulation and IUI. After ET or
insemination patients were randomized in 2 different luteal phase support protocols. No reply from
author in 2004
Trounson 1986 This study was excluded in the previous version of this review as this RCT assessed luteal support with
progesterone i.m. or hCG given only around the time of oocyte retrieval (n=42)
Unfer 2004 This RCT is excluded because it contains more cycles (n=284) than women (n=213). No reply from
author
Unfer 2004a This RCT is excluded because it contains more cycles (n=734) than women (n=320). No reply from
author
Valentino 2004 This study was excluded in the previous version of this review as this RCT compared vaginal and i.m.
progesterone (n=40), but pregnancy rates were not provided (the main outcome measures were side
effects and convenience). Attempts to contact the author were unsuccessful
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van Steirteghem 1988 Study does not report the percentage of GIFT procedures.
Var 2011 This is a quasi-RCT, allocation based on application number.
Wang 2009 Not a randomized trial - a cohort study comparing crinone 8% gel vs utrogestan capsules
Wilcox 2001 This study was excluded in the previous version of this review as this RCT compared luteal support
with progesterone vaginal gel alone or in combination with IM progesterone in frozen embryo transfer
cycles (n=97)
Ye 2009 This RCT investigated luteal estradiol pre-treatment before the GnRH antagonist protocol and the
GnRH agonist protocol
Yigit 2002 This studywas excluded in the previous versionof this review as it is not a randomized trial - according to
information from the author, this was a retrospective study comparing vaginal gel and i.m. progesterone
Yovich 1984 This is a quasi-RCT, allocation based on study number. Author contacted in 2004
Yovich 1985 This is a quasi-RCT.
Yovich 1991 This RCT included ZIFT cycles only.
Characteristics of studies awaiting assessment [ordered by study ID]
Esra 2010
Methods Randomized controlled trial.
Participants Women undergoing ICSI, age under 40 (n=288).
Interventions PD/COH: GnRH analogue.
LPS: vaginal progesterone gel + 2 mg oral estradiol vs vaginal progesterone gel + 4 mg oral estradiol vs vaginal
progesterone gel + 6 mg oral estradiol. Estradiol from day after ET, progesterone from day of OPU
Outcomes Clinical pregnancy (not defined).
Notes Only study with this comparison.
Gallardo 2004
Methods
Participants
Interventions
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Gallardo 2004 (Continued)
Outcomes
Notes Translation needs to be obtained to assess eligibility.
Humaidan 2006
Methods Randomized controlled trial.
Participants Women undergoing IVF/ICSI-ET with a baseline FSH and LH <12 IU/l, menstrual cycles between 25 and 34 days,
body mass index (BMI) >18 and <30, both ovaries present and absence of uterine abnormalities, aged 25-40 (n=45)
Interventions PD/COH: GnRH antagonist 0.25 mg sc + r-FSH 150-200 IU sc.
ET: day 2 or 3, 2 embryos transferred.
LPS:micronized vaginal progesterone gel 90mgdaily + single bolus hCG1500 IU im12hrs after trigger vsmicronized
vaginal progesterone gel 90 mg daily + single bolus hCG 1500 IU im 35 hrs after trigger. Progesterone from day after
OPU until ß-hCG test
Outcomes Clinical pregnancy (intrauterine gestational sac with a heartbeat 3 weeks after a positive HCG test)
Notes Only study with this comparison.
Jung 2010
Methods Prospective study.
Participants Women undergoing IVF/ICSI, mean age 33 (n=124).
Interventions PD/COH: GnRH agonist.
ET: mean 2.9 embryos transferred.
LPS: progesterone 50 mg IM daily from oocyte retrieval vs progesterone 50 mg IM daily from oocyte retrieval + hCG
2000 IU sc on day 0, 2, 4 from oocyte retrieval vs progesterone 50 mg IM daily from oocyte retrieval + hCG 2000
IU sc on day 0, 2, 4 from oocyte retrieval + estradiol valerate 6 mg oral daily
Outcomes Clinical pregnancy, OHSS, miscarriage.
Notes Only abstract available. Author contacted, awaiting reply about randomization
Mochtar 2006
Methods Randomized controlled trial.
Participants Women undergoing their first IVF cycle, mean age 34 (n=355).
Interventions PD/COH: GnRH agonist.
LPS: micronized vaginal progesterone 200 mg twice daily starting at the evening of HCG administration for final
oocyte maturation vs micronized vaginal progesterone 200 mg twice daily starting at the evening after oocyte retrieval
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Mochtar 2006 (Continued)
vs micronized vaginal progesterone 200 mg twice daily starting at the evening after ET
Outcomes Biochemical pregnancies (serum HCG >2 IU/ml or a positive pregnancy test at the 18th day after oocyte retrieval)
, clinical pregnancies (gestational sac seen by transvaginal ultrasound at day 35 after oocyte retrieval), ongoing
pregnancies (positive fetal heartbeat by transvaginal ultrasound 10 weeks after oocyte retrieval)
Notes Only study with this comparison.
Paredes 2004
Methods
Participants
Interventions
Outcomes
Notes Translation needs to be obtained to assess eligibility.
Shamma 1992
Methods Randomized controlled trial.
Participants Women undergoing IVF-ET (n=80).
Interventions PD/COH: GnRH agonist.
LPS: Vaginal progesterone 25 mg 3 times daily + 5000 IU hCG im on day 5 and 10 versus vaginal progesterone 25
mg 3 times daily + 0.1 mg transdermal estrogen daily every 3 days from day 5
Outcomes Clinical pregnancy (not defined), miscarriage.
Notes Only study with this comparison.
Silverberg 2010
Methods Prospective trial.
Participants Women undergoing IVF.
Interventions PD/COH: FSH.
ET: day 3 or 5.
LPS: vaginal gel 90 mg daily vs progesterone IM.
Outcomes Pregnancy (not defined), delivery.
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Silverberg 2010 (Continued)
Notes Authors contacted to obtain information about use of randomization. Awaiting reply
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D A T A A N D A N A L Y S E S
Comparison 1. Human chorionic gonatotropin (hCG) versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live Birth Rate 1 38 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.25 [0.37, 13.80]
2 Clinical Pregnancy Rate 5 746 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.30 [0.90, 1.88]
3 Ongoing Pregnancy Rate 3 527 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.75 [1.09, 2.81]
4 Miscarriage Rate 2 140 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.49 [0.32, 6.85]
5 OHSS 1 387 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.62 [1.85, 7.06]
7 Subgroup analysis 1 (Clinical
Pregnancy Rate)
5 746 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.30 [0.90, 1.88]
7.1 clomiphene citrate alone
without GnRH agonists
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 human gonadotropins
with clomiphene citrate
without GnRH agonists
1 131 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.24 [0.54, 2.85]
7.3 human gonadotropins
with or without GnRH
agonists
3 513 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.50 [0.94, 2.39]
7.4 human gonadotropins
with or without GnRH
antagonists
1 102 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.82 [0.34, 1.98]
Comparison 2. Progesterone versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live Birth Rate 1 156 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.95 [1.02, 8.56]
2 Clinical Pregnancy Rate 7 841 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.83 [1.29, 2.61]
3 Ongoing Pregnancy Rate 5 642 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.87 [1.19, 2.94]
4 Miscarriage Rate 3 425 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.19 [0.47, 2.99]
6 Multiple pregnancy 1 34 Peto Odds Ratio (Peto, Fixed, 95% CI) 17.00 [0.28, 1027.
28]
7 Subgroup analysis 1 (Clinical
Pregnancy Rate)
7 841 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.83 [1.29, 2.61]
7.1 clomiphene citrate alone
without GnRH agonists
1 56 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.73 [0.69, 20.06]
7.2 human gonadotropins
with clomiphene citrate
without GnRH agonists
2 306 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.57 [0.86, 2.86]
7.3 human gonadotropins
with or without GnRH
agonists
4 479 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.90 [1.21, 2.99]
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7.4 human gonadotropins
with or without GnRH
antagonists
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Subgroup analysis 3 (Clinical
Pregnancy Rate)
7 841 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.83 [1.29, 2.61]
9.1 Stop at pregnancy test 3 257 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.40 [0.74, 2.64]
9.2 Up to 12 weeks 4 584 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.07 [1.35, 3.17]
Comparison 3. Progesterone versus hCG regimens
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live Birth Rate 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 versus hCG 2 203 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.41 [0.14, 1.18]
1.2 versus progesterone +
hCG
1 132 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.52 [0.12, 2.16]
2 Clinical Pregnancy Rate 15 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 versus hCG 10 1448 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.14 [0.90, 1.45]
2.2 versus progesterone +
hCG
7 1080 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.96 [0.74, 1.25]
3 Ongoing Pregnancy Rate 4 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
3.1 versus hCG 3 413 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.09 [0.66, 1.80]
3.2 versus progesterone +
hCG
2 434 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.04 [0.65, 1.68]
4 Miscarriage Rate 5 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
4.1 versus hCG 5 770 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.34 [0.69, 2.60]
4.2 versus progesterone +
hCG
1 132 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.88 [0.21, 3.66]
5 OHSS 5 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
5.1 versus hCG 4 706 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.63 [0.38, 1.03]
5.2 versus progesterone +
hCG
3 713 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.45 [0.26, 0.79]
6 Multiple pregnancy 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
6.1 versus hCG 1 147 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.40 [0.05, 2.88]
6.2 versus progesterone +
hCG
1 132 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.32 [0.04, 2.30]
8 Subgroup analysis 1:
Progesterone vs progesterone +
hCG (Clinical Pregnancy Rate)
4 722 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.65, 1.29]
8.1 clomiphene citrate alone
without GnRH agonists
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 human gonadotropins
with clomiphene citrate
without GnRH agonists
1 20 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.66 [0.23, 11.94]
8.3 human gonadotropins
with or without GnRH
agonists
3 702 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.90 [0.63, 1.27]
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8.4 human gonadotropins
with or without GnRH
antagonists
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Subgroup analysis 3:
Progesterone vs hCG (Clinical
Pregnancy Rate)
6 839 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.10 [0.81, 1.51]
11.1 Stop at pregnancy test 5 750 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.10 [0.78, 1.54]
11.2 Up to 12 weeks when
pregnant
1 89 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.15 [0.47, 2.82]
Comparison 4. Progesterone versus progesterone + estrogen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live Birth Rate 1 100 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.13 [0.43, 2.94]
2 Clinical Pregnancy Rate 7 1345 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.80 [0.63, 1.01]
2.1 Oral 3 642 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.96 [0.67, 1.38]
2.2 Transdermal 2 325 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.50 [0.31, 0.82]
2.3 Vaginal 2 301 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.07 [0.67, 1.71]
2.4 Oral and transdermal 1 77 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.33 [0.12, 0.94]
3 Ongoing Pregnancy Rate 5 993 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.00 [0.76, 1.31]
3.1 Oral 2 608 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.89 [0.62, 1.29]
3.2 Transdermal 2 219 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.97 [0.57, 1.66]
3.3 Vaginal 1 166 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.40 [0.76, 2.57]
4 Miscarriage Rate 6 1281 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.01 [0.70, 1.45]
4.1 Oral 3 743 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.21 [0.75, 1.93]
4.2 Transdermal 1 160 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.85 [0.25, 2.87]
4.3 Vaginal 2 301 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.44, 1.90]
4.4 Oral and transdermal 1 77 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.25 [0.05, 1.29]
5 OHSS 1 59 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.14 [0.01, 2.21]
5.1 Transdermal 1 59 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.14 [0.01, 2.21]
7 Subgroup analysis 1 (Clinical
Pregnancy Rate)
6 989 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.00 [0.76, 1.31]
7.1 clomiphene citrate alone
without GnRH agonists
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 human gonadotropins
with clomiphene citrate
without GnRH agonists
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 human gonadotropins
with or without GnRH
agonists
5 886 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.98 [0.73, 1.32]
7.4 human gonadotropins
with or without GnRH
antagonists
2 103 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.12 [0.52, 2.42]
9 Subgroup analysis 3 (Clinical
Pregnancy Rate)
7 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
9.1 Stop at pregnancytest 2 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
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9.2 Up to 12 weeks when
pregnant
5 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Progesterone versus progesterone + GnRH agonist
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live Birth Rate 3 455 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.26, 0.61]
1.1 Single dose 1 154 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.17, 0.77]
1.2 Multiple dose 2 301 Odds Ratio (M-H, Fixed, 95% CI) 0.42 [0.25, 0.70]
2 Clinical Pregnancy Rate 6 1646 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.74 [0.60, 0.90]
2.1 Single dose 3 1324 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.75 [0.60, 0.93]
2.2 Multiple dose 3 322 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.67 [0.42, 1.07]
3 Ongoing Pregnancy Rate 2 1170 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.60, 0.97]
3.1 Single dose 2 1170 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.60, 0.97]
3.2 Multiple dose 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Miscarriage Rate 1 120 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.70 [0.41, 7.10]
4.1 Single dose 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Multiple dose 1 120 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.70 [0.41, 7.10]
6 Multiple pregnancy 2 724 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.84 [0.55, 1.26]
6.1 Single dose 2 724 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.84 [0.55, 1.26]
6.2 Multiple dose 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Subgroup analysis 1 (Clinical
Pregnancy Rate)
6 1646 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.74 [0.60, 0.90]
7.1 clomiphene citrate alone
without GnRH agonists
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 human gonadotropins
with clomiphene citrate
without GnRH agonists
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 human gonadotropins
with or without GnRH
agonists
4 1171 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.81 [0.64, 1.02]
7.4 human gonadotropins
with or without GnRH
antagonists
3 475 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.57 [0.39, 0.83]
9 Subgroup analysis 3 (Clinical
Pregnancy Rate)
5 1526 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.78 [0.63, 0.96]
9.1 Stop at pregnancytest 3 935 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.67 [0.52, 0.88]
9.2 Up to 12 weeks when
pregnant
2 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.98 [0.70, 1.36]
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Comparison 6. Progesterone regimens
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live Birth Rate 9 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 IM versus Oral 1 40 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.14, 3.57]
1.2 IM versus Vaginal/rectal 4 1222 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.17 [0.91, 1.51]
1.3 Vaginal/rectal versus Oral 2 713 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.66, 1.48]
1.4 Low dose vaginal versus
high dose vaginal
2 1485 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.79, 1.24]
1.5 Short protocol versus long
protocol
1 97 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.88 [0.40, 1.95]
1.6 Micronized versus
synthetic
2 470 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.90 [0.52, 1.56]
2 Clinical Pregnancy Rate 31 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 IM versus Oral 3 123 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.92 [0.89, 4.14]
2.2 IM versus Vaginal/rectal 13 2932 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.14 [0.97, 1.33]
2.3 Vaginal/rectal versus Oral 6 2735 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.87 [0.73, 1.04]
2.4 Low dose vaginal versus
high dose vaginal
12 4973 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.04 [0.92, 1.17]
2.5 Short protocol versus long
protocol
1 97 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.43, 2.24]
2.6 Micronized versus
synthetic
4 2388 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.65, 0.96]
3 Ongoing Pregnancy Rate 11 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
3.1 IM versus Oral 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 IM versus Vaginal/rectal 4 1223 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.34 [1.05, 1.71]
3.3 Vaginal/rectal versus Oral 2 347 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.45 [0.89, 2.34]
3.4 Low dose vaginal versus
high dose vaginal
5 3034 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.85, 1.15]
3.5 Short protocol versus long
protocol
1 97 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.73 [0.33, 1.63]
3.6 Micronized versus
synthetic
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Miscarriage Rate 17 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
4.1 IM versus Oral 3 123 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.66 [0.28, 9.79]
4.2 IM versus Vaginal/rectal 5 1324 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.85 [0.58, 1.25]
4.3 Vaginal/rectal versus Oral 4 2140 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.18 [0.76, 1.85]
4.4 Low dose vaginal versus
high dose vaginal
8 2350 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.53, 1.17]
4.5 Short protocol versus long
protocol
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Micronized versus
synthetic
2 1793 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.16 [0.70, 1.91]
5 OHSS 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
5.1 IM versus Oral 1 40 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.0 [0.06, 16.58]
5.2 IM versus Vaginal/rectal 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Vaginal/rectal versus Oral 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Low dose vaginal versus
high dose vaginal
1 1211 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.57, 1.46]
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5.5 Short protocol versus long
protocol
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 Micronized versus
synthetic
1 40 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.0 [0.06, 16.58]
6 Multiple pregnancy 10 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
6.1 IM versus Oral 2 83 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.39 [1.28, 15.01]
6.2 IM versus Vaginal/rectal 1 505 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.97 [0.60, 1.59]
6.3 Vaginal/rectal versus Oral 1 283 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.13 [0.50, 2.58]
6.4 Low dose vaginal versus
high dose vaginal
4 905 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.06 [0.63, 1.76]
6.5 Short protocol versus long
protocol
2 317 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.62 [0.75, 3.50]
6.6 Micronized versus
synthetic
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Subgroup analysis 1: IM
versus Vaginal/rectal (Clinical
Pregnancy Rate)
11 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
7.1 clomiphene citrate alone
without GnRH agonists
0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 human gonadotropins
with clomiphene citrate
without GnRH agonists
0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 human gonadotropins
with or without GnRH
agonists
10 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 human gonadotropins
with or without GnRH
antagonists
1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Subgroup analysis 1: Low dose
vaginal versus high dose vaginal
(Clinical Pregnancy Rate)
9 3512 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.91, 1.22]
8.1 clomiphene citrate alone
without GnRH agonists
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 human gonadotropins
with clomiphene citrate
without GnRH agonists
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 human gonadotropins
with or without GnRH
agonists
8 3388 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.91, 1.22]
8.4 human gonadotropins
with or without GnRH
antagonists
1 124 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.04 [0.49, 2.21]
10 Subgroup analysis 3: IM
versus Vaginal/rectal (Clinical
Pregnancy Rate)
7 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
10.1 Stop at pregnancy test 2 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Up to 12 weeks when
pregnant
5 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Subgroup analysis 3:
Vaginal/rectal versus Oral
(Clinical Pregnancy Rate)
5 2695 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.85 [0.71, 1.02]
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11.1 Stop at pregnancy test 2 619 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.70 [0.50, 0.98]
11.2 Up to 12 weeks when
pregnant
3 2076 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.93 [0.75, 1.15]
12 Subgroup analysis 3: Low dose
vaginal versus high dose vaginal
(Clinical Pregnancy Rate)
10 4811 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.04 [0.92, 1.17]
12.1 Stop at pregnancy test 3 318 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.10 [0.67, 1.82]
12.2 Up to 12 weeks when
pregnant
7 4493 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.03 [0.91, 1.17]
Analysis 1.1. Comparison 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment,
Outcome 1 Live Birth Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment
Outcome: 1 Live Birth Rate
Study or subgroup hCG
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Beckers 2000 (1) 3/13 3/25 100.0 % 2.25 [ 0.37, 13.80 ]
Total (95% CI) 13 25 100.0 % 2.25 [ 0.37, 13.80 ]
Total events: 3 (hCG), 3 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Placebo/no treatment Favours hCG
(1) IM hCG 1500 IU 4 times
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Analysis 1.2. Comparison 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment,
Outcome 2 Clinical Pregnancy Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment
Outcome: 2 Clinical Pregnancy Rate
Study or subgroup hCG
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Artini 1995 (1) 6/44 4/44 8.0 % 1.56 [ 0.42, 5.79 ]
Beckers 2000 (2) 4/13 3/25 4.7 % 3.37 [ 0.61, 18.58 ]
Belaisch-Allart 1990 (3) 39/193 30/194 50.4 % 1.38 [ 0.82, 2.32 ]
Kupferminc 1990 (4) 12/51 14/51 17.4 % 0.82 [ 0.34, 1.98 ]
Torode 1987 (5) 14/60 14/71 19.5 % 1.24 [ 0.54, 2.85 ]
Total (95% CI) 361 385 100.0 % 1.30 [ 0.90, 1.88 ]
Total events: 75 (hCG), 65 (Placebo/no treatment)
Heterogeneity: Chi2 = 2.41, df = 4 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo/no treatment Favours hCG
(1) hCG 2000 IU every 3 days
(2) IM hCG 1500 IU 4 times
(3) sc hCG 1500 IU two times
(4) IM hCG 2500 IU 3 times
(5) hCG 1500 IU every other day
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Analysis 1.3. Comparison 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment,
Outcome 3 Ongoing Pregnancy Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment
Outcome: 3 Ongoing Pregnancy Rate
Study or subgroup hCG
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Beckers 2000 (1) 3/13 3/25 6.9 % 2.25 [ 0.37, 13.80 ]
Belaisch-Allart 1990 (2) 36/193 18/194 68.4 % 2.18 [ 1.23, 3.87 ]
Kupferminc 1990 (3) 10/51 11/51 24.7 % 0.89 [ 0.34, 2.31 ]
Total (95% CI) 257 270 100.0 % 1.75 [ 1.09, 2.81 ]
Total events: 49 (hCG), 32 (Placebo/no treatment)
Heterogeneity: Chi2 = 2.57, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo/no treatment Favours hCG
(1) IM hCG 1500 IU 4 times
(2) sc hCG 1500 IU two times
(3) IM hCG 2500 IU 3 times
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Analysis 1.4. Comparison 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment,
Outcome 4 Miscarriage Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment
Outcome: 4 Miscarriage Rate
Study or subgroup hCG
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Beckers 2000 (1) 1/13 0/25 13.6 % 18.60 [ 0.30, 1157.95 ]
Kupferminc 1990 (2) 3/51 3/51 86.4 % 1.00 [ 0.19, 5.16 ]
Total (95% CI) 64 76 100.0 % 1.49 [ 0.32, 6.85 ]
Total events: 4 (hCG), 3 (Placebo/no treatment)
Heterogeneity: Chi2 = 1.66, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hCG Favours Placebo/no treatment
(1) IM hCG 1500 IU 4 times
(2) IM hCG 2500 IU 3 times
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Analysis 1.5. Comparison 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment,
Outcome 5 OHSS.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment
Outcome: 5 OHSS
Study or subgroup hCG
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Belaisch-Allart 1990 (1) 30/193 8/194 100.0 % 3.62 [ 1.85, 7.06 ]
Total (95% CI) 193 194 100.0 % 3.62 [ 1.85, 7.06 ]
Total events: 30 (hCG), 8 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 3.77 (P = 0.00016)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hCG Favours Placebo/no treatment
(1) sc hCG 1500 IU two times
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Analysis 1.7. Comparison 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment,
Outcome 7 Subgroup analysis 1 (Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 1 Human chorionic gonatotropin (hCG) versus placebo or no treatment
Outcome: 7 Subgroup analysis 1 (Clinical Pregnancy Rate)
Study or subgroup hCG
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 clomiphene citrate alone without GnRH agonists
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (hCG), 0 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 human gonadotropins with clomiphene citrate without GnRH agonists
Torode 1987 (1) 14/60 14/71 19.5 % 1.24 [ 0.54, 2.85 ]
Subtotal (95% CI) 60 71 19.5 % 1.24 [ 0.54, 2.85 ]
Total events: 14 (hCG), 14 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
3 human gonadotropins with or without GnRH agonists
Artini 1995 (2) 6/44 4/44 8.0 % 1.56 [ 0.42, 5.79 ]
Beckers 2000 (3) 4/13 3/25 4.7 % 3.37 [ 0.61, 18.58 ]
Belaisch-Allart 1990 (4) 39/193 30/194 50.4 % 1.38 [ 0.82, 2.32 ]
Subtotal (95% CI) 250 263 63.1 % 1.50 [ 0.94, 2.39 ]
Total events: 49 (hCG), 37 (Placebo/no treatment)
Heterogeneity: Chi2 = 0.97, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.088)
4 human gonadotropins with or without GnRH antagonists
Kupferminc 1990 (5) 12/51 14/51 17.4 % 0.82 [ 0.34, 1.98 ]
Subtotal (95% CI) 51 51 17.4 % 0.82 [ 0.34, 1.98 ]
Total events: 12 (hCG), 14 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 361 385 100.0 % 1.30 [ 0.90, 1.88 ]
Total events: 75 (hCG), 65 (Placebo/no treatment)
Heterogeneity: Chi2 = 2.41, df = 4 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Chi2 = 1.44, df = 2 (P = 0.49), I2 =0.0%
0.01 0.1 1 10 100
Favours Placebo/no treatment Favours hCG
134Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(1) CC + hMG
(2) GnRH agonist + FSH
(3) GnRH agonist + hMG
(4) GnRH agonist + hMG
(5) hMG
Analysis 2.1. Comparison 2 Progesterone versus placebo or no treatment, Outcome 1 Live Birth Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 2 Progesterone versus placebo or no treatment
Outcome: 1 Live Birth Rate
Study or subgroup Progesterone
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Abate 1999a (1) 15/104 2/52 100.0 % 2.95 [ 1.02, 8.56 ]
Total (95% CI) 104 52 100.0 % 2.95 [ 1.02, 8.56 ]
Total events: 15 (Progesterone), 2 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.046)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours placebo Favours progesterone
(1) IM progesterone 50 mg daily or vaginal progesterone gel 90 mg daily
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Analysis 2.2. Comparison 2 Progesterone versus placebo or no treatment, Outcome 2 Clinical Pregnancy
Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 2 Progesterone versus placebo or no treatment
Outcome: 2 Clinical Pregnancy Rate
Study or subgroup Progesterone
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Abate 1999 (1) 14/43 8/43 13.5 % 2.06 [ 0.79, 5.41 ]
Abate 1999a (2) 28/104 4/52 18.6 % 3.23 [ 1.42, 7.34 ]
Artini 1995 (3) 13/88 4/44 10.8 % 1.65 [ 0.56, 4.85 ]
Belaisch-Allart 1987 (4) 27/141 20/145 32.2 % 1.47 [ 0.79, 2.75 ]
Hurd 1996 (5) 5/30 1/26 4.4 % 3.73 [ 0.69, 20.06 ]
Kupferminc 1990 (6) 16/54 14/51 17.7 % 1.11 [ 0.48, 2.58 ]
Wong 1990 (7) 3/10 1/10 2.8 % 3.28 [ 0.39, 27.75 ]
Total (95% CI) 470 371 100.0 % 1.83 [ 1.29, 2.61 ]
Total events: 106 (Progesterone), 52 (Placebo/no treatment)
Heterogeneity: Chi2 = 4.70, df = 6 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00081)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours progesterone
(1) IM 17-OHPc 341 mg every 3 days
(2) IM progesterone 50 mg daily or vaginal progesterone gel 90 mg daily
(3) IM progesterone 50 mg daily or vaginal progesterone cream 100 mg daily
(4) Oral dydrogesterone 10 mg 3 times daily
(5) Vaginal progesterone suppositories 100 mg twice daily + oral E2 2 mg 3 times daily
(6) Oral dydrogesterone 10 mg 3 times daily
(7) IM progesterone 50 mg daily
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Analysis 2.3. Comparison 2 Progesterone versus placebo or no treatment, Outcome 3 Ongoing Pregnancy
Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 2 Progesterone versus placebo or no treatment
Outcome: 3 Ongoing Pregnancy Rate
Study or subgroup Progesterone
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Abate 1999a (1) 21/104 2/52 23.4 % 3.64 [ 1.43, 9.28 ]
Belaisch-Allart 1987 (2) 20/141 16/145 42.0 % 1.33 [ 0.66, 2.67 ]
Colwell 1991 (3) 3/15 0/24 3.6 % 15.56 [ 1.43, 169.72 ]
Hurd 1996 (4) 4/30 1/26 6.1 % 3.15 [ 0.51, 19.51 ]
Kupferminc 1990 (5) 13/54 11/51 24.9 % 1.15 [ 0.46, 2.85 ]
Total (95% CI) 344 298 100.0 % 1.87 [ 1.19, 2.94 ]
Total events: 61 (Progesterone), 30 (Placebo/no treatment)
Heterogeneity: Chi2 = 7.29, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 2.71 (P = 0.0067)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours placebo Favours progesterone
(1) IM progesterone 50 mg daily or vaginal progesterone gel 90 mg daily
(2) Oral dydrogesterone 10 mg 3 times daily
(3) Oral progesterone 200 mg 4 times daily
(4) Vaginal progesterone suppositories 100 mg twice daily + oral E2 2 mg 3 times daily
(5) Oral dydrogesterone 10 mg 3 times daily
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Analysis 2.4. Comparison 2 Progesterone versus placebo or no treatment, Outcome 4 Miscarriage Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 2 Progesterone versus placebo or no treatment
Outcome: 4 Miscarriage Rate
Study or subgroup Progesterone
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Belaisch-Allart 1987 (1) 7/141 4/145 58.7 % 1.81 [ 0.54, 6.04 ]
Colwell 1991 (2) 0/12 2/22 9.8 % 0.20 [ 0.01, 3.86 ]
Kupferminc 1990 (3) 3/54 3/51 31.5 % 0.94 [ 0.18, 4.86 ]
Total (95% CI) 207 218 100.0 % 1.19 [ 0.47, 2.99 ]
Total events: 10 (Progesterone), 9 (Placebo/no treatment)
Heterogeneity: Chi2 = 1.93, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours progesterone Favours placebo/no treatment
(1) Oral dydrogesterone 10 mg 3 times daily
(2) Oral progesterone 200 mg 4 times daily
(3) Oral dydrogesterone 10 mg 3 times daily
138Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.6. Comparison 2 Progesterone versus placebo or no treatment, Outcome 6 Multiple pregnancy.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 2 Progesterone versus placebo or no treatment
Outcome: 6 Multiple pregnancy
Study or subgroup Progesterone
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Colwell 1991 (1) 1/12 0/22 100.0 % 17.00 [ 0.28, 1027.28 ]
Total (95% CI) 12 22 100.0 % 17.00 [ 0.28, 1027.28 ]
Total events: 1 (Progesterone), 0 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours progesterone Favours placebo/no treatment
(1) Oral progesterone 200 mg 4 times daily
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Analysis 2.7. Comparison 2 Progesterone versus placebo or no treatment, Outcome 7 Subgroup analysis 1
(Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 2 Progesterone versus placebo or no treatment
Outcome: 7 Subgroup analysis 1 (Clinical Pregnancy Rate)
Study or subgroup Progesterone
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 clomiphene citrate alone without GnRH agonists
Hurd 1996 (1) 5/30 1/26 4.4 % 3.73 [ 0.69, 20.06 ]
Subtotal (95% CI) 30 26 4.4 % 3.73 [ 0.69, 20.06 ]
Total events: 5 (Progesterone), 1 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
2 human gonadotropins with clomiphene citrate without GnRH agonists
Belaisch-Allart 1987 (2) 27/141 20/145 32.2 % 1.47 [ 0.79, 2.75 ]
Wong 1990 (3) 3/10 1/10 2.8 % 3.28 [ 0.39, 27.75 ]
Subtotal (95% CI) 151 155 34.9 % 1.57 [ 0.86, 2.86 ]
Total events: 30 (Progesterone), 21 (Placebo/no treatment)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
3 human gonadotropins with or without GnRH agonists
Abate 1999 (4) 14/43 8/43 13.5 % 2.06 [ 0.79, 5.41 ]
Abate 1999a (5) 28/104 4/52 18.6 % 3.23 [ 1.42, 7.34 ]
Artini 1995 (6) 13/88 4/44 10.8 % 1.65 [ 0.56, 4.85 ]
Kupferminc 1990 (7) 16/54 14/51 17.7 % 1.11 [ 0.48, 2.58 ]
Subtotal (95% CI) 289 190 60.6 % 1.90 [ 1.21, 2.99 ]
Total events: 71 (Progesterone), 30 (Placebo/no treatment)
Heterogeneity: Chi2 = 3.24, df = 3 (P = 0.36); I2 =8%
Test for overall effect: Z = 2.76 (P = 0.0057)
4 human gonadotropins with or without GnRH antagonists
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Progesterone), 0 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 470 371 100.0 % 1.83 [ 1.29, 2.61 ]
Total events: 106 (Progesterone), 52 (Placebo/no treatment)
Heterogeneity: Chi2 = 4.70, df = 6 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00081)
Test for subgroup differences: Chi2 = 0.96, df = 2 (P = 0.62), I2 =0.0%
0.01 0.1 1 10 100
Favours placebo Favours progesterone
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(1) CC
(2) Mostly CC+hMG, sometimes FSH, hMG or FSH+hMG
(3) CC + hMG
(4) FSH + GnRH agonist
(5) FSH + GnRH agonist
(6) FSH + GnRH agonist
(7) hMG
Analysis 2.9. Comparison 2 Progesterone versus placebo or no treatment, Outcome 9 Subgroup analysis 3
(Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 2 Progesterone versus placebo or no treatment
Outcome: 9 Subgroup analysis 3 (Clinical Pregnancy Rate)
Study or subgroup Progesterone
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Stop at pregnancy test
Artini 1995 13/88 4/44 10.8 % 1.65 [ 0.56, 4.85 ]
Kupferminc 1990 16/54 14/51 17.7 % 1.11 [ 0.48, 2.58 ]
Wong 1990 3/10 1/10 2.8 % 3.28 [ 0.39, 27.75 ]
Subtotal (95% CI) 152 105 31.2 % 1.40 [ 0.74, 2.64 ]
Total events: 32 (Progesterone), 19 (Placebo/no treatment)
Heterogeneity: Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.30)
2 Up to 12 weeks
Abate 1999 14/43 8/43 13.5 % 2.06 [ 0.79, 5.41 ]
Abate 1999a 28/104 4/52 18.6 % 3.23 [ 1.42, 7.34 ]
Belaisch-Allart 1987 27/141 20/145 32.2 % 1.47 [ 0.79, 2.75 ]
Hurd 1996 5/30 1/26 4.4 % 3.73 [ 0.69, 20.06 ]
Subtotal (95% CI) 318 266 68.8 % 2.07 [ 1.35, 3.17 ]
Total events: 74 (Progesterone), 33 (Placebo/no treatment)
0.01 0.1 1 10 100
Favours placebo Favours progesterone
(Continued . . . )
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(. . . Continued)
Study or subgroup Progesterone
Placebo/no
treatment
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: Chi2 = 2.72, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.33 (P = 0.00086)
Total (95% CI) 470 371 100.0 % 1.83 [ 1.29, 2.61 ]
Total events: 106 (Progesterone), 52 (Placebo/no treatment)
Heterogeneity: Chi2 = 4.70, df = 6 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00081)
Test for subgroup differences: Chi2 = 0.99, df = 1 (P = 0.32), I2 =0.0%
0.01 0.1 1 10 100
Favours placebo Favours progesterone
Analysis 3.1. Comparison 3 Progesterone versus hCG regimens, Outcome 1 Live Birth Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 3 Progesterone versus hCG regimens
Outcome: 1 Live Birth Rate
Study or subgroup Progesterone hCG regimen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 versus hCG
Golan 1993 (1) 1/26 6/30 44.9 % 0.23 [ 0.05, 1.13 ]
Ludwig 2001 (2) 3/70 5/77 55.1 % 0.65 [ 0.16, 2.71 ]
Subtotal (95% CI) 96 107 100.0 % 0.41 [ 0.14, 1.18 ]
Total events: 4 (Progesterone), 11 (hCG regimen)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.10)
2 versus progesterone + hCG
Ludwig 2001 (3) 3/70 5/62 100.0 % 0.52 [ 0.12, 2.16 ]
Subtotal (95% CI) 70 62 100.0 % 0.52 [ 0.12, 2.16 ]
Total events: 3 (Progesterone), 5 (hCG regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
0.01 0.1 1 10 100
Favours hCG regimen Favours Progesterone
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(1) IM progesterone 100 mg daily vs IM hCG 1000 IU or 2500 IU 4 times
(2) Vaginal progesterone 200 mg 3 times daily vs hCG 5000 IU twice and 2500 IU twice
(3) Vaginal progesterone 200 mg 3 times daily vs vaginal progesterone 200 mg 3 times daily + single dose hCG 5000 IU
Analysis 3.2. Comparison 3 Progesterone versus hCG regimens, Outcome 2 Clinical Pregnancy Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 3 Progesterone versus hCG regimens
Outcome: 2 Clinical Pregnancy Rate
Study or subgroup Progesterone hCG
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 versus hCG
Albert 1991 (1) 5/23 6/34 3.2 % 1.29 [ 0.34, 4.89 ]
Artini 1995 (2) 13/88 6/44 5.4 % 1.10 [ 0.39, 3.06 ]
Golan 1993 (3) 1/26 7/30 2.6 % 0.21 [ 0.05, 0.93 ]
Kupferminc 1990 (4) 16/54 12/51 7.7 % 1.36 [ 0.58, 3.22 ]
Lam 2008 (5) 39/89 32/89 16.0 % 1.39 [ 0.76, 2.52 ]
Loh 1996 (6) 12/73 11/83 7.3 % 1.29 [ 0.53, 3.11 ]
Ludwig 2001 (7) 13/70 15/77 8.5 % 0.94 [ 0.41, 2.14 ]
Martinez 2000 (8) 65/168 47/142 26.5 % 1.27 [ 0.80, 2.03 ]
Ugur 2001 (9) 40/137 24/81 15.8 % 0.98 [ 0.54, 1.79 ]
Vimpeli 2001 (10) 14/44 13/45 7.1 % 1.15 [ 0.47, 2.82 ]
Subtotal (95% CI) 772 676 100.0 % 1.14 [ 0.90, 1.45 ]
Total events: 218 (Progesterone), 173 (hCG)
Heterogeneity: Chi2 = 6.34, df = 9 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
2 versus progesterone + hCG
Caligara 2007 (11) 28/45 26/47 10.1 % 1.33 [ 0.58, 3.03 ]
Fujimoto 2002 (12) 7/51 20/63 9.2 % 0.37 [ 0.16, 0.88 ]
Geber 2007 (13) 33/75 29/66 15.6 % 1.00 [ 0.52, 1.95 ]
Ludwig 2001 (14) 13/70 13/62 9.4 % 0.86 [ 0.37, 2.03 ]
0.05 0.2 1 5 20
Favours hCG regimen Favours Progesterone
(Continued . . . )
143Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Progesterone hCG
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Macrolin 1993 (15) 45/152 43/150 28.1 % 1.05 [ 0.64, 1.72 ]
Ugur 2001 (16) 40/137 40/142 25.7 % 1.05 [ 0.63, 1.77 ]
Wong 1990 (17) 3/10 2/10 1.8 % 1.66 [ 0.23, 11.94 ]
Subtotal (95% CI) 540 540 100.0 % 0.96 [ 0.74, 1.25 ]
Total events: 169 (Progesterone), 173 (hCG)
Heterogeneity: Chi2 = 5.81, df = 6 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Chi2 = 0.93, df = 1 (P = 0.34), I2 =0.0%
0.05 0.2 1 5 20
Favours hCG regimen Favours Progesterone
(1) IM progesterone 50 mg once, then 12,5 mg daily vs hCG 1500 IU 4 times
(2) IM progesterone 50 mg daily or vaginal progesterone cream 100 mg daily vs hCG 2000 IU every 3 days
(3) IM progesterone 100 mg daily vs IM hCG 1000 IU or 2500 IU 4 times
(4) Oral dydrogesterone 10 mg 3 times daily vs IM hCG 2500 IU 3 times
(5) Vaginal progesterone 200 mg 3 times daily for 9 days + IM hCG 2000 IU 4 times vs IM hCG 2000 IU 4 times
(6) Information not available
(7) Vaginal progesterone 200 mg 3 times daily vs hCG 5000 IU twice and 2500 IU twice
(8) Vaginal progesterone 100 mg 3 times daily vs IM 2500 IU hCG 3 times
(9) Vaginal progesterone 400 mg daily vs hCG 1500 IU every 3 days
(10) Vaginal progesterone capsules 200 3 times daily vs IM hCG 1500 IU 3 times
(11) Vaginal progesterone 400 mg daily vs vaginal progesterone 400 mg daily + sc hCG 1000 IU 3 times
(12) IM progesterone 25 mg daily vs IM progesterone 25 mg daily + IM hCG 3000 IU 3 times
(13) Vaginal progesterone daily vs vaginal progesterone + rLH 4 times
(14) Vaginal progesterone 200 mg 3 times daily vs vaginal progesterone 200 mg 3 times daily + single dose hCG 5000 IU
(15) Vaginal progesterone 400 mg daily vs vaginal progesterone 400 mg daily + hCG 1500 IU every other day 3 times
(16) Vaginal progesterone 400 mg daily vs vaginal progesterone 400 mg daily + single dose hCG 3000 IU
(17) IM progesterone 50 mg daily vs IM progesterone 50 mg daily + hCG 1500 IU 6 times
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Analysis 3.3. Comparison 3 Progesterone versus hCG regimens, Outcome 3 Ongoing Pregnancy Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 3 Progesterone versus hCG regimens
Outcome: 3 Ongoing Pregnancy Rate
Study or subgroup Progesterone hCG regimen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 versus hCG
Kupferminc 1990 (1) 13/54 10/51 29.6 % 1.30 [ 0.52, 3.25 ]
Ludwig 2001 (2) 10/70 11/77 29.5 % 1.00 [ 0.40, 2.51 ]
Tay 2005 (3) 44/126 12/35 40.9 % 1.03 [ 0.47, 2.25 ]
Subtotal (95% CI) 250 163 100.0 % 1.09 [ 0.66, 1.80 ]
Total events: 67 (Progesterone), 33 (hCG regimen)
Heterogeneity: Chi2 = 0.19, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
2 versus progesterone + hCG
Ludwig 2001 (4) 10/70 9/62 24.0 % 0.98 [ 0.37, 2.59 ]
Macrolin 1993 (5) 34/152 32/150 76.0 % 1.06 [ 0.62, 1.83 ]
Subtotal (95% CI) 222 212 100.0 % 1.04 [ 0.65, 1.68 ]
Total events: 44 (Progesterone), 41 (hCG regimen)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
0.01 0.1 1 10 100
Favours hCG regimen Favours Progesterone
(1) Oral dydrogesterone 10 mg 3 times daily vs IM hCG 2500 IU 3 times
(2) Vaginal progesterone 200 mg 3 times daily vs hCG 5000 IU twice and 2500 IU twice
(3) Vaginal progesterone gel 90 mg daily or rectal progesterone 200 mg twice daily or vaginal progesterone 200 mg, 400 mg or 600 mg vs sc hCG 1500 IU twice
(4) Vaginal progesterone 200 mg 3 times daily vs vaginal progesterone 200 mg 3 times daily + single dose hCG 5000 IU
(5) Vaginal progesterone 400 mg daily vs vaginal progesterone 400 mg daily + hCG 1500 IU every other day 3 times
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Analysis 3.4. Comparison 3 Progesterone versus hCG regimens, Outcome 4 Miscarriage Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 3 Progesterone versus hCG regimens
Outcome: 4 Miscarriage Rate
Study or subgroup Progesterone hCG regimen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 versus hCG
Golan 1993 (1) 0/26 1/30 2.8 % 0.15 [ 0.00, 7.87 ]
Kupferminc 1990 (2) 3/54 3/51 16.2 % 0.94 [ 0.18, 4.86 ]
Lam 2008 (3) 3/89 4/89 19.2 % 0.74 [ 0.16, 3.36 ]
Ludwig 2001 (4) 4/70 2/77 16.4 % 2.20 [ 0.43, 11.26 ]
Martinez 2000 (5) 11/142 6/142 45.5 % 1.87 [ 0.70, 4.96 ]
Subtotal (95% CI) 381 389 100.0 % 1.34 [ 0.69, 2.60 ]
Total events: 21 (Progesterone), 16 (hCG regimen)
Heterogeneity: Chi2 = 2.72, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
2 versus progesterone + hCG
Ludwig 2001 (6) 4/70 4/62 100.0 % 0.88 [ 0.21, 3.66 ]
Subtotal (95% CI) 70 62 100.0 % 0.88 [ 0.21, 3.66 ]
Total events: 4 (Progesterone), 4 (hCG regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
Favours Progesterone Favours hCG regimen
(1) IM progesterone 100 mg daily vs IM hCG 1000 IU or 2500 IU 4 times
(2) Oral dydrogesterone 10 mg 3 times daily vs IM hCG 2500 IU 3 times
(3) Vaginal progesterone 200 mg 3 times daily for 9 days + IM hCG 2000 IU 4 times vs IM hCG 2000 IU 4 times
(4) Vaginal progesterone 200 mg 3 times daily vs hCG 5000 IU twice and 2500 IU twice
(5) Vaginal progesterone 100 mg 3 times daily vs IM 2500 IU hCG 3 times
(6) Vaginal progesterone 200 mg 3 times daily vs vaginal progesterone 200 mg 3 times daily + single dose hCG 5000 IU
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Analysis 3.5. Comparison 3 Progesterone versus hCG regimens, Outcome 5 OHSS.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 3 Progesterone versus hCG regimens
Outcome: 5 OHSS
Study or subgroup Progesterone hCG regimen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 versus hCG
Albert 1991 (1) 0/23 3/34 4.4 % 0.18 [ 0.02, 1.84 ]
Ludwig 2001 (2) 11/70 15/77 34.3 % 0.77 [ 0.33, 1.80 ]
Martinez 2000 (3) 12/142 14/142 37.8 % 0.84 [ 0.38, 1.89 ]
Ugur 2001 (4) 7/137 10/81 23.5 % 0.37 [ 0.13, 1.02 ]
Subtotal (95% CI) 372 334 100.0 % 0.63 [ 0.38, 1.03 ]
Total events: 30 (Progesterone), 42 (hCG regimen)
Heterogeneity: Chi2 = 2.94, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
2 versus progesterone + hCG
Ludwig 2001 (5) 11/70 7/62 32.0 % 1.45 [ 0.54, 3.92 ]
Macrolin 1993 0/152 4/150 8.1 % 0.13 [ 0.02, 0.94 ]
Ugur 2001 (6) 7/137 26/142 59.9 % 0.28 [ 0.14, 0.59 ]
Subtotal (95% CI) 359 354 100.0 % 0.45 [ 0.26, 0.79 ]
Total events: 18 (Progesterone), 37 (hCG regimen)
Heterogeneity: Chi2 = 8.43, df = 2 (P = 0.01); I2 =76%
Test for overall effect: Z = 2.80 (P = 0.0052)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
0.01 0.1 1 10 100
Favours Progesterone Favours hCG regimen
(1) IM progesterone 50 mg once, then 12,5 mg daily vs hCG 1500 IU 4 times
(2) Vaginal progesterone 200 mg 3 times daily vs hCG 5000 IU twice and 2500 IU twice
(3) Vaginal progesterone 100 mg 3 times daily vs IM 2500 IU hCG 3 times
(4) Vaginal progesterone 400 mg daily vs hCG 1500 IU every 3 days
(5) Vaginal progesterone 200 mg 3 times daily vs vaginal progesterone 200 mg 3 times daily + single dose hCG 5000 IU
(6) Vaginal progesterone 400 mg daily vs vaginal progesterone 400 mg daily + single dose hCG 3000 IU
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Analysis 3.6. Comparison 3 Progesterone versus hCG regimens, Outcome 6 Multiple pregnancy.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 3 Progesterone versus hCG regimens
Outcome: 6 Multiple pregnancy
Study or subgroup Progesterone hCG regimen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 versus hCG
Ludwig 2001 (1) 1/70 3/77 100.0 % 0.40 [ 0.05, 2.88 ]
Subtotal (95% CI) 70 77 100.0 % 0.40 [ 0.05, 2.88 ]
Total events: 1 (Progesterone), 3 (hCG regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
2 versus progesterone + hCG
Ludwig 2001 (2) 1/70 3/62 100.0 % 0.32 [ 0.04, 2.30 ]
Subtotal (95% CI) 70 62 100.0 % 0.32 [ 0.04, 2.30 ]
Total events: 1 (Progesterone), 3 (hCG regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.87), I2 =0.0%
0.01 0.1 1 10 100
Favours Progesterone Favours hCG regimen
(1) Vaginal progesterone 200 mg 3 times daily vs hCG 5000 IU twice and 2500 IU twice
(2) Vaginal progesterone 200 mg 3 times daily vs vaginal progesterone 200 mg 3 times daily + single dose hCG 5000 IU
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Analysis 3.8. Comparison 3 Progesterone versus hCG regimens, Outcome 8 Subgroup analysis 1:
Progesterone vs progesterone + hCG (Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 3 Progesterone versus hCG regimens
Outcome: 8 Subgroup analysis 1: Progesterone vs progesterone + hCG (Clinical Pregnancy Rate)
Study or subgroup Progesterone hCG regimen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 clomiphene citrate alone without GnRH agonists
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Progesterone), 0 (hCG regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 human gonadotropins with clomiphene citrate without GnRH agonists
Wong 1990 (1) 3/10 2/10 3.0 % 1.66 [ 0.23, 11.94 ]
Subtotal (95% CI) 10 10 3.0 % 1.66 [ 0.23, 11.94 ]
Total events: 3 (Progesterone), 2 (hCG regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.61)
3 human gonadotropins with or without GnRH agonists
Fujimoto 2002 (2) 7/51 20/63 15.7 % 0.37 [ 0.16, 0.88 ]
Ludwig 2001 (3) 13/70 13/62 16.0 % 0.86 [ 0.37, 2.03 ]
Macrolin 1993 (4) 95/306 43/150 65.2 % 1.12 [ 0.73, 1.71 ]
Subtotal (95% CI) 427 275 97.0 % 0.90 [ 0.63, 1.27 ]
Total events: 115 (Progesterone), 76 (hCG regimen)
Heterogeneity: Chi2 = 5.03, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 0.62 (P = 0.54)
4 human gonadotropins with or without GnRH antagonists
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Progesterone), 0 (hCG regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 437 285 100.0 % 0.91 [ 0.65, 1.29 ]
Total events: 118 (Progesterone), 78 (hCG regimen)
Heterogeneity: Chi2 = 5.39, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 0.36, df = 1 (P = 0.55), I2 =0.0%
0.01 0.1 1 10 100
Favours hCG regimen Favours progesterone
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(1) CC + hMG
(2) GnRHa + hMG
(3) GnRH agonist + r-FSH or hMG
(4) GnRHa + hMG
Analysis 3.11. Comparison 3 Progesterone versus hCG regimens, Outcome 11 Subgroup analysis 3:
Progesterone vs hCG (Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 3 Progesterone versus hCG regimens
Outcome: 11 Subgroup analysis 3: Progesterone vs hCG (Clinical Pregnancy Rate)
Study or subgroup Progesterone hCG
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Stop at pregnancy test
Artini 1995 13/88 6/44 9.4 % 1.10 [ 0.39, 3.06 ]
Golan 1993 1/26 7/30 4.5 % 0.21 [ 0.05, 0.93 ]
Kupferminc 1990 16/54 12/51 13.3 % 1.36 [ 0.58, 3.22 ]
Ludwig 2001 13/70 15/77 14.7 % 0.94 [ 0.41, 2.14 ]
Martinez 2000 65/168 47/142 45.9 % 1.27 [ 0.80, 2.03 ]
Subtotal (95% CI) 406 344 87.8 % 1.10 [ 0.78, 1.54 ]
Total events: 108 (Progesterone), 87 (hCG)
Heterogeneity: Chi2 = 5.53, df = 4 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Up to 12 weeks when pregnant
Vimpeli 2001 14/44 13/45 12.2 % 1.15 [ 0.47, 2.82 ]
Subtotal (95% CI) 44 45 12.2 % 1.15 [ 0.47, 2.82 ]
Total events: 14 (Progesterone), 13 (hCG)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
Total (95% CI) 450 389 100.0 % 1.10 [ 0.81, 1.51 ]
Total events: 122 (Progesterone), 100 (hCG)
Heterogeneity: Chi2 = 5.54, df = 5 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
0.01 0.1 1 10 100
Favours hCG Favours progesterone
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Analysis 4.1. Comparison 4 Progesterone versus progesterone + estrogen, Outcome 1 Live Birth Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 4 Progesterone versus progesterone + estrogen
Outcome: 1 Live Birth Rate
Study or subgroup Progesterone
Progesterone
+ estrogen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Lewin 1994 (1) 11/50 10/50 100.0 % 1.13 [ 0.43, 2.94 ]
Total (95% CI) 50 50 100.0 % 1.13 [ 0.43, 2.94 ]
Total events: 11 (Progesterone), 10 (Progesterone + estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours progesterone + estrogen Favours progesterone
(1) IM progesterone 50 mg daily vs IM progesterone 50 mg daily E2 2 mg oral daily
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Analysis 4.2. Comparison 4 Progesterone versus progesterone + estrogen, Outcome 2 Clinical Pregnancy
Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 4 Progesterone versus progesterone + estrogen
Outcome: 2 Clinical Pregnancy Rate
Study or subgroup Progesterone
Progesterone
+ estrogen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Oral
Elgindy 2010 (1) 13/45 33/90 10.2 % 0.71 [ 0.33, 1.50 ]
Lewin 1994 (2) 14/50 13/50 7.5 % 1.11 [ 0.46, 2.66 ]
Yanushpolsky 2010 (3) 197/305 65/102 26.4 % 1.04 [ 0.65, 1.66 ]
Subtotal (95% CI) 400 242 44.1 % 0.96 [ 0.67, 1.38 ]
Total events: 224 (Progesterone), 111 (Progesterone + estrogen)
Heterogeneity: Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
2 Transdermal
Ceyhan 2008 (4) 13/29 13/30 5.6 % 1.06 [ 0.38, 2.94 ]
Gorkemli 2004 (5) 18/115 50/151 18.7 % 0.40 [ 0.23, 0.70 ]
Subtotal (95% CI) 144 181 24.3 % 0.50 [ 0.31, 0.82 ]
Total events: 31 (Progesterone), 63 (Progesterone + estrogen)
Heterogeneity: Chi2 = 2.70, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 2.78 (P = 0.0054)
3 Vaginal
Elgindy 2010 (6) 14/45 41/90 11.0 % 0.55 [ 0.27, 1.14 ]
Engmann 2008 (7) 52/82 42/84 15.4 % 1.72 [ 0.93, 3.17 ]
Subtotal (95% CI) 127 174 26.4 % 1.07 [ 0.67, 1.71 ]
Total events: 66 (Progesterone), 83 (Progesterone + estrogen)
Heterogeneity: Chi2 = 5.51, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.29 (P = 0.77)
4 Oral and transdermal
Drakakis 2007 (8) 5/38 13/39 5.2 % 0.33 [ 0.12, 0.94 ]
Subtotal (95% CI) 38 39 5.2 % 0.33 [ 0.12, 0.94 ]
Total events: 5 (Progesterone), 13 (Progesterone + estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.038)
Total (95% CI) 709 636 100.0 % 0.80 [ 0.63, 1.01 ]
Total events: 326 (Progesterone), 270 (Progesterone + estrogen)
Heterogeneity: Chi2 = 17.84, df = 7 (P = 0.01); I2 =61%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Chi2 = 8.80, df = 3 (P = 0.03), I2 =66%
0.05 0.2 1 5 20
Favours progesterone + estrogen Favours progesterone
valerate 2 mg + norgestrel 0.5 mg 3 times daily + transdermal estradiol hemihydrate 50 g every 4 days
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(1) IM progesterone 100 mg daily vs IM progesterone 100 mg daily + E2 valerate 2 mg 3 times daily
(2) IM progesterone 50 mg daily vs IM progesterone 50 mg daily E2 2 mg daily
(3) IM progesterone 50 mg daily or vaginal progesterone gel 90 mg daily vs IM progesterone 50 mg daily or vaginal progesterone gel 90 mg daily + E2 3 mg twice daily
(4) Vaginal progesterone 600 mg daily vs vaginal progesterone 600 mg daily + transdermal E2 2 g twice weekly
(5) Vaginal progesterone 200 mg 3 times daily vs vaginal progesterone 200 mg 3 times daily + estradiol 100 g daily
(6) IM progesterone 100 mg daily vs IM progesterone 100 mg daily + vaginal E2 valerate 2 mg 3 times daily
(7) IM progesterone 50 mg daily vs IM progesterone 50 mg daily + vaginal E2 2 mg twice daily
(8) Oral progesterone 100 g 3 times daily + vaginal progesterone 200 g 3 times daily vs oral progesterone 100 g 3 times daily + vaginal progesterone 200
g 3 times daily + oral estradiol
Analysis 4.3. Comparison 4 Progesterone versus progesterone + estrogen, Outcome 3 Ongoing Pregnancy
Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 4 Progesterone versus progesterone + estrogen
Outcome: 3 Ongoing Pregnancy Rate
Study or subgroup Progesterone
Progesterone
+ estrogen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Oral
Fatemi 2006 (1) 26/100 30/101 19.3 % 0.83 [ 0.45, 1.54 ]
Yanushpolsky 2010 (2) 132/305 46/102 35.8 % 0.93 [ 0.59, 1.46 ]
Subtotal (95% CI) 405 203 55.1 % 0.89 [ 0.62, 1.29 ]
Total events: 158 (Progesterone), 76 (Progesterone + estrogen)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
2 Transdermal
Ceyhan 2008 (3) 10/29 11/30 6.5 % 0.91 [ 0.32, 2.62 ]
Serna 2008 (4) 33/79 34/81 18.6 % 0.99 [ 0.53, 1.86 ]
Subtotal (95% CI) 108 111 25.1 % 0.97 [ 0.57, 1.66 ]
Total events: 43 (Progesterone), 45 (Progesterone + estrogen)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
0.01 0.1 1 10 100
Favours progesterone + estrogen Favours progesterone
(Continued . . . )
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(. . . Continued)
Study or subgroup Progesterone
Progesterone
+ estrogen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
3 Vaginal
Engmann 2008 (5) 46/82 40/84 19.8 % 1.40 [ 0.76, 2.57 ]
Subtotal (95% CI) 82 84 19.8 % 1.40 [ 0.76, 2.57 ]
Total events: 46 (Progesterone), 40 (Progesterone + estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Total (95% CI) 595 398 100.0 % 1.00 [ 0.76, 1.31 ]
Total events: 247 (Progesterone), 161 (Progesterone + estrogen)
Heterogeneity: Chi2 = 1.66, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 1.56, df = 2 (P = 0.46), I2 =0.0%
0.01 0.1 1 10 100
Favours progesterone + estrogen Favours progesterone
(1) Vaginal progesterone 200 mg 3 times daily vs vaginal progesterone 200 mg 3 times daily + E2 valerate 2 mg twice daily
(2) IM progesterone 50 mg daily or vaginal progesterone gel 90 mg daily vs IM progesterone 50 mg daily or vaginal progesterone gel 90 mg daily + E2 3 mg twice daily
(3) Vaginal progesterone 600 mg daily vs vaginal progesterone 600 mg daily + 2 g twice weekly
(4) Vaginal progesterone 200 mg twice daily vs vaginal progesterone 200 mg twice daily + E2 10 g daily
(5) IM progesterone 50 mg daily vs IM progesterone 50 mg daily + vaginal E2 2 mg twice daily
154Luteal phase support for assisted reproduction cycles (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.4. Comparison 4 Progesterone versus progesterone + estrogen, Outcome 4 Miscarriage Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 4 Progesterone versus progesterone + estrogen
Outcome: 4 Miscarriage Rate
Study or subgroup Progesterone
Progesterone
+ estrogen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Oral
Elgindy 2010 (1) 3/45 1/90 3.0 % 6.81 [ 0.83, 55.73 ]
Fatemi 2006 (2) 8/100 9/101 13.7 % 0.89 [ 0.33, 2.40 ]
Yanushpolsky 2010 (3) 65/305 19/102 44.0 % 1.18 [ 0.68, 2.05 ]
Subtotal (95% CI) 450 293 60.8 % 1.21 [ 0.75, 1.93 ]
Total events: 76 (Progesterone), 29 (Progesterone + estrogen)
Heterogeneity: Chi2 = 2.97, df = 2 (P = 0.23); I2 =33%
Test for overall effect: Z = 0.78 (P = 0.43)
2 Transdermal
Serna 2008 (4) 5/79 6/81 9.0 % 0.85 [ 0.25, 2.87 ]
Subtotal (95% CI) 79 81 9.0 % 0.85 [ 0.25, 2.87 ]
Total events: 5 (Progesterone), 6 (Progesterone + estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
3 Vaginal
Elgindy 2010 (5) 3/45 1/90 3.0 % 6.81 [ 0.83, 55.73 ]
Engmann 2008 (6) 13/82 18/84 22.2 % 0.69 [ 0.32, 1.51 ]
Subtotal (95% CI) 127 174 25.3 % 0.91 [ 0.44, 1.90 ]
Total events: 16 (Progesterone), 19 (Progesterone + estrogen)
Heterogeneity: Chi2 = 3.98, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.24 (P = 0.81)
4 Oral and transdermal
Drakakis 2007 (7) 1/38 5/39 4.9 % 0.25 [ 0.05, 1.29 ]
Subtotal (95% CI) 38 39 4.9 % 0.25 [ 0.05, 1.29 ]
Total events: 1 (Progesterone), 5 (Progesterone + estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.098)
Total (95% CI) 694 587 100.0 % 1.01 [ 0.70, 1.45 ]
Total events: 98 (Progesterone), 59 (Progesterone + estrogen)
Heterogeneity: Chi2 = 10.44, df = 6 (P = 0.11); I2 =43%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 3.49, df = 3 (P = 0.32), I2 =14%
0.01 0.1 1 10 100
Favours progesterone Favours progesterone + estrogen
valerate 2 mg + norgestrel 0.5 mg 3 times daily + transdermal estradiol hemihydrate 50 g every 4 days
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(1) IM progesterone 100 mg daily vs IM progesterone 100 mg daily + E2 valerate 2 mg 3 times daily
(2) Vaginal progesterone 200 mg 3 times daily vs vaginal progesterone 200 mg 3 times daily + E2 valerate 2 mg twice daily
(3) IM progesterone 50 mg daily or vaginal progesterone gel 90 mg daily vs IM progesterone 50 mg daily or vaginal progesterone gel 90 mg daily + E2 3 mg twice daily
(4) Vaginal progesterone 200 mg twice daily vs vaginal progesterone 200 mg twice daily + E2 10 g daily
(5) IM progesterone 100 mg daily vs IM progesterone 100 mg daily + vaginal E2 valerate 2 mg 3 times daily
(6) IM progesterone 50 mg daily vs IM progesterone 50 mg daily + vaginal E2 2 mg twice daily
(7) Oral progesterone 100 g 3 times daily + vaginal progesterone 200 g 3 times daily vs oral progesterone 100 g 3 times daily + vaginal progesterone 200
g 3 times daily +oral estradiol
Analysis 4.5. Comparison 4 Progesterone versus progesterone + estrogen, Outcome 5 OHSS.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 4 Progesterone versus progesterone + estrogen
Outcome: 5 OHSS
Study or subgroup Progesterone
Progesterone
+ estrogen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Transdermal
Ceyhan 2008 (1) 0/29 2/30 100.0 % 0.14 [ 0.01, 2.21 ]
Total (95% CI) 29 30 100.0 % 0.14 [ 0.01, 2.21 ]
Total events: 0 (Progesterone), 2 (Progesterone + estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours progesterone Favours progesterone + estrogen
(1) Vaginal progesterone 600 mg daily vs vaginal progesterone 600 mg daily + transdermal E2 2 g twice weekly
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Analysis 4.7. Comparison 4 Progesterone versus progesterone + estrogen, Outcome 7 Subgroup analysis 1
(Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 4 Progesterone versus progesterone + estrogen
Outcome: 7 Subgroup analysis 1 (Clinical Pregnancy Rate)
Study or subgroup Progesterone
Progesterone
+ estrogen
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 clomiphene citrate alone without GnRH agonists
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Progesterone), 0 (Progesterone + estrogen)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 human gonadotropins with clomiphene citrate without GnRH agonists
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Progesterone), 0 (Progesterone + estrogen)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 human gonadotropins with or without GnRH agonists
Drakakis 2007 (1) 5/38 13/39 7.0 % 0.33 [ 0.12, 0.94 ]
Elgindy 2010 (2) 27/90 33/90 20.1 % 0.74 [ 0.40, 1.38 ]
Engmann 2008 (3) 42/63 30/59 14.9 % 1.91 [ 0.93, 3.93 ]
Lewin 1994 (4) 14/50 13/50 10.0 % 1.11 [ 0.46, 2.66 ]
Yanushpolsky 2010 (5) 197/305 65/102 35.2 % 1.04 [ 0.65, 1.66 ]
Subtotal (95% CI) 546 340 87.1 % 0.98 [ 0.73, 1.32 ]
Total events: 285 (Progesterone), 154 (Progesterone + estrogen)
Heterogeneity: Chi2 = 8.39, df = 4 (P = 0.08); I2 =52%
Test for overall effect: Z = 0.14 (P = 0.89)
4 human gonadotropins with or without GnRH antagonists
Ceyhan 2008 (6) 13/29 13/30 7.4 % 1.06 [ 0.38, 2.94 ]
Engmann 2008 (7) 10/19 12/25 5.5 % 1.20 [ 0.37, 3.90 ]
Subtotal (95% CI) 48 55 12.9 % 1.12 [ 0.52, 2.42 ]
Total events: 23 (Progesterone), 25 (Progesterone + estrogen)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 594 395 100.0 % 1.00 [ 0.76, 1.31 ]
Total events: 308 (Progesterone), 179 (Progesterone + estrogen)
Heterogeneity: Chi2 = 8.52, df = 6 (P = 0.20); I2 =30%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
0.01 0.1 1 10 100
Favours Progesterone + estrogen Favours Progesterone
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(1) GnRH agonist + rFSH
(2) GnRH agonist + rFSH + hMG
(3) GnRH agonist + rFSH or rFSH + hMG
(4) GnRHa + hMG
(5) GnRH agonist
(6) GnRH antagonist + rFSH
(7) GnRH antagonist + rFSH or rFSH + hMG
Analysis 4.9. Comparison 4 Progesterone versus progesterone + estrogen, Outcome 9 Subgroup analysis 3
(Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 4 Progesterone versus progesterone + estrogen
Outcome: 9 Subgroup analysis 3 (Clinical Pregnancy Rate)
Study or subgroup Progesterone
Progesterone
+ estrogen
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Stop at pregnancytest
Drakakis 2007 5/38 13/39 0.33 [ 0.12, 0.94 ]
Lewin 1994 14/50 13/50 1.11 [ 0.46, 2.66 ]
2 Up to 12 weeks when pregnant
Ceyhan 2008 13/29 13/30 1.06 [ 0.38, 2.94 ]
Elgindy 2010 27/90 41/90 0.52 [ 0.28, 0.94 ]
Engmann 2008 52/82 42/84 1.72 [ 0.93, 3.17 ]
Gorkemli 2004 18/115 50/151 0.40 [ 0.23, 0.70 ]
Yanushpolsky 2010 197/305 65/102 1.04 [ 0.65, 1.66 ]
0.02 0.1 1 10 50
Favours Progesterone + estrogen Favours Progesterone
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Analysis 5.1. Comparison 5 Progesterone versus progesterone + GnRH agonist, Outcome 1 Live Birth Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 5 Progesterone versus progesterone + GnRH agonist
Outcome: 1 Live Birth Rate
Study or subgroup Progesterone
Progesterone
+ GnRH
agonist Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Single dose
Isik 2009 (1) 13/80 26/74 33.0 % 0.36 [ 0.17, 0.77 ]
Subtotal (95% CI) 80 74 33.0 % 0.36 [ 0.17, 0.77 ]
Total events: 13 (Progesterone), 26 (Progesterone + GnRH agonist)
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0083)
2 Multiple dose
Isikoglu 2007 (2) 34/90 45/91 40.6 % 0.62 [ 0.34, 1.12 ]
Qublan 2008 (3) 3/60 19/60 26.3 % 0.11 [ 0.03, 0.41 ]
Subtotal (95% CI) 150 151 67.0 % 0.42 [ 0.25, 0.70 ]
Total events: 37 (Progesterone), 64 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 5.66, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 3.29 (P = 0.00099)
Total (95% CI) 230 225 100.0 % 0.40 [ 0.26, 0.61 ]
Total events: 50 (Progesterone), 90 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 5.90, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 4.21 (P = 0.000026)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
0.01 0.1 1 10 100
Favours progesterone + single-dose GnRH agonist Favours progesterone
ET
(1) Vaginal progesterone 200 mg 3 times daily + single dose hCG 1500 IU vs vaginal progesterone 200 mg 3 times daily + single dose hCG 1500 IU + sc leuprolide
acetate 0.5 mg on day 6 after
(2) Progesterone 50 mg im daily vs progesterone 50 mg im daily + GnRH agonist 0.25 mg sc daily for 12 days
(3) Cyclogest (not defined) + placebo vs Cyclogest (not defined) + sc tripstorelin 0.1 mg 3 times
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Analysis 5.2. Comparison 5 Progesterone versus progesterone + GnRH agonist, Outcome 2 Clinical
Pregnancy Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 5 Progesterone versus progesterone + GnRH agonist
Outcome: 2 Clinical Pregnancy Rate
Study or subgroup Progesterone
Progesterone
+ GnRH
agonist
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Single dose
Ata 2008 (1) 120/285 122/285 35.9 % 0.97 [ 0.70, 1.35 ]
Isik 2009 (2) 16/80 30/74 8.3 % 0.38 [ 0.19, 0.75 ]
Tesarik 2006 (3) 113/300 141/300 37.7 % 0.68 [ 0.49, 0.94 ]
Subtotal (95% CI) 665 659 82.0 % 0.75 [ 0.60, 0.93 ]
Total events: 249 (Progesterone), 293 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 6.48, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 2.57 (P = 0.010)
2 Multiple dose
Isikoglu 2007 (4) 44/90 45/91 11.7 % 0.98 [ 0.55, 1.75 ]
Pirard 2006 (5) 1/5 2/16 0.5 % 1.79 [ 0.11, 29.48 ]
Qublan 2008 (6) 8/60 22/60 5.8 % 0.29 [ 0.13, 0.66 ]
Subtotal (95% CI) 155 167 18.0 % 0.67 [ 0.42, 1.07 ]
Total events: 53 (Progesterone), 69 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 6.04, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 1.66 (P = 0.096)
Total (95% CI) 820 826 100.0 % 0.74 [ 0.60, 0.90 ]
Total events: 302 (Progesterone), 362 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 12.70, df = 5 (P = 0.03); I2 =61%
Test for overall effect: Z = 3.03 (P = 0.0025)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
0.02 0.1 1 10 50
Favours progesterone + GnRH agonist Favours progesterone
ET
4 mg daily + sc triptorelin 0.1 mg on day 6 after ET
(1) Vaginal progesterone gel 90 mg daily + placebo vs vaginal progesterone gel 90 mg daily + sc triptorelin 0.1 mg on day 6 after ET
(2) Vaginal progesterone 200 mg 3 times daily + single dose hCG 1500 IU vs vaginal progesterone 200 mg 3 times daily + single dose hCG 1500 IU + sc leuprolide
acetate 0.5 mg on day 6 after
(3) Vaginal progesterone 400 mg daily + single dose hCG 250 g + E2 valerate injection 4 mg daily vs vaginal progesterone 400 mg daily + single dose hCG 250
g + E2 valerate injection
(4) Progesterone 50 mg im daily vs progesterone 50 mg im daily + GnRH agonist 0.25 mg sc daily for 12 days
(5) vaginal micronized progesterone 200 mg 3x daily vs 200 g GnRH agonist (buserelin) intranasal (IN) followed by 100 g IN every 2 days, daily, 2 or 3 times daily
(6) Cyclogest (not defined) + placebo vs Cyclogest (not defined) + sc tripstorelin 0.1 mg 3 times
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Analysis 5.3. Comparison 5 Progesterone versus progesterone + GnRH agonist, Outcome 3 Ongoing
Pregnancy Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 5 Progesterone versus progesterone + GnRH agonist
Outcome: 3 Ongoing Pregnancy Rate
Study or subgroup Progesterone
Progesterone
+ GnRH
agonist
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Single dose
Ata 2008 (1) 84/285 89/285 45.9 % 0.92 [ 0.64, 1.32 ]
Tesarik 2006 (2) 100/300 131/300 54.1 % 0.65 [ 0.47, 0.90 ]
Subtotal (95% CI) 585 585 100.0 % 0.76 [ 0.60, 0.97 ]
Total events: 184 (Progesterone), 220 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 2.22 (P = 0.026)
2 Multiple dose
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Progesterone), 0 (Progesterone + GnRH agonist)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 585 585 100.0 % 0.76 [ 0.60, 0.97 ]
Total events: 184 (Progesterone), 220 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours progesterone + GnRH agonist Favours progesterone
4 mg daily + sc triptorelin 0.1 mg on day 6 after ET
(1) Vaginal progesterone gel 90 mg daily + placebo vs vaginal progesterone gel 90 mg daily + sc triptorelin 0.1 mg on day 6 after ET
(2) Vaginal progesterone 400 mg daily + single dose hCG 250 g + E2 valerate injection 4 mg daily vs vaginal progesterone 400 mg daily + single dose hCG 250
g + E2 valerate injection
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Analysis 5.4. Comparison 5 Progesterone versus progesterone + GnRH agonist, Outcome 4 Miscarriage
Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 5 Progesterone versus progesterone + GnRH agonist
Outcome: 4 Miscarriage Rate
Study or subgroup Progesterone
Progesterone
+ GnRH
agonist
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Single dose
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Progesterone), 0 (Progesterone + GnRH agonist)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Multiple dose
Qublan 2008 (1) 5/60 3/60 100.0 % 1.70 [ 0.41, 7.10 ]
Subtotal (95% CI) 60 60 100.0 % 1.70 [ 0.41, 7.10 ]
Total events: 5 (Progesterone), 3 (Progesterone + GnRH agonist)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 60 60 100.0 % 1.70 [ 0.41, 7.10 ]
Total events: 5 (Progesterone), 3 (Progesterone + GnRH agonist)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours progesterone Favours progesterone + GnRH agonist
(1) Cyclogest (not defined) + placebo vs Cyclogest (not defined) + sc tripstorelin 0.1 mg 3 times
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Analysis 5.6. Comparison 5 Progesterone versus progesterone + GnRH agonist, Outcome 6 Multiple
pregnancy.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 5 Progesterone versus progesterone + GnRH agonist
Outcome: 6 Multiple pregnancy
Study or subgroup Progesterone
Progesterone
+ GnRH
agonist
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Single dose
Ata 2008 (1) 37/285 40/285 73.3 % 0.91 [ 0.57, 1.48 ]
Isik 2009 (2) 13/80 17/74 26.7 % 0.65 [ 0.29, 1.45 ]
Subtotal (95% CI) 365 359 100.0 % 0.84 [ 0.55, 1.26 ]
Total events: 50 (Progesterone), 57 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
2 Multiple dose
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Progesterone), 0 (Progesterone + GnRH agonist)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 365 359 100.0 % 0.84 [ 0.55, 1.26 ]
Total events: 50 (Progesterone), 57 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours progesterone Favours progesterone + GnRH agonist
ET
(1) Vaginal progesterone gel 90 mg daily + placebo vs vaginal progesterone gel 90 mg daily + sc triptorelin 0.1 mg on day 6 after ET
(2) Vaginal progesterone 200 mg 3 times daily + single dose hCG 1500 IU vs vaginal progesterone 200 mg 3 times daily + single dose hCG 1500 IU + sc leuprolide
acetate 0.5 mg on day 6 after
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Analysis 5.7. Comparison 5 Progesterone versus progesterone + GnRH agonist, Outcome 7 Subgroup
analysis 1 (Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 5 Progesterone versus progesterone + GnRH agonist
Outcome: 7 Subgroup analysis 1 (Clinical Pregnancy Rate)
Study or subgroup Progesterone
Progesterone
+ GnRH
agonist
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 clomiphene citrate alone without GnRH agonists
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Progesterone), 0 (Progesterone + GnRH agonist)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 human gonadotropins with clomiphene citrate without GnRH agonists
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Progesterone), 0 (Progesterone + GnRH agonist)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 human gonadotropins with or without GnRH agonists
Ata 2008 (1) 120/285 122/285 35.9 % 0.97 [ 0.70, 1.35 ]
Isikoglu 2007 (2) 44/90 45/91 11.7 % 0.98 [ 0.55, 1.75 ]
Qublan 2008 (3) 8/60 22/60 5.8 % 0.29 [ 0.13, 0.66 ]
Tesarik 2006 (4) 59/150 72/150 19.0 % 0.70 [ 0.45, 1.11 ]
Subtotal (95% CI) 585 586 72.4 % 0.81 [ 0.64, 1.02 ]
Total events: 231 (Progesterone), 261 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 7.86, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 1.76 (P = 0.079)
4 human gonadotropins with or without GnRH antagonists
Isik 2009 (5) 16/80 30/74 8.3 % 0.38 [ 0.19, 0.75 ]
Pirard 2006 (6) 1/5 2/16 0.5 % 1.79 [ 0.11, 29.48 ]
Tesarik 2006 (7) 54/150 69/150 18.7 % 0.66 [ 0.42, 1.05 ]
Subtotal (95% CI) 235 240 27.6 % 0.57 [ 0.39, 0.83 ]
Total events: 71 (Progesterone), 101 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 2.43, df = 2 (P = 0.30); I2 =18%
Test for overall effect: Z = 2.92 (P = 0.0035)
Total (95% CI) 820 826 100.0 % 0.74 [ 0.60, 0.90 ]
Total events: 302 (Progesterone), 362 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 12.73, df = 6 (P = 0.05); I2 =53%
Test for overall effect: Z = 3.03 (P = 0.0025)
Test for subgroup differences: Chi2 = 2.44, df = 1 (P = 0.12), I2 =59%
0.01 0.1 1 10 100
Favours Progesterone + GnRH agonist Favours Progesterone
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(1) GnRH agonist + rFSH
(2) GnRH agonist + FSH
(3) GnRH agonist + hMG
(4) GnRH agonist + rFSH + hMG
(5) GnRH antagonist + FSH
(6) hMG/FSH
(7) GnRH antagonist + rFSH + hMG
Analysis 5.9. Comparison 5 Progesterone versus progesterone + GnRH agonist, Outcome 9 Subgroup
analysis 3 (Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 5 Progesterone versus progesterone + GnRH agonist
Outcome: 9 Subgroup analysis 3 (Clinical Pregnancy Rate)
Study or subgroup Progesterone
Progesterone
+ GnRH
agonist
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Stop at pregnancytest
Isik 2009 16/80 30/74 8.9 % 0.38 [ 0.19, 0.75 ]
Isikoglu 2007 44/90 45/91 12.4 % 0.98 [ 0.55, 1.75 ]
Tesarik 2006 113/300 141/300 40.1 % 0.68 [ 0.49, 0.94 ]
Subtotal (95% CI) 470 465 61.4 % 0.67 [ 0.52, 0.88 ]
Total events: 173 (Progesterone), 216 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 4.30, df = 2 (P = 0.12); I2 =54%
Test for overall effect: Z = 2.96 (P = 0.0031)
2 Up to 12 weeks when pregnant
Pirard 2006 1/5 2/16 0.5 % 1.79 [ 0.11, 29.48 ]
Ata 2008 120/285 122/285 38.1 % 0.97 [ 0.70, 1.35 ]
Subtotal (95% CI) 290 301 38.6 % 0.98 [ 0.70, 1.36 ]
Total events: 121 (Progesterone), 124 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
Total (95% CI) 760 766 100.0 % 0.78 [ 0.63, 0.96 ]
0.01 0.1 1 10 100
Favours Progesterone + GnRH agonist Favours Progesterone
(Continued . . . )
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(. . . Continued)
Study or subgroup Progesterone
Progesterone
+ GnRH
agonist
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 294 (Progesterone), 340 (Progesterone + GnRH agonist)
Heterogeneity: Chi2 = 7.52, df = 4 (P = 0.11); I2 =47%
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Chi2 = 3.04, df = 1 (P = 0.08), I2 =67%
0.01 0.1 1 10 100
Favours Progesterone + GnRH agonist Favours Progesterone
Analysis 6.1. Comparison 6 Progesterone regimens, Outcome 1 Live Birth Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 1 Live Birth Rate
Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 IM versus Oral
Iwase 2008 (1) 3/20 4/20 100.0 % 0.71 [ 0.14, 3.57 ]
Subtotal (95% CI) 20 20 100.0 % 0.71 [ 0.14, 3.57 ]
Total events: 3 (Treatment A), 4 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
2 IM versus Vaginal/rectal
Abate 1999a (2) 11/52 4/52 5.5 % 2.95 [ 0.99, 8.75 ]
Dal Prato 2008 (3) 36/138 73/274 30.2 % 0.97 [ 0.61, 1.54 ]
Propst 2001 (4) 39/99 25/102 18.5 % 1.98 [ 1.09, 3.58 ]
Zegers-Hochschild 2000 (5) 81/262 77/243 45.8 % 0.96 [ 0.66, 1.41 ]
Subtotal (95% CI) 551 671 100.0 % 1.17 [ 0.91, 1.51 ]
Total events: 167 (Treatment A), 179 (Treatment B)
Heterogeneity: Chi2 = 7.41, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 1.23 (P = 0.22)
0.01 0.1 1 10 100
Favours treatment B Favours treatment A
(Continued . . . )
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(. . . Continued)
Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
3 Vaginal/rectal versus Oral
Chakravarty 2005 (6) 80/351 19/79 48.0 % 0.93 [ 0.52, 1.66 ]
Pouly 1996 (7) 32/139 32/144 52.0 % 1.05 [ 0.60, 1.83 ]
Subtotal (95% CI) 490 223 100.0 % 0.99 [ 0.66, 1.48 ]
Total events: 112 (Treatment A), 51 (Treatment B)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
4 Low dose vaginal versus high dose vaginal
Dal Prato 2008 (8) 32/137 41/137 17.6 % 0.72 [ 0.42, 1.22 ]
Doody 2009 (9) 153/403 295/808 82.4 % 1.06 [ 0.83, 1.36 ]
Subtotal (95% CI) 540 945 100.0 % 0.99 [ 0.79, 1.24 ]
Total events: 185 (Treatment A), 336 (Treatment B)
Heterogeneity: Chi2 = 1.75, df = 1 (P = 0.19); I2 =43%
Test for overall effect: Z = 0.07 (P = 0.95)
5 Short protocol versus long protocol
Goudge 2010 (10) 25/51 24/46 100.0 % 0.88 [ 0.40, 1.95 ]
Subtotal (95% CI) 51 46 100.0 % 0.88 [ 0.40, 1.95 ]
Total events: 25 (Treatment A), 24 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
6 Micronized versus synthetic
Chakravarty 2005 (11) 80/351 19/79 88.6 % 0.93 [ 0.52, 1.66 ]
Iwase 2008 (12) 3/20 4/20 11.4 % 0.71 [ 0.14, 3.57 ]
Subtotal (95% CI) 371 99 100.0 % 0.90 [ 0.52, 1.56 ]
Total events: 83 (Treatment A), 23 (Treatment B)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 1.72, df = 5 (P = 0.89), I2 =0.0%
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(1) chlormadione acetate 6 mg oral 2x daily vs progesterone im 25 mg daily from day 2 to 6, 50 mg daily from day 7 to 14
(2) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(3) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily or vaginal progesterone gel 90 mg twice daily
(4) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(5) IM progesterone 50 mg daily vs vaginal progesterone ring 1 mg
(6) Vaginal progesterone 200 mg 3 times daily vs oral dydrogesterone 10 mg twice daily
(7) Vaginal progesterone gel 90 mg daily vs oral progesterone 300 mg daily
(8) Crinone 8% vs Crinone 8% twice daily
(9) Crinone 8% vs vaginal progesterone 100 mg twice daily or vaginal progesterone 100 mg 3 times daily
(10) progesterone 50 mg IM for 11 days vs progesterone 50 mg IM for 6 weeks
(11) Vaginal progesterone 200 mg 3 times daily vs oral dydrogesterone 10 mg twice daily
(12) Progesterone im 25 mg daily from day 2 to 6, 50 mg daily from day 7 to 14 vs chlormadione acetate 6 mg oral 2x daily
Analysis 6.2. Comparison 6 Progesterone regimens, Outcome 2 Clinical Pregnancy Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 2 Clinical Pregnancy Rate
Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 IM versus Oral
Iwase 2008 (1) 5/20 4/20 27.3 % 1.32 [ 0.31, 5.73 ]
Licciardi 1999 (2) 11/19 11/24 41.4 % 1.60 [ 0.49, 5.27 ]
Saucedo 2000 (3) 8/20 3/20 31.2 % 3.40 [ 0.86, 13.37 ]
Subtotal (95% CI) 59 64 100.0 % 1.92 [ 0.89, 4.14 ]
Total events: 24 (Treatment A), 18 (Treatment B)
Heterogeneity: Chi2 = 1.00, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.094)
2 IM versus Vaginal/rectal
Abate 1999a (4) 18/52 10/52 3.3 % 2.17 [ 0.92, 5.14 ]
0.01 0.1 1 10 100
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Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Artini 1995 (5) 6/44 7/44 1.8 % 0.84 [ 0.26, 2.70 ]
Dal Prato 2008 (6) 45/138 87/274 12.6 % 1.04 [ 0.67, 1.61 ]
Geusa 2001 (7) 42/150 40/150 9.4 % 1.07 [ 0.64, 1.78 ]
Miller 2010 (8) 38/81 37/84 6.5 % 1.12 [ 0.61, 2.07 ]
Perino 1997 (9) 69/150 41/150 11.0 % 2.23 [ 1.39, 3.56 ]
Porcu 2003 (10) 27/112 30/112 6.7 % 0.87 [ 0.48, 1.58 ]
Propst 2001 (11) 48/99 31/102 7.6 % 2.13 [ 1.21, 3.74 ]
Saucedo 2000 (12) 8/20 7/20 1.5 % 1.23 [ 0.35, 4.36 ]
Saucedo 2003 (13) 13/42 17/44 3.1 % 0.72 [ 0.30, 1.73 ]
Sumita 2003 (14) 13/50 17/50 3.3 % 0.69 [ 0.29, 1.61 ]
Yanushpolsky 2010 (15) 125/201 137/206 14.7 % 0.83 [ 0.55, 1.24 ]
Zegers-Hochschild 2000 (16) 96/262 89/243 18.5 % 1.00 [ 0.70, 1.44 ]
Subtotal (95% CI) 1401 1531 100.0 % 1.14 [ 0.97, 1.33 ]
Total events: 548 (Treatment A), 550 (Treatment B)
Heterogeneity: Chi2 = 21.29, df = 12 (P = 0.05); I2 =44%
Test for overall effect: Z = 1.63 (P = 0.10)
3 Vaginal/rectal versus Oral
Chakravarty 2005 (17) 109/351 25/79 11.4 % 0.97 [ 0.57, 1.65 ]
Friedler 1999 (18) 16/32 10/32 3.2 % 2.15 [ 0.80, 5.78 ]
Ganesh 2011 (19) 242/941 121/422 46.8 % 0.86 [ 0.66, 1.11 ]
Patki 2007 (20) 70/247 122/308 25.5 % 0.61 [ 0.43, 0.86 ]
Pouly 1996 (21) 40/139 36/144 11.5 % 1.21 [ 0.72, 2.05 ]
Saucedo 2000 (22) 7/20 3/20 1.6 % 2.83 [ 0.69, 11.63 ]
Subtotal (95% CI) 1730 1005 100.0 % 0.87 [ 0.73, 1.04 ]
Total events: 484 (Treatment A), 317 (Treatment B)
Heterogeneity: Chi2 = 11.57, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 1.52 (P = 0.13)
4 Low dose vaginal versus high dose vaginal
Dal Prato 2008 (23) 36/137 51/137 5.5 % 0.60 [ 0.36, 1.00 ]
Doody 2009 (24) 174/403 346/808 24.4 % 1.01 [ 0.80, 1.29 ]
Dunstone 1999 (25) 2/15 3/23 0.4 % 1.03 [ 0.15, 6.84 ]
Ganesh 2011 (26) 138/482 104/459 16.7 % 1.37 [ 1.02, 1.83 ]
Geber 2007a (27) 54/122 44/122 5.5 % 1.40 [ 0.84, 2.34 ]
Kleinstein 2005 (28) 47/212 55/218 7.2 % 0.84 [ 0.54, 1.32 ]
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Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Ludwig 2002 (29) 21/73 10/53 2.1 % 1.70 [ 0.75, 3.85 ]
Ng 2003 (30) 7/30 9/30 1.1 % 0.72 [ 0.23, 2.22 ]
Ng 2007 (31) 18/66 19/66 2.5 % 0.93 [ 0.44, 1.98 ]
Rodriguez-Pezino 2004 (32) 18/40 37/84 2.5 % 1.04 [ 0.49, 2.21 ]
Stadtmauer 2010 (33) 307/651 310/646 30.0 % 0.97 [ 0.78, 1.20 ]
Strehler 1999 (34) 18/45 18/51 2.1 % 1.22 [ 0.54, 2.78 ]
Subtotal (95% CI) 2276 2697 100.0 % 1.04 [ 0.92, 1.17 ]
Total events: 840 (Treatment A), 1006 (Treatment B)
Heterogeneity: Chi2 = 12.40, df = 11 (P = 0.33); I2 =11%
Test for overall effect: Z = 0.58 (P = 0.56)
5 Short protocol versus long protocol
Goudge 2010 (35) 32/51 29/46 100.0 % 0.99 [ 0.43, 2.24 ]
Subtotal (95% CI) 51 46 100.0 % 0.99 [ 0.43, 2.24 ]
Total events: 32 (Treatment A), 29 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
6 Micronized versus synthetic
Chakravarty 2005 (36) 109/351 25/79 13.4 % 0.97 [ 0.57, 1.65 ]
Ganesh 2011 (37) 242/941 121/422 54.9 % 0.86 [ 0.66, 1.11 ]
Iwase 2008 (38) 5/20 4/20 1.7 % 1.32 [ 0.31, 5.73 ]
Patki 2007 (39) 70/247 122/308 30.0 % 0.61 [ 0.43, 0.86 ]
Subtotal (95% CI) 1559 829 100.0 % 0.79 [ 0.65, 0.96 ]
Total events: 426 (Treatment A), 272 (Treatment B)
Heterogeneity: Chi2 = 3.61, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 13.56, df = 5 (P = 0.02), I2 =63%
0.01 0.1 1 10 100
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(1) chlormadione acetate 6 mg oral 2x daily vs progesterone im 25 mg daily from day 2 to 6, 50 mg daily from day 7 to 14
(2) IM progesterone 50 mg daily vs oral progesterone 200 mg 3 times daily
(3) IM progesterone 50 mg daily vs oral progesterone 400 mg daily
(4) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(5) IM progesterone 50 mg daily vs vaginal progesterone cream 100 mg daily
(6) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily or vaginal progesterone gel 90 mg twice daily
(7) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(8) IM progesterone 50 mg daily vs vaginal Endometrin (not defined)
(9) IM progesterone 50 mg daily vs vaginal progesterone 200 mg daily
(10) IM progesterone 50 mg daily vs vaginal progesterone 200 mg daily
(11) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(12) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(13) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(14) IM progesterone 50 mg daily vs vaginal progesterone 600 mg daily
(15) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(16) 50 mg progesterone IM vs progesterone vaginal ring 1 mg
(17) Vaginal progesterone 200 mg 3 times daily vs oral dydrogesterone 10 mg twice daily
(18) Vaginal progesterone 100 mg twice daily vs oral progesterone 200 mg 4 times daily
(19) Vaginal progesterone 200 mg 3 times daily or vaginal progesterone gel 90 mg daily vs oral dydrogesterone 10 mg daily
(20) Vaginal progesterone 600 mg daily vs vaginal progesterone 600 mg daily + oral dydrogesterone 20 mg daily
(21) Vaginal progesterone gel 90 mg daily vs oral progesterone 300 mg daily
(22) Vaginal progesterone gel 90 mg daily vs oral progesterone 400 mg daily
(23) Crinone 8% vs Crinone 8% twice daily
(24) Crinone 8% vs vaginal progesterone 100 mg twice daily
(25) Crinone 8% vs vaginal progesterone pessaries 400 mg twice daily
(26) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(27) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(28) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(29) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(30) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(31) Progesterone capsules 100 mg 2 times daily vs Progesterone pessaries 400 mg 2 times daily
(32) Crinone 8% vs vaginal progesterone capsule 200 mg twice daily or vaginal progesterone suppositories 200 mg daily
(33) Vaginal gel vs vaginal ring
(34) Crinone 8% vs Utrogestan (not defined)
(35) progesterone 50 mg IM for 11 days vs progesterone 50 mg IM for 6 weeks
(36) Vaginal progesterone 200 mg 3 times daily vs oral dydrogesterone 10 mg twice daily
(37) Vaginal progesterone 200 mg 3 times daily or vaginal progesterone gel 90 mg daily vs oral dydrogesterone 10 mg twice daily
(38) Progesterone im 25 mg daily from day 2 to 6, 50 mg daily from day 7 to 14 vs chlormadione acetate 6 mg oral 2x daily
(39) Vaginal progesterone 600 mg daily vs vaginal progesterone 600 mg daily + oral dydrogesterone 20 mg daily
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Analysis 6.3. Comparison 6 Progesterone regimens, Outcome 3 Ongoing Pregnancy Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 3 Ongoing Pregnancy Rate
Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 IM versus Oral
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment A), 0 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 IM versus Vaginal/rectal
Abate 1999a (1) 15/52 6/52 6.6 % 2.90 [ 1.12, 7.51 ]
Dal Prato 2008 (2) 38/138 74/274 28.4 % 1.03 [ 0.65, 1.63 ]
Perino 1997 (3) 66/150 33/150 25.9 % 2.70 [ 1.67, 4.36 ]
Yanushpolsky 2010 (4) 85/201 93/206 39.1 % 0.89 [ 0.60, 1.32 ]
Subtotal (95% CI) 541 682 100.0 % 1.34 [ 1.05, 1.71 ]
Total events: 204 (Treatment A), 206 (Treatment B)
Heterogeneity: Chi2 = 16.12, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 2.32 (P = 0.020)
3 Vaginal/rectal versus Oral
Friedler 1999 (5) 14/32 6/32 21.1 % 3.14 [ 1.10, 8.97 ]
Pouly 1996 (6) 36/139 33/144 78.9 % 1.17 [ 0.68, 2.02 ]
Subtotal (95% CI) 171 176 100.0 % 1.45 [ 0.89, 2.34 ]
Total events: 50 (Treatment A), 39 (Treatment B)
Heterogeneity: Chi2 = 2.67, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.50 (P = 0.13)
4 Low dose vaginal versus high dose vaginal
Dal Prato 2008 (7) 32/137 42/137 8.0 % 0.69 [ 0.41, 1.18 ]
Doody 2009 (8) 170/403 327/808 38.2 % 1.07 [ 0.84, 1.37 ]
Ludwig 2002 (9) 18/73 9/53 3.1 % 1.57 [ 0.67, 3.71 ]
Stadtmauer 2010 (10) 294/651 300/646 47.3 % 0.95 [ 0.76, 1.18 ]
Tay 2005 (11) 13/36 31/90 3.5 % 1.08 [ 0.48, 2.41 ]
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Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Subtotal (95% CI) 1300 1734 100.0 % 0.99 [ 0.85, 1.15 ]
Total events: 527 (Treatment A), 709 (Treatment B)
Heterogeneity: Chi2 = 3.46, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
5 Short protocol versus long protocol
Goudge 2010 (12) 26/51 27/46 100.0 % 0.73 [ 0.33, 1.63 ]
Subtotal (95% CI) 51 46 100.0 % 0.73 [ 0.33, 1.63 ]
Total events: 26 (Treatment A), 27 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
6 Micronized versus synthetic
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment A), 0 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 6.50, df = 3 (P = 0.09), I2 =54%
0.01 0.1 1 10 100
Favours treatment B Favours treatment A
(1) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(2) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily or vaginal progesterone gel 90 mg twice daily
(3) IM progesterone 50 mg daily vs vaginal progesterone 200 mg daily
(4) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(5) Vaginal progesterone 100 mg twice daily vs oral progesterone 200 mg 4 times daily
(6) Vaginal progesterone gel 90 mg daily vs oral progesterone 300 mg daily
(7) Crinone 8% vs Crinone 8% twice daily
(8) Crinone 8% vs vaginal progesterone 100 mg twice daily or vaginal progesterone 100 mg 3 times daily
(9) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(10) Vaginal gel vs vaginal ring
(11) Crinone 8% vs rectal progesterone 200 mg twice daily or vaginal progesterone 200 mg, 400 mg or 600 mg daily
(12) progesterone 50 mg IM for 11 days vs progesterone 50 mg IM for 6 weeks
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Analysis 6.4. Comparison 6 Progesterone regimens, Outcome 4 Miscarriage Rate.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 4 Miscarriage Rate
Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 IM versus Oral
Iwase 2008 (1) 2/20 0/20 40.0 % 7.79 [ 0.47, 129.11 ]
Licciardi 1999 (2) 0/19 2/24 39.5 % 0.16 [ 0.01, 2.69 ]
Saucedo 2000 (3) 1/20 0/20 20.5 % 7.39 [ 0.15, 372.38 ]
Subtotal (95% CI) 59 64 100.0 % 1.66 [ 0.28, 9.79 ]
Total events: 3 (Treatment A), 2 (Treatment B)
Heterogeneity: Chi2 = 4.36, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 0.56 (P = 0.58)
2 IM versus Vaginal/rectal
Dal Prato 2008 (4) 6/138 13/274 15.4 % 0.91 [ 0.34, 2.42 ]
Miller 2010 (5) 5/81 6/84 9.8 % 0.86 [ 0.25, 2.90 ]
Perino 1997 (6) 3/150 8/150 10.1 % 0.39 [ 0.12, 1.30 ]
Saucedo 2000 (7) 1/20 0/20 1.0 % 7.39 [ 0.15, 372.38 ]
Yanushpolsky 2010 (8) 40/201 44/206 63.7 % 0.91 [ 0.57, 1.48 ]
Subtotal (95% CI) 590 734 100.0 % 0.85 [ 0.58, 1.25 ]
Total events: 55 (Treatment A), 71 (Treatment B)
Heterogeneity: Chi2 = 2.89, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
3 Vaginal/rectal versus Oral
Chakravarty 2005 (9) 29/351 6/79 24.7 % 1.09 [ 0.45, 2.67 ]
Friedler 1999 (10) 2/32 4/32 7.0 % 0.48 [ 0.09, 2.57 ]
Ganesh 2011 (11) 37/941 14/422 53.6 % 1.19 [ 0.65, 2.17 ]
Pouly 1996 (12) 8/139 4/144 14.7 % 2.08 [ 0.65, 6.59 ]
Subtotal (95% CI) 1463 677 100.0 % 1.18 [ 0.76, 1.85 ]
Total events: 76 (Treatment A), 28 (Treatment B)
Heterogeneity: Chi2 = 2.04, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
4 Low dose vaginal versus high dose vaginal
Dal Prato 2008 (13) 4/137 9/137 12.8 % 0.45 [ 0.15, 1.36 ]
Ganesh 2011 (14) 18/482 19/459 36.6 % 0.90 [ 0.47, 1.73 ]
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Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Geber 2007a (15) 8/122 7/122 14.6 % 1.15 [ 0.41, 3.27 ]
Kleinstein 2005 (16) 9/212 10/218 18.7 % 0.92 [ 0.37, 2.31 ]
Ludwig 2002 (17) 3/73 1/53 3.9 % 2.05 [ 0.27, 15.28 ]
Ng 2007 (18) 1/66 5/66 5.9 % 0.25 [ 0.05, 1.28 ]
Rodriguez-Pezino 2004 (19) 0/20 4/84 2.5 % 0.28 [ 0.02, 3.48 ]
Strehler 1999 (20) 2/48 3/51 4.9 % 0.70 [ 0.12, 4.21 ]
Subtotal (95% CI) 1160 1190 100.0 % 0.79 [ 0.53, 1.17 ]
Total events: 45 (Treatment A), 58 (Treatment B)
Heterogeneity: Chi2 = 5.21, df = 7 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
5 Short protocol versus long protocol
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment A), 0 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Micronized versus synthetic
Chakravarty 2005 (21) 29/351 6/79 31.5 % 1.09 [ 0.45, 2.67 ]
Ganesh 2011 (22) 37/941 14/422 68.5 % 1.19 [ 0.65, 2.17 ]
Subtotal (95% CI) 1292 501 100.0 % 1.16 [ 0.70, 1.91 ]
Total events: 66 (Treatment A), 20 (Treatment B)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Chi2 = 3.11, df = 4 (P = 0.54), I2 =0.0%
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(1) chlormadione acetate 6 mg oral 2x daily vs progesterone im 25 mg daily from day 2 to 6, 50 mg daily from day 7 to 14
(2) IM progesterone 50 mg daily vs oral progesterone 200 mg 3 times daily
(3) IM progesterone 50 mg daily vs oral progesterone 400 mg daily
(4) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily or vaginal progesterone gel 90 mg twice daily
(5) IM progesterone 50 mg daily vs vaginal Endometrin (not defined)
(6) IM progesterone 50 mg daily vs vaginal progesterone 200 mg daily
(7) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(8) IM progesterone 50 mg daily vs vaginal progesterone gel 90 mg daily
(9) Vaginal progesterone 200 mg 3 times daily vs oral dydrogesterone 10 mg twice daily
(10) Vaginal progesterone 100 mg twice daily vs oral progesterone 200 mg 4 times daily
(11) Vaginal progesterone 200 mg 3 times daily or vaginal progesterone gel 90 mg daily vs oral dydrogesterone 10 mg daily
(12) Vaginal progesterone gel 90 mg daily vs oral progesterone 300 mg daily
(13) Crinone 8% vs Crinone 8% twice daily
(14) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(15) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(16) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(17) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(18) Progesterone capsules 100 mg 2 times daily vs Progesterone pessaries 400 mg 2 times daily
(19) Crinone 8% vs vaginal progesterone suppositories 200 mg daily or vaginal progesterone capsule 200 mg twice daily
(20) Crinone 8% vs Utrogestan (not defined)
(21) Vaginal progesterone 200 mg 3 times daily vs oral dydrogesterone 10 mg twice daily
(22) Vaginal progesterone 200 mg 3 times daily or vaginal progesterone gel 90 mg daily vs oral dydrogesterone 10 mg daily
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Analysis 6.5. Comparison 6 Progesterone regimens, Outcome 5 OHSS.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 5 OHSS
Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 IM versus Oral
Iwase 2008 (1) 1/20 1/20 100.0 % 1.00 [ 0.06, 16.58 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.06, 16.58 ]
Total events: 1 (Treatment A), 1 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 IM versus Vaginal/rectal
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment A), 0 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Vaginal/rectal versus Oral
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment A), 0 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Low dose vaginal versus high dose vaginal
Doody 2009 (2) 26/403 57/808 100.0 % 0.91 [ 0.57, 1.46 ]
Subtotal (95% CI) 403 808 100.0 % 0.91 [ 0.57, 1.46 ]
Total events: 26 (Treatment A), 57 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
5 Short protocol versus long protocol
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment A), 0 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Micronized versus synthetic
Iwase 2008 (3) 1/20 1/20 100.0 % 1.00 [ 0.06, 16.58 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.06, 16.58 ]
Total events: 1 (Treatment A), 1 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.01, df = 2 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
Favours treatment A Favours treatment B
(1) Progesterone im 25 mg daily from day 2 to 6, 50 mg daily from day 7 to 14 vs chlormadione acetate 6 mg oral 2x daily
(2) Crinone 8% vs vaginal progesterone 100 mg twice daily or vaginal progesterone 100 mg 3 times daily
(3) Progesterone im 25 mg daily from day 2 to 6, 50 mg daily from day 7 to 14 vs chlormadione acetate 6 mg oral 2x daily
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Analysis 6.6. Comparison 6 Progesterone regimens, Outcome 6 Multiple pregnancy.
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 6 Multiple pregnancy
Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 IM versus Oral
Iwase 2008 (1) 1/20 0/20 9.8 % 7.39 [ 0.15, 372.38 ]
Licciardi 1999 (2) 9/19 4/24 90.2 % 4.14 [ 1.13, 15.13 ]
Subtotal (95% CI) 39 44 100.0 % 4.39 [ 1.28, 15.01 ]
Total events: 10 (Treatment A), 4 (Treatment B)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.36 (P = 0.018)
2 IM versus Vaginal/rectal
Zegers-Hochschild 2000 (3) 39/262 37/243 100.0 % 0.97 [ 0.60, 1.59 ]
Subtotal (95% CI) 262 243 100.0 % 0.97 [ 0.60, 1.59 ]
Total events: 39 (Treatment A), 37 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
3 Vaginal/rectal versus Oral
Pouly 1996 (4) 13/139 12/144 100.0 % 1.13 [ 0.50, 2.58 ]
Subtotal (95% CI) 139 144 100.0 % 1.13 [ 0.50, 2.58 ]
Total events: 13 (Treatment A), 12 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
4 Low dose vaginal versus high dose vaginal
Geber 2007a (5) 10/122 8/122 28.5 % 1.27 [ 0.49, 3.31 ]
Kleinstein 2005 (6) 10/212 16/218 41.6 % 0.63 [ 0.29, 1.39 ]
Ng 2007 (7) 8/66 4/66 18.7 % 2.07 [ 0.63, 6.75 ]
Strehler 1999 (8) 4/48 3/51 11.2 % 1.45 [ 0.31, 6.68 ]
Subtotal (95% CI) 448 457 100.0 % 1.06 [ 0.63, 1.76 ]
Total events: 32 (Treatment A), 31 (Treatment B)
Heterogeneity: Chi2 = 3.17, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 0.21 (P = 0.84)
0.01 0.1 1 10 100
Favours treatment A Favours treatment B
(Continued . . . )
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(. . . Continued)
Study or subgroup Treatment A Treatment B
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
5 Short protocol versus long protocol
Goudge 2010 (9) 12/51 4/46 52.3 % 2.90 [ 1.00, 8.45 ]
Kohls 2010 (10) 6/110 7/110 47.7 % 0.85 [ 0.28, 2.60 ]
Subtotal (95% CI) 161 156 100.0 % 1.62 [ 0.75, 3.50 ]
Total events: 18 (Treatment A), 11 (Treatment B)
Heterogeneity: Chi2 = 2.42, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 1.22 (P = 0.22)
6 Micronized versus synthetic
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment A), 0 (Treatment B)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 5.80, df = 4 (P = 0.21), I2 =31%
0.01 0.1 1 10 100
Favours treatment A Favours treatment B
(1) chlormadione acetate 6 mg oral 2x daily vs progesterone im 25 mg daily from day 2 to 6, 50 mg daily from day 7 to 14
(2) IM progesterone 50 mg daily vs oral progesterone 200 mg 3 times daily
(3) 50 mg progesterone IM vs progesterone vaginal ring 1 mg
(4) Vaginal progesterone gel 90 mg daily vs oral progesterone 300 mg daily
(5) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(6) Crinone 8% vs vaginal progesterone capsule 200 mg 3 times daily
(7) Progesterone capsules 100 mg 2 times daily vs Progesterone pessaries 400 mg 2 times daily
(8) Crinone 8% vs Utrogestan (not defined)
(9) progesterone 50 mg IM for 11 days vs progesterone 50 mg IM for 6 weeks
(10) Progesterone vaginal 200 mg twice daily until US vs progesterone vaginal 200 mg twice daily until 8 weeks pregnant
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Analysis 6.7. Comparison 6 Progesterone regimens, Outcome 7 Subgroup analysis 1: IM versus
Vaginal/rectal (Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 7 Subgroup analysis 1: IM versus Vaginal/rectal (Clinical Pregnancy Rate)
Study or subgroup IM progesterone
Vaginal/rectal
progesterone
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 clomiphene citrate alone without GnRH agonists
2 human gonadotropins with clomiphene citrate without GnRH agonists
3 human gonadotropins with or without GnRH agonists
Abate 1999a (1) 18/52 10/52 2.17 [ 0.92, 5.14 ]
Artini 1995 (2) 6/44 7/44 0.84 [ 0.26, 2.70 ]
Dal Prato 2008 (3) 45/138 87/174 0.49 [ 0.31, 0.77 ]
Geusa 2001 (4) 42/150 40/150 1.07 [ 0.64, 1.78 ]
Perino 1997 (5) 69/150 41/150 2.23 [ 1.39, 3.56 ]
Porcu 2003 (6) 27/112 30/112 0.87 [ 0.48, 1.58 ]
Saucedo 2003 (7) 13/42 17/44 0.72 [ 0.30, 1.73 ]
Sumita 2003 (8) 13/50 17/50 0.69 [ 0.29, 1.61 ]
Yanushpolsky 2010 (9) 125/201 137/206 0.83 [ 0.55, 1.24 ]
Zegers-Hochschild 2000 96/262 89/243 1.00 [ 0.70, 1.44 ]
4 human gonadotropins with or without GnRH antagonists
Miller 2010 (10) 38/81 37/84 1.12 [ 0.61, 2.07 ]
0.01 0.1 1 10 100
Favours vaginal/rectal Favours IM
(1) GnRH agonist + FSH
(2) GnRH agonist + FSH + hMG
(3) GnRH agonist + FSH
(4) GnRH agonist + rFSH
(5) GnRH agonist + FSH
(6) GnRH agonist
(7) GnRH agonist + rFSH
(8) GnRH agonist + FSH
(9) GnRH agonist
(10) GnRH antagonist + Menopur or r-FSH
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Analysis 6.8. Comparison 6 Progesterone regimens, Outcome 8 Subgroup analysis 1: Low dose vaginal
versus high dose vaginal (Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 8 Subgroup analysis 1: Low dose vaginal versus high dose vaginal (Clinical Pregnancy Rate)
Study or subgroup Low dose High dose
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 clomiphene citrate alone without GnRH agonists
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Low dose), 0 (High dose)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 human gonadotropins with clomiphene citrate without GnRH agonists
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Low dose), 0 (High dose)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 human gonadotropins with or without GnRH agonists
Dal Prato 2008 (1) 36/137 51/137 8.2 % 0.60 [ 0.36, 1.00 ]
Doody 2009 (2) 174/403 346/808 36.2 % 1.01 [ 0.80, 1.29 ]
Ganesh 2011 (3) 138/482 104/459 24.7 % 1.37 [ 1.02, 1.83 ]
Geber 2007a (4) 54/122 44/122 8.1 % 1.40 [ 0.84, 2.34 ]
Kleinstein 2005 (5) 47/212 55/218 10.7 % 0.84 [ 0.54, 1.32 ]
Ng 2003 (6) 7/30 9/30 1.6 % 0.72 [ 0.23, 2.22 ]
Ng 2007 (7) 18/66 19/66 3.7 % 0.93 [ 0.44, 1.98 ]
Strehler 1999 (8) 18/45 18/51 3.1 % 1.22 [ 0.54, 2.78 ]
Subtotal (95% CI) 1497 1891 96.3 % 1.05 [ 0.91, 1.22 ]
Total events: 492 (Low dose), 646 (High dose)
Heterogeneity: Chi2 = 10.58, df = 7 (P = 0.16); I2 =34%
Test for overall effect: Z = 0.67 (P = 0.50)
4 human gonadotropins with or without GnRH antagonists
Rodriguez-Pezino 2004 (9) 18/40 37/84 3.7 % 1.04 [ 0.49, 2.21 ]
Subtotal (95% CI) 40 84 3.7 % 1.04 [ 0.49, 2.21 ]
Total events: 18 (Low dose), 37 (High dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI) 1537 1975 100.0 % 1.05 [ 0.91, 1.22 ]
Total events: 510 (Low dose), 683 (High dose)
0.01 0.1 1 10 100
Favours high dose Favours low dose
(Continued . . . )
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(. . . Continued)
Study or subgroup Low dose High dose
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: Chi2 = 10.58, df = 8 (P = 0.23); I2 =24%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
0.01 0.1 1 10 100
Favours high dose Favours low dose
(1) GnRH agonist + FSH
(2) GnRH agonist + hMG (Menopur) + FSH (Bravelle)
(3) GnRH agonists + FSH
(4) GnRH agonist + FSH
(5) GnRH agonist + hMG or FSH
(6) GnRH agonist
(7) GnRH agonist + hMG
(8) GnRH agonist + hMG
(9) GnRH antagonist + rFSH + LH + hCG
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Analysis 6.10. Comparison 6 Progesterone regimens, Outcome 10 Subgroup analysis 3: IM versus
Vaginal/rectal (Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 10 Subgroup analysis 3: IM versus Vaginal/rectal (Clinical Pregnancy Rate)
Study or subgroup IM progesterone
Vaginal/rectal
progesterone
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Stop at pregnancy test
Artini 1995 6/44 7/44 0.84 [ 0.26, 2.70 ]
Perino 1997 69/150 41/150 2.23 [ 1.39, 3.56 ]
2 Up to 12 weeks when pregnant
Abate 1999a 18/52 10/52 2.17 [ 0.92, 5.14 ]
Dal Prato 2008 55/138 87/274 1.43 [ 0.93, 2.20 ]
Propst 2001 48/99 31/102 2.13 [ 1.21, 3.74 ]
Sumita 2003 13/50 17/44 0.56 [ 0.24, 1.34 ]
Yanushpolsky 2010 125/201 137/206 0.83 [ 0.55, 1.24 ]
0.01 0.1 1 10 100
Favours Vaginal/rectal progesterone Favours IM progesterone
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Analysis 6.11. Comparison 6 Progesterone regimens, Outcome 11 Subgroup analysis 3: Vaginal/rectal
versus Oral (Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 11 Subgroup analysis 3: Vaginal/rectal versus Oral (Clinical Pregnancy Rate)
Study or subgroup
Vaginal/rectal
progesterone Oral progesterone
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Stop at pregnancy test
Friedler 1999 16/32 10/32 3.3 % 2.15 [ 0.80, 5.78 ]
Patki 2007 70/247 122/308 25.9 % 0.61 [ 0.43, 0.86 ]
Subtotal (95% CI) 279 340 29.2 % 0.70 [ 0.50, 0.98 ]
Total events: 86 (Vaginal/rectal progesterone), 132 (Oral progesterone)
Heterogeneity: Chi2 = 5.55, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 2.10 (P = 0.035)
2 Up to 12 weeks when pregnant
Chakravarty 2005 109/351 25/79 11.6 % 0.97 [ 0.57, 1.65 ]
Ganesh 2011 242/941 121/422 47.6 % 0.86 [ 0.66, 1.11 ]
Pouly 1996 40/139 36/144 11.6 % 1.21 [ 0.72, 2.05 ]
Subtotal (95% CI) 1431 645 70.8 % 0.93 [ 0.75, 1.15 ]
Total events: 391 (Vaginal/rectal progesterone), 182 (Oral progesterone)
Heterogeneity: Chi2 = 1.35, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 1710 985 100.0 % 0.85 [ 0.71, 1.02 ]
Total events: 477 (Vaginal/rectal progesterone), 314 (Oral progesterone)
Heterogeneity: Chi2 = 8.86, df = 4 (P = 0.06); I2 =55%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Chi2 = 1.96, df = 1 (P = 0.16), I2 =49%
0.01 0.1 1 10 100
Favours oral Favours vaginal/rectal
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Analysis 6.12. Comparison 6 Progesterone regimens, Outcome 12 Subgroup analysis 3: Low dose vaginal
versus high dose vaginal (Clinical Pregnancy Rate).
Review: Luteal phase support for assisted reproduction cycles
Comparison: 6 Progesterone regimens
Outcome: 12 Subgroup analysis 3: Low dose vaginal versus high dose vaginal (Clinical Pregnancy Rate)
Study or subgroup Low dose High dose
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Stop at pregnancy test
Ludwig 2002 21/73 10/53 2.2 % 1.70 [ 0.75, 3.85 ]
Ng 2003 7/30 9/30 1.1 % 0.72 [ 0.23, 2.22 ]
Ng 2007 18/66 19/66 2.6 % 0.93 [ 0.44, 1.98 ]
Subtotal (95% CI) 169 149 5.9 % 1.10 [ 0.67, 1.82 ]
Total events: 46 (Low dose), 38 (High dose)
Heterogeneity: Chi2 = 1.83, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
2 Up to 12 weeks when pregnant
Dal Prato 2008 36/137 51/137 5.7 % 0.60 [ 0.36, 1.00 ]
Doody 2009 174/403 346/808 25.2 % 1.01 [ 0.80, 1.29 ]
Ganesh 2011 138/482 104/459 17.2 % 1.37 [ 1.02, 1.83 ]
Geber 2007a 54/122 44/122 5.6 % 1.40 [ 0.84, 2.34 ]
Kleinstein 2005 47/212 55/218 7.4 % 0.84 [ 0.54, 1.32 ]
Stadtmauer 2010 307/651 310/646 30.9 % 0.97 [ 0.78, 1.20 ]
Strehler 1999 18/45 18/51 2.2 % 1.22 [ 0.54, 2.78 ]
Subtotal (95% CI) 2052 2441 94.1 % 1.03 [ 0.91, 1.17 ]
Total events: 774 (Low dose), 928 (High dose)
Heterogeneity: Chi2 = 10.50, df = 6 (P = 0.10); I2 =43%
Test for overall effect: Z = 0.49 (P = 0.63)
Total (95% CI) 2221 2590 100.0 % 1.04 [ 0.92, 1.17 ]
Total events: 820 (Low dose), 966 (High dose)
Heterogeneity: Chi2 = 12.40, df = 9 (P = 0.19); I2 =27%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.01 0.1 1 10 100
Favours high dose Favours low dose
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A D D I T I O N A L T A B L E S
Table 1. Sensitivity analysis for studies with outlying results in comparison 3.2.1
Peto OR 95% CI
Before SA 1.14 [0.90, 1.45]
After SA 1.19 [0.94, 1.52]
Without Golan 1993
Table 2. Sensitivity analysis for studies with outlying results in comparison 3.5.2
Peto OR 95% CI
Before SA 0.45 0.45 [0.26, 0.79]
Without Ludwig 2001 0.26 0.26 [0.13, 0.51]
Without Ugur 2001 0.89 0.89 [0.37, 2.16]
Table 3. Sensitivity analysis for studies with outlying results in comparison 4.2
Peto OR 95% CI
Before SA 0.80 0.80 [0.63, 1.01]
After SA 1.06 [0.38, 2.94]
Without Gorkemli 2004
Table 4. Sensitivity analysis for studies with high risk of bias in comparison 4.3
Peto OR 95% CI
Before SA 1.00 [0.76, 1.31]
After SA 0.94 [0.72, 1.22]
Without Fatemi 2006
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Table 5. Sensitivity analysis for studies with high risk of bias in comparison 4.4
Peto OR 95% CI
Before SA 1.01 [0.70, 1.45]
After SA 1.03 [0.69, 1.53]
Without Fatemi 2006
Table 6. Sensitivity analysis for studies with outlying results in comparison 5.2
Peto OR 95% CI
Before SA 0.74 [0.60, 0.90]
After SA 0.73 [0.60, 0.89]
Without Pirard 2006
Table 7. Sensitivity analysis for studies with high risk of bias in comparison 6.1.1
Peto OR 95% CI
Before SA 1.40 [0.28, 7.02]
After SA
Without Iwase 2008: not possible, as this is the only included study in this comparison
Table 8. Sensitivity analysis for studies with high risk of bias in comparison 6.1.6
Peto OR 95% CI
Before SA 0.90 [0.52, 1.56]
After SA 0.93 [0.52, 1.66]
Without Iwase 2008
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Table 9. Sensitivity analysis for studies with high risk of bias in comparison 6.2.1
Peto OR 95% CI
Before SA 1.92 [0.89, 4.14]
After SA 2.21 [0.90, 5.44]
Without Iwase 2008
Table 10. Sensitivity analysis for studies with outlying results in comparison 6.2.2
Peto OR 95% CI
Before SA 1.14 [0.97, 1.33]
After SA 1.05 [0.89, 1.24]
Without Perino 1997
Table 11. Sensitivity analysis for studies with high risk of bias in comparison 6.2.4
Peto OR 95% CI
Before SA 1.04 [0.92, 1.17]
After SA 1.02 [0.91, 1.16]
Without Ludwig 2002
Table 12. Sensitivity analysis for studies with high risk of bias in comparison 6.2.6
Peto OR 95% CI
Before SA 0.79 [0.65, 0.96]
After SA 0.79 [0.65, 0.96]
Without Iwase 2008
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Table 13. Sensitivity analysis for studies with outlying results in comparison 6.3.2
Peto OR 95% CI
Before SA 1.34 [1.05, 1.71]
After SA 1.04 [0.79, 1.39]
Without Perino 1997
Table 14. Sensitivity analysis for studies with high risk of bias in comparison 6.3.4
Peto OR 95% CI
Before SA 0.99 [0.85, 1.15]
After SA 0.98 [0.84, 1.14]
Without Ludwig 2002
Table 15. Sensitivity analysis for studies with high risk of bias in comparison 6.4.1
Peto OR 95% CI
Before SA 1.66 [0.28, 9.79]
After SA 0.59 [0.06, 5.85]
Without Iwase 2008
Table 16. Sensitivity analysis for studies with outlying results in comparison 6.4.1
Peto OR 95% CI
Before SA 1.66 [0.28, 9.79]
After SA 7.65 [0.78, 75.00]
Without Licciardi 1999
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Table 17. Sensitivity analysis for studies with outlying results in comparison 6.4.2
Peto OR 95% CI
Before SA 0.85 [0.58, 1.25]
After SA 0.83 [0.57, 1.22]
Without Saucedo 2000
Table 18. Sensitivity analysis for studies with outlying results in comparison 6.4.3
Peto OR 95% CI
Before SA 1.18 [0.76, 1.85]
After SA 1.27 [0.80, 2.01]
Without Friedler 1999
Table 19. Sensitivity analysis for studies with high risk of bias in comparison 6.4.4
Peto OR 95% CI
Before SA 0.79 [0.53, 1.17]
After SA 0.76 [0.50, 1.13]
Without Ludwig 2002
Table 20. Sensitivity analysis for studies with high risk of bias in comparison 6.5.1
Peto OR 95% CI
Before SA 1.00 [0.06, 16.58]
After SA
Without Iwase 2008: not possible, as this is the only included study in this comparison
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Table 21. Sensitivity analysis for studies with high risk of bias in comparison 6.5.6
Peto OR 95% CI
Before SA 1.00 [0.06, 16.58]
After SA
Without Iwase 2008: not possible, as this is the only included study in this comparison
Table 22. Sensitivity analysis for studies with high risk of bias in comparison 6.6.1
Peto OR 95% CI
Before SA 4.14 [1.13, 15.13]
After SA 4.39 [1.28, 15.01]
Without Iwase 2008
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
EBM Reviews - Cochrane Central Register of Controlled Trials <1st Quarter 2011>
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ (1475)
2 embryo transfer$.tw. (830)
3 in vitro fertili?ation.tw. (1251)
4 ivf-et.tw. (241)
5 (ivf or et).tw. (5634)
6 icsi.tw. (604)
7 intracytoplasmic sperm injection$.tw. (370)
8 (blastocyst adj2 transfer$).tw. (59)
9 exp Insemination, Artificial/ (254)
10 Insemination$.tw. (574)
11 iui.tw. (257)
12 or/1-11 (7219)
13 exp Luteal Phase/ (402)
14 (luteal adj5 support$).tw. (191)
15 (luteal adj5 phase).tw. (821)
16 (ischemic adj5 phase).tw. (104)
17 post ovulat$.tw. (11)
18 (post adj5 transfer$).tw. (41)
19 (after adj5 transfer$).tw. (5503)
20 (post adj5 trigger$).tw. (9)
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21 (after adj5 trigger$).tw. (1908)
22 or/13-21 (8262)
23 12 and 22 (1414)
24 exp Progesterone/ (2063)
25 Progesterone$.tw. (2091)
26 dydrogesterone.tw. (142)
27 utrogest.tw. (7)
28 17 alpha-hydroxyprogesterone.tw. (66)
29 Prontogest.tw. (5)
30 exp chorionic gonadotropin/ or exp chorionic gonadotropin, beta subunit, human/ (569)
31 HCG.tw. (934)
32 crinone.tw. (33)
33 chorionic gonadotropin$.tw. (375)
34 chorionic gonadotrophin$.tw. (231)
35 or/24-34 (4352)
36 23 and 35 (517)
37 limit 36 to yr=“2004 -Current” (176)
Appendix 2. MEDLINE search strategy
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to
Present>
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ (27911)
2 embryo transfer$.tw. (6799)
3 in vitro fertili?ation.tw. (14234)
4 ivf-et.tw. (1585)
5 (ivf or et).tw. (143650)
6 icsi.tw. (4216)
7 intracytoplasmic sperm injection$.tw. (3918)
8 (blastocyst adj2 transfer$).tw. (383)
9 exp Insemination, Artificial/ (9085)
10 Insemination$.tw. (10982)
11 iui.tw. (955)
12 or/1-11 (176082)
13 exp Luteal Phase/ (4163)
14 (luteal adj5 support$).tw. (451)
15 (luteal adj5 phase).tw. (7790)
16 (ischemic adj5 phase).tw. (735)
17 post ovulat$.tw. (584)
18 (post adj5 transfer$).tw. (811)
19 (after adj5 transfer$).tw. (14407)
20 (post adj5 trigger$).tw. (259)
21 (after adj5 trigger$).tw. (1864)
22 or/13-21 (27661)
23 12 and 22 (3711)
24 exp Progesterone/ (59378)
25 Progesterone$.tw. (59979)
26 dydrogesterone.tw. (323)
27 utrogest.tw. (4)
28 17 alpha-hydroxyprogesterone.tw. (1141)
29 Prontogest.tw. (5)
30 exp chorionic gonadotropin/ or exp chorionic gonadotropin, beta subunit, human/ (27265)
31 HCG.tw. (19044)
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32 crinone.tw. (43)
33 chorionic gonadotropin$.tw. (12102)
34 chorionic gonadotrophin$.tw. (3926)
35 or/24-34 (115420)
36 23 and 35 (1351)
37 randomized controlled trial.pt. (299607)
38 controlled clinical trial.pt. (81716)
39 randomized.ab. (215850)
40 placebo.tw. (129148)
41 clinical trials as topic.sh. (152093)
42 randomly.ab. (159397)
43 trial.ti. (92430)
44 (crossover or cross-over or cross over).tw. (49454)
45 or/37-44 (732909)
46 exp animals/ not humans.sh. (3532377)
47 45 not 46 (677343)
48 36 and 47 (273)
49 (2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$ or 2010$ or 2011$).ed. (5591829)
50 48 and 49 (113)
Appendix 3. EMBASE search strategy
EMBASE <1980 to 2011 Week 06>
1 exp embryo transfer/ or exp fertilization in vitro/ or exp intracytoplasmic sperm injection/ (40509)
2 embryo$ transfer$.tw. (8875)
3 in vitro fertili?ation.tw. (16194)
4 ivf-et.tw. (1916)
5 icsi.tw. (6134)
6 intracytoplasmic sperm injection$.tw. (4671)
7 (blastocyst adj2 transfer$).tw. (542)
8 (ivf or et).tw. (267654)
9 exp artificial insemination/ (10631)
10 Insemination$.tw. (11124)
11 iui.tw. (1292)
12 or/1-11 (306873)
13 exp luteal phase/ (5832)
14 (luteal adj5 support$).tw. (583)
15 (luteal adj5 phase).tw. (7986)
16 (ischemic adj5 phase).tw. (880)
17 post ovulat$.tw. (521)
18 (post adj5 transfer$).tw. (941)
19 (after adj5 transfer$).tw. (15304)
20 (post adj5 trigger$).tw. (316)
21 (after adj5 trigger$).tw. (2141)
22 or/13-21 (29757)
23 12 and 22 (4718)
24 exp PROGESTERONE/ (61175)
25 Progesterone$.tw. (60300)
26 dydrogesterone.tw. (391)
27 utrogest.tw. (31)
28 17 alpha-hydroxyprogesterone.tw. (452)
29 Prontogest.tw. (59)
30 exp chorionic gonadotropin/ (32624)
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31 HCG.tw. (20115)
32 crinone.tw. (234)
33 chorionic gonadotropin$.tw. (11827)
34 chorionic gonadotrophin$.tw. (3894)
35 or/24-34 (120217)
36 23 and 35 (2001)
37 Clinical Trial/ (826633)
38 Randomized Controlled Trial/ (289177)
39 exp randomization/ (53408)
40 Single Blind Procedure/ (13857)
41 Double Blind Procedure/ (101415)
42 Crossover Procedure/ (30112)
43 Placebo/ (174852)
44 Randomi?ed controlled trial$.tw. (59579)
45 Rct.tw. (6444)
46 random allocation.tw. (1018)
47 randomly allocated.tw. (15167)
48 allocated randomly.tw. (1692)
49 (allocated adj2 random).tw. (683)
50 Single blind$.tw. (10736)
51 Double blind$.tw. (116027)
52 ((treble or triple) adj blind$).tw. (232)
53 placebo$.tw. (155118)
54 prospective study/ (163294)
55 or/37-54 (1118108)
56 case study/ (11164)
57 case report.tw. (196960)
58 abstract report/ or letter/ (769582)
59 or/56-58 (973999)
60 55 not 59 (1085709)
61 36 and 60 (513)
62 (2010$ or 2011$).em. (1278972)
63 61 and 62 (93)
Appendix 4. PsycINFO search strategy
PsycINFO <1806 to February Week 2 2011>
1 exp Reproductive Technology/ (1044)
2 embryo transfer$.tw. (74)
3 in vitro fertili?ation.tw. (409)
4 ivf-et.tw. (14)
5 (ivf or et).tw. (74694)
6 icsi.tw. (35)
7 intracytoplasmic sperm injection$.tw. (26)
8 (blastocyst adj2 transfer$).tw. (2)
9 Insemination$.tw. (526)
10 iui.tw. (15)
11 or/1-10 (75914)
12 (luteal adj5 support$).tw. (1)
13 (luteal adj5 phase).tw. (703)
14 (ischemic adj5 phase).tw. (24)
15 post ovulat$.tw. (10)
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16 (post adj5 transfer$).tw. (104)
17 (after adj5 transfer$).tw. (856)
18 (post adj5 trigger$).tw. (22)
19 (after adj5 trigger$).tw. (136)
20 or/12-19 (1846)
21 11 and 20 (62)
22 exp Progesterone/ (1589)
23 Progesterone$.tw. (2864)
24 dydrogesterone.tw. (8)
25 utrogest.tw. (0)
26 17 alpha-hydroxyprogesterone.tw. (4)
27 Prontogest.tw. (0)
28 exp Gonadotropic Hormones/ (3296)
29 HCG.tw. (57)
30 crinone.tw. (0)
31 chorionic gonadotropin$.tw. (65)
32 chorionic gonadotrophin$.tw. (8)
33 or/22-32 (6137)
34 21 and 33 (2)
Appendix 5. MDSG search strategy
MV263 MDSG Search string
Keywords CONTAINS “luteal phase” or “luteal phase support” or “luteal phase support timing” or “luteal phase supprt” or “luteal
support” or Title CONTAINS “luteal phase” or “luteal phase support” or “luteal phase support timing” or “luteal phase supprt” or
“luteal support”
AND
Keywords CONTAINS “Progesterone” or “progesterone capsule” or “progesterone gel” or “progesterone, micronized” or “proges-
terone receptor agonist” or “HCG” or “human chorionic gonadotrophin” or “human chorionic gonadotropin” or “dydrogesterone”
or “dydrogestrone” or “utrogestan” or “vaginal micronised progesterone” or “vaginal micronized progesterone capsules” or “vaginal
micronized progesterone gel” or “vaginal progesterone” or “17-alpha hydroxyprogesterone” or Title CONTAINS “Progesterone” or
“progesterone capsule” or “progesterone gel” or “progesterone, micronized” or “progesterone receptor agonist” or “HCG” or “human
chorionic gonadotrophin” or “human chorionic gonadotropin” or “dydrogesterone” or “dydrogestrone” or “utrogestan” or “vaginal
micronised progesterone” or “vaginal micronized progesterone capsules” or “vaginal micronized progesterone gel” or “vaginal proges-
terone” or “17-alpha hydroxyprogesterone”
Searched on 17 February 2011, 85 Results.
Appendix 6. CINAHL search strategy
From 1982 to Present
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# Query
S12 S10 and S11
S11 S1 or S2
S10 S3 or S4 or S5 or S6 or S7 or S8 or S9
S9 “vaginal micronised progesterone”
S8 (MH “Gonadotropins, Chorionic”) OR “hCG”
S7 “dydrogestrone”
S6 (MH “Gonadotropins, Chorionic”) OR “human chorionic gonadotrophin”
S5 “progesterone micronized”
S4 “progesterone gel”
S3 (MH “Progesterone”) OR “progesterone”
S2 “luteal support”
S1 (MM “Luteal Phase”) OR “luteal phase”
Appendix 7. The Cochrane Library - DARE search strategy
ID Search
#1 utrogestan in Other Reviews
#2 vaginal micronised progesterone in Other Reviews
#3 dydrogestrone in Other Reviews
#4 Progesterone in Other Reviews
#5 human chorionic gonadotrophin in Other Reviews
#6 human chorionic gonadotropin in Other Reviews
#7 luteal phase in Other Reviews
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(Continued)
#8 luteal phase support in Other Reviews
#9 luteal phase support in Other Reviews
#10 (( #1 OR #2 OR #3 OR #4 OR #5 OR #6 ) AND ( #7 OR #8 OR #9 ))
Appendix 8. Web of Knowledge search strategy
Set Results
#9 97 #7
Databases=SCI-EXPANDED, CPCI-S Timespan=2004-2011
#8 233 #7
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
#7 233 #5 AND #6
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All Years
#6 28,648 TS=(embryo transfer) OR TS=(ivf ) OR TS=(in vitro fertilisation) OR TS=(in vitro infertilization) OR TS=(iui) OR
TS=(icsi)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All Years
#5 631 #1 AND #4
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All Years
#4 3,540 #3 AND #2
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All Years
#3 24,758 TS=(hcg) OR TS=(chorionic gonadotropin) OR TS=(chorionic gonadotrophin) OR TS=(human chorionic go-
nadotropin) OR TS=(human chorionic gonadotrophin)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All Years
#2 64,007 TS=(progesterone) OR TS=(progesteron) OR TS=(dydrogesterone) OR TS=(utrogest) OR TS=(prontogest) OR
TS=(17 alpha-hydroxyprogesterone)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All Years
#1 7,275 TS=(Luteal phase) OR TS=(luteal support) OR TS=(Luteal phase support)
Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All Years
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Appendix 9. Study eligibility form
Study ID
Report ID
ID Review Author
Date form completed
Report authors
Complete reference
Publication type
Report author contact details
Study characteris-
tics
Review inclusion
criteria
Assessment Quotation
Yes No Unclear
Type of study RCT or Cross-over?
Participants Women undergoing
ART?
When used: GIFT
or ZIFT < 20%?
Interventions No frozen ET?
No other substances
than progesterone /
hCG / estrogen?
No ET from do-
nated oocytes?
No ET from frozen
oocytes/frozen ovar-
ian tissue?
No in vivo matura-
tion (IVM)?
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(Continued)
Include pro-
gesterone adminis-
tration (any route/
type/duration) and/
or hCG adminis-
tration (any route/
type/duration)?
Progesterone ad-
ministration for at
least 5 days in luteal
phase?
At least 2 times hCG
administration in
luteal phase?
Final decision:
o Include (if all ‘yes’)
o Exclude (if any ‘no’)
Reason for exclusion:
If Unclear, action undertaken:
Appendix 10. Data extraction form
General information
Study ID
ID Review author
Date form completed
Complete reference
Published? o Yes
o No
Publication type Journal / Abstract / other (specify)
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(Continued)
Report author contact details
Notes:
Study eligibility
Confirm eligibility o Included
o Excluded
Reason for exclusion:
o Unclear
Reason:
Action undertaken:
Study details
Study intention Description as stated in report Reference
Aim of study
Setting o Multicentre
o Single centre
o Unclear
Type of study o RCT
o Cross-over
Country
Power calculation done o Yes
o No
o Unclear
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Methods
Methods Description as stated in report Reference
Inclusion / Exclusion criteria for participa-
tion in study
Total # of intervention groups (specify)
Allocation concealment?
Moment of randomization
Method randomization sequence
Blinding Clinician
o Yes
o No
o Unclear
Researcher
o Yes
o No
o Unclear
Patient
o Yes
o No
o Unclear
Method of blinding
Reporting bias
Participants
Participants Description Reference
Total # randomised
Total # analysed
Reason why not analysed
#Cycles per woman
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(Continued)
# allocated to each intervention group
# and reasons for exclusions for each inter-
vention groups
Age (median, mean, range if available)
# IVF
# ICSI
# previous cycles
# transferred embryo’s
Intervention group
Group name:
Intervention Description Reference
Type
Dosage
# doses
Route
Duration
Duration of follow-up
Protocol for ovulation induction
Scheme for trigger
GnRH o Agonist
o Antagonist
GnRH scheme o Duration
o Dose
o Route of administration
Comparison group
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Group name:
Comparison Description Reference
Type
Dosage
# doses
Route
Duration
Duration of follow-up
Protocol for ovulation induction
Scheme for trigger
GnRH o Agonist
o Antagonist
GnRH scheme o Duration
o Dose
o Route of administration
Outcome
Outcomes Yes No Definition? References
LBR
CPR
OPR
MR
OHSS
MPR
Other (specify)
Results
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Copy table for each comparison.
Comparison
ITT?
Results Intervention: Comparison:
Events # participants Events # participants
ET
CPR
OPR
LBR
OHSS
MR
MultiP
# missing participants
Reasons for missing
participants
Any other results re-
ported
Other relevant information
Information Description References
Funding source and possible conflict of in-
terest
Notes review author
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(Continued)
Correspondence required (specify) o No
o Yes
o E-mail sent on
o Letter sent on
o Fax sent on
Reaction received: Yes / No
USE NEW FORM WITH COMPLETE
INFO
Appendix 11. Risk of Bias
Entry Judgement Description Reference
Adequate sequence generation? High risk
Unclear risk
Low risk
Method used to produce compa-
rable groups
Adequate allocation conceal-
ment?
High risk
Unclear risk
Low risk
Method used in detail
Adequate blinding? High risk
Unclear risk
Low risk
All measures used
Incomplete outcome data ad-
dressed?
High risk
Unclear risk
Low risk
Completeness of data primary
outcome (LBR) incl attrition and
exclusions from analysis
Free of selective reporting? High risk
Unclear risk
Low risk
State how possibility of selective
outcome reporting is examined
Free of other bias? High risk
Unclear risk
Low risk
State any important concerns
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WH A T ’ S N E W
Last assessed as up-to-date: 25 May 2011.
Date Event Description
2 April 2014 Amended Correction to analyses: all now set to record “event” rather than “non-event”. No change to conclusions
H I S T O R Y
Protocol first published: Issue 6, 2011
Review first published: Issue 10, 2011
Date Event Description
4 June 2012 Amended Correction to Summary of main results: Progesterone and estrogen for luteal
phase support
11 May 2012 Amended Correction of erroneous data for Elgindy 2010 (analyses 4.2.1 and 4.2.3)
16 March 2011 New search has been performed This is an update of a previously published review with the same title. There is
a new authoring team
C O N T R I B U T I O N S O F A U T H O R S
MvdL, MM and KB extracted data. MvdL entered data and wrote the review. CF acted as a third reviewer in case of disagreements,
helped drafting the review, acted as a clinical expert and commented on the review. JK acted as a clinical expert and commented on the
review.
D E C L A R A T I O N S O F I N T E R E S T
None
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S O U R C E S O F S U P P O R T
Internal sources
• MDSG, Not specified.
External sources
• Stichting Nijmeegs Universiteitsfonds, Netherlands.
Scholarship to support students from the Radboud University Nijmegen to study, do an internship or research abroad.
• Commissie Voorzieningen Studenten Budget (CVSB), Netherlands.
Grant to subsidise activities of (medical) student organisation and foreign internships of individual students from the medical faculty
of the Radboud University Nijmegen.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We changed the objective from “To determine the effectiveness and safety of luteal phase support in subfertile women undergoing
assisted reproductive technology” to “To determine the relative effectiveness and safety of methods of luteal phase support in subfertile
women undergoing assisted reproductive technology”. We made this change because we not only investigated the use of luteal phase
support but also the different ways of luteal phase support.
In the protocol we stated we would exclude studies using any other substance in the luteal phase than progesterone, hCG or GnRH
agonists. We found one study investigating LH instead of hCG (Geber 2007). Because LH is very similar to hCGwe decided to include
this study in the comparison of progesterone versus progesterone + hCG.We also decided to delete the exclusion criterion “use of other
substances for luteal phase support than progesterone, hCG or oestrogen”. This means that in the future we are able to include new
agents.
We stated 10 comparisons in the protocol, namely:
1. progesterone versus placebo or no treatment;
2. progesterone versus hCG;
3. progesterone versus progesterone and hCG;
4. progesterone versus progesterone and estrogen;
5. progesterone versus progesterone and GnRH agonist;
6. comparison of the different methods of administration of progesterone: IM versus vaginal versus rectal versus oral;
7. micronized versus synthetic progesterone;
8. hCG versus placebo or no treatment;
9. urinary versus recombinant hCG;
10. single-dose GnRH agonist versus placebo.
We changed these to:
1. hCG versus placebo or no treatment;
2. progesterone versus placebo or no treatment;
3. progesterone versus hCG regimens
i) progesterone versus hCG,
ii) progesterone versus progesterone and hCG;
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4. progesterone versus progesterone and estrogen;
5. progesterone versus progesterone and GnRH agonist;
6. progesterone regimens
i) IM progesterone versus oral progesterone,
ii) IM progesterone versus vaginal or rectal progesterone,
iii) vaginal or rectal progesterone versus oral progesterone,
iv) low dose vaginal progesterone (≤ 100 mg) versus high dose vaginal progesterone (> 100 mg),
v) micronized progesterone versus synthetic progesterone.
To keep things clear we split comparison six in the protocol into three different subgroups but combined vaginal and rectal administration
of progesterone. After our search, we found a large number of studies which researched different types and dosages of vaginal progesterone
administration. Therefore we added comparison nine: low dose vaginal progesterone versus high dose vaginal progesterone. We also
found some studies comparing different durations of progesterone administration, which we included in comparison 10: short protocol
progesterone versus long protocol progesterone.
We did not find any studies comparing urinary hCG and recombinant hCG or studies comparing only single-dose GnRH agonist versus
placebo, but we did come across some studies using multiple doses of a GnRH agonist. Therefore we included these in comparison
five, changing ’single dose GnRH agonist’ to ’GnRH agonist’. It is unlikely that the comparisons for urinary hCG versus recombinant
hCG and GnRH agonist versus placebo will be made in the future, as hCG is an older method for luteal phase support and is known
for its high risk of OHSS; we do not expect new trials will be conducted to investigate the differences between urinary and recombinant
hCG. Nowadays progesterone is an accepted method for luteal phase support and it is considered unethical to not provide any form
of luteal phase support. Therefore we do not expect any new trials investigating the effect of GnRH agonists for luteal phase support
versus a placebo. For these reasons we chose to remove these comparisons.
We feel that these changes in the comparisons enabled us to present an overview of luteal phase support in assisted reproduction cycles
which is as complete as possible.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Reproductive Techniques, Assisted; Chorionic Gonadotropin [∗therapeutic use]; Estrogens [∗therapeutic use]; Gonadotropin-Re-
leasing Hormone [∗agonists]; Live Birth [epidemiology]; Luteal Phase [∗drug effects; physiology]; Progesterone [∗therapeutic use];
Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
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